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Abstract 
	 ﾠ
	 ﾠ
In age-related macular disease (AMD) accumulation of complement proteins in the 
sub-retinal space is believed to contribute to either the malfunction or apoptosis of 
retinal  pigment  epithelial  (RPE)  cells  and  ultimately  the  death  of  the  associated 
photoreceptors. Here, the effects of basal formation of the terminal membrane attack 
complex, C5b-9, were examined using primary porcine RPE (pRPE) cells.  
 
Immunohistochemical analysis showed that C5b-9 complex formation appeared to 
stabilise at 4 h on the basal surface of pRPE cells, after which it steadily decreased 
and was eliminated from the cell surface by 48 h. Within 1 h of C5b-9 formation 
there was a significant increase in trans-epithelial resistance (TER) when compared 
to untreated cells. Treatment with dynasore, an endocytosis inhibitor, suggested that 
pRPE cells may endocytose the C5b-9 complex, as this chemical reagent blocked the 
removal of C5b-9 from the cell surface. Surprisingly, treatment of pRPE cells with 
dynasore inhibited the C5b-9-mediated increase in TER. C5b-9 did not appear to 
have an effect on the expression of either the negative complement regulators CD59 
and  DAF,  or  the  expression  of  the  junctional  protein  ZO-1.  However, 
immunofluorescence analysis demonstrated strong junctional staining for claudin-19 
in  C5b-9-treated  pRPE  cells  when  compared  to  control  conditions.  Also,  the 
prolonged presence of C5b-9 appeared to reduce both mitochondria numbers and the 
localisation of Tim23, a trans-membrane mitochondrial channel. We also observed 
that basal assembly of C5b-9 slowed the binding of photoreceptor outer segments 
(POS) to the apical surface of pRPE cells. However, POS internalisation and the 
activation levels of MerTK, FAK and Src were not affected by the presence of C5b-
9. 
  
In conclusion, work in this thesis demonstrated that C5b-9 rapidly forms on the basal 
surface  of  pRPE  cells,  and  that  in  doing  so  it  modulates  a  number  of  RPE  cell 
properties. RPE cells survive C5b-9 attack by endocytosing the complex, but when 
this process is blocked they exhibit signs of cellular stress. These studies provide 
mechanistic insight into some of the chronic cytotoxic effects of C5b-9 that could 
ultimately drive RPE cell loss and dysfunction in AMD. 	 ﾠ 4	 ﾠ
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1.1 The retinal pigment epithelium 
 
The retinal pigment epithelium (RPE) is a monolayer of cuboidal cells that forms the 
most anterior part of the blood-retinal barrier (BRB) (Ablonczy et al., 2011). It is 
vital  that  the  RPE  remains  fully  functional  since  its  many  roles  (Figure  1)  are 
required to maintain a healthy retina. These important roles include functions such as 
the transfer of various molecules (ions, metabolic end products, oxygen and water) 
from  the  neuro-retinal  microenvironment  to  the  choriocapillaris  (Ablonczy  et  al., 
2011).  In  addition,  as  the  RPE  is  situated  between  the  photoreceptors  and  the 
choroidal blood supply, it also transports glucose and fatty acids from the blood to 
supply  the  photoreceptors.  Other  specialised  functions  of  the  RPE  include  the 
absorption of scattered light, the secretion of growth factors and the sustainability of 
the visual cycle (Bandyopadhyay and Rohrer, 2012, McBee et al., 2001). The visual 
cycle is the biochemical transformation of all-trans-retinal to 11-cis retinal. Since 
photoreceptors are not able to transform retinal from the all-trans to the 11-cis state, 
to maintain their excitability, it is essential that retinal reaches the RPE (through 
phagocytosis and/or protein transportation), where it is re-isomerized. During visual 
cycle, all-trans retinal leaves the intradiscal space of photoreceptors to access their 
cytosol,  where  it  will  be  converted  to  all-trans  retinol  by  the  all-retinol 
dehydrogenase, termed as RDH. From the cytosol of photoreceptors, all-trans retinol 
is then delivered to the RPE by binding to a carrier protein known as interstitial 
retinol binding protein (IRBP). Within the RPE, all-trans retinol binds to the cellular 
retinol binding protein (CRBP), which will in turn deliver all-trans retinol to a multi-
protein complex, essential for the regeneration of 11-cis retinal. In more detail, this 
complex contains four essential proteins: RPE65, lecithin:retinol transferase (LRAT), 
cellular  retinaldehyde  binding  protein  (CRALBP)  and  the  retinol  dehydrogenase 
(RDH5). The first three proteins are required for the binding and conversion of all-
trans retinol to 11-cis retinol, while RDH5 is responsible for the oxidation of 11-cis 
retinol to 11-cis retinal. Once recycling is complete, 11-cis retinal is delivered from 
the RPE to the sub-retinal space, from where it will return to the photoreceptors 
through binding to IRBP (Baehr et al., 2003, Sun and Nathans, 2001, Rattner et al., 
2000, Gonzalez-Fernandez, 2003, Saari et al., 2002, Ruiz et al., 1999, Redmond et 
al., 1998, Jang et al., 2001, Saari et al., 2001). 
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 In order for the RPE to carry out these specialised functions, polarisation of the 
epithelial  cell  is  essential.  The  apical  surface  of  RPE  cells  consists  of  elongated 
structures, known as microvilli, which surround the tips of the photoreceptor outer 
segments (POS). This physical interaction enables the RPE to sustain the survival of 
photoreceptors by phagocytosing shed outer segments (Nguyen-Legros and Hicks, 
2000).  In  contrast  the  basal  membrane  of  the  RPE  faces  the  Bruch’s  membrane 
which separates the choriocapillaris from the neuroretina (Gulcan et al., 1993). 
 
 
Figure  1.  Schematic  representation  of  the  main  functions  of  RPE  cells.  RPE  cells  perform  a 
number  of  specialised  functions  including:  scattered  light  absorption,  transportation  of  glucose, 
vitamin A and ions from the blood to the photoreceptors and they sustain the visual cycle by recycling 
11-cis  retinal.  They  also  maintain  the  survival  of  photoreceptors  by  phagocytosing  shed  outer 
segments and finally they produce and secrete growth factors, essential for the maintenance of a 
healthy  retina:  pigment-epithelium  growth  factor  (PEDF)  from  the  apical  surface  and  vascular 
endothelial growth factor (VEGF) from their basal surface (Strauss, 2005).  
 
 
1.2 Polarity of the RPE 
 
The RPE develops an apical-to-basolateral polarity in terms of its unique structure, 
positioning of organelles, and the distribution of membrane proteins (Marmorstein, 
2001). On the apical side, where melanosomes are also localised, microvilli enable 
RPE cells to perform physical interactions with POS, whilst the basal side, where 
mitochondria are concentrated, is characterized by membraneous in-foldings which 
increase the surface area for exchange with the choriocapillaris (Figure 2-A, -B) 
(Marmorstein, 2001). Several membrane proteins show a polarised distribution in 
order to carry out their specific functions at either the apical or basal surface (Rizzolo 
and Zhou, 1995). Such proteins include the Na/K-ATPase (an ion pump), (Rizzolo 
and Zhou, 1995), the αvß5 integrin (essential for binding of POS on the RPE cell 
membranes)  (Nandrot  et  al.,  2004),  and  neural  cell  adhesion  molecule  (N-CAM-	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140), which is a morpho-regulator (Marmorstein et al., 1998). The aforementioned 
proteins have been demonstrated to localise on the apical surface of RPE cells. On 
the basal side, different proteins can be found such as monocarboxylate transporter 1 
(MCT1) (associated with the controlled transportation of lactate and water from the 
RPE to the choroid) (Philp et al., 1998).  
Figure 2. Schematic representation of the retina. (A) On the apical surface of RPE, microvilli 
allow cells to attach to outer segments (OS) in order to phagocytose photoreceptor outer segments 
(Ph). Membraneous in-foldings (MI) on the basal side increase the surface area with which RPE 
cells attach to bruch’s membrane (BM). (B) 3D schematic representation of the retina and its 
underlying  RPE  monolayer.  Sourced  and  adapted  from:  http://dev.ellex.com/2rt  and 
http://dev.biologists.org/content/140/12/2576.figures-only. 
 
 
1.3 Phagocytosis 
Human vision depends on the presence of both, the melanopsin-expressing retina 
ganglion  cells  and  the  retinal  photoreceptors  (PR):  the  rods  and  cones.  These 
ganglion cells are strongly activated by rods and cones and produce melanopsin, a 
photo-pigment  molecule  which  helps  to  detect  changes  in  light  intensity.  Gross 
changes in light intensity will therefore aid the functions of circadian rhythm and 
pupil constriction (Dacey et al., 2005). Rods are required for nocturnal vision due to 
their high light sensitivity (Rodieck and Rushton, 1976). In order for cones to be 
activated they need elevated light conditions, hence they are used for diurnal vision 
and  are  necessary  for  colour  discrimination  (Hestrin  and  Korenbrot,  1990).  Both 
types  need  to  be  renewed  by  synthesising  new  membranes  at  the  base  of  outer 
segments (OS) and by removing any aged membranes (Young and Bok, 1969). This 
renewal  process  is  dependent  on  the  underlying  RPE  monolayer,  which  is 
responsible for POS uptake and degradation (Young and Bok, 1969). In order for PR 
to maintain their excitability it is essential that POS phagocytosis from the RPE is 
regulated  in  a  circadian  manner  (LaVail,  1976).  Every  morning,  light  conditions 
stimulate the phagocytic activity of RPE, which has been found to maintain a peak 	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for 1-2 h (Young and Droz, 1968). Within approximately 10 days, a whole length of 
a POS can be regenerated. Circadian regulation has been linked to various other 
cellular processes in the retina such as melatonin synthesis, ion channel sensitivity 
and  visual  pigment  synthesis  (Tosini,  2000,  Ko  et  al.,  2001,  von  Schantz  et  al., 
1999). 
 
The  circadian  phagocytosis  of  shed  POS  involves  several  stages,  including  the 
binding,  internalisation,  degradation  and/or  the  recycling  of  constituents  of  the 
segments (Qin and Rodrigues, 2012). In order for RPE cells to carry out this process, 
they express a number of specific proteins such as ανβ5 integrin for binding (Nandrot 
et al., 2004), Mer tyrosine kinase (MerTK) (D'Cruz et al., 2000) and focal adhesion 
kinase (FAK), both necessary for internalization (Figure 3) (Finnemann, 2003). 
 
Previous studies have demonstrated that the apically-expressed vitronectin receptor, 
αvβ5, is also essential for the attachment of POS to the surface of RPE cells, since 
blockade of αvβ5 with a neutralizing antibody impaired POS binding to the RPE but 
did  not  affect  the  internalisation  of  POS  which  were  already  bound  to  the  cells 
(Finnemann et al., 1997). This integrin is required for the binding of POS, as beta5
-/-  
RPE cells in culture failed to take up isolated POS (Nandrot et al., 2004). 
 
The αvβ5 integrin, which mediates POS binding, activates a signaling cascade that 
leads to the re-organisation of the actin cytoskeleton in the RPE in order to allow the 
internalisation  of  bound  POS  (Finnemann  et  al.,  1997).  These  signaling  events 
involve activation of FAK, which is located at sites of integrin clustering on the 
apical side of the RPE cells (Finnemann, 2003). 
 
Activated FAK in turn activates (through tyrosine phosphorylation) MerTK which 
translocates to the site of POS binding, which is also necessary for the engulfment of 
the POS (Feng et al., 2002, Finnemann, 2003). Studies showed that in the Royal 
College  of  Surgeons  (RCS)  rat  that  lacks  MerTK,  internalisation  of  the  POS  is 
severely  compromised  leading  to  rapid  early  onset  photoreceptor  degeneration 
(Chaitin  and  Hall,  1983).  Ectopic  expression  of  MerTK  can  rescue  the  RCS 
phenotype, demonstrating that this kinase plays a key role in the engulfment of outer 
segments (Feng et al., 2002). 	 ﾠ 23	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The final stages of POS phagocytosis include digestion of these lipoproteinaceous 
bodies within RPE lysosomes (Deguchi et al., 1994). Since phagocytosis generates 
reactive oxygen species (ROS), and RPE cells perform this activity throughout a 
lifetime,  RPE  cells  have  developed  mechanisms  that  protect  them  against  photo-
oxidation of lipids and proteins in order to mitigate the harmful effects of oxidative 
stress  (Miceli  et  al.,  1994).  These  mechanisms  involve  the  production  of  large 
amounts  of  anti-oxidants,  which  remove  ROS,  filtration  of  light  by  the  RPE  in 
melanosomes and mechanisms to repair damaged nucleic acids, lipids and proteins 
(Kaemmerer et al., 2007). 
 
Figure  3.  Schematic  representation  of  RPE-specific  POS  phagocytosis.  αvβ5  receptors  are 
essential for the binding of POS on the apical surface of RPE cells. Successful binding of POS 
triggers  the  phosphorylation  (activation)  of  FAK,  which  in  turn  phosphorylates  (activates)  its 
downstream  target,  MerTK,  essential  for  the  internalisation  of  POS.  Internalised  POS  will 	 ﾠ 24	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eventually be degraded in the lysosomes, a process known to cause production of reactive oxygen 
species (ROS) in RPE cells. 
 
 
1.4 Secretory activity of the RPE 
 
The RPE secretes a number of growth factors that are essential in maintaining the 
health of both the neuroretina and the choriocapillaris (Marneros et al., 2005). Two 
of the best-characterised growth factors secreted by the RPE are vascular endothelial 
growth factor (VEGF) and pigment-epithelium-derived factor (PEDF) (Sonoda et al., 
2010). VEGF is required for choriocapillaris development and plays a major role in 
pathological neovascularisation in the eye (Marneros et al., 2005). The RPE is the 
main site of VEGF production in the posterior segment (Marneros et al., 2005), with 
secretion being necessary for the homeostasis of the extra-cellular space close to the 
Bruch’s  membrane,  and  modulation  of  endothelial  cell  fenestrations  in  the 
choriocapillaris (Roberts and Palade, 1995, Maminishkis et al., 2006). 
 
PEDF is a member of the Serpin family of proteins with anti-angiogenic and neuro-
protective  actions,  (Tombran-Tink  et  al.,  1995).  It  is  produced  by  RPE  cells  but 
unlike  VEGF,  PEDF  is  predominantly  secreted  from  the  apical  side  which  is 
essential  for  preserving  an  anti-angiogenic  environment  in  the  outer  retina 
(Maminishkis et al., 2006). 
 
Previous work using cultured human fetal RPE (hfRPE cells) in vitro, suggested that 
a fine balance in the production and secretion of both VEGF and PEDF is essential 
for  RPE  cells  to  maintain  their  functionality  (Sonoda  et  al.,  2010).  Thus,  PEDF 
(either present in culture media or endogenously expressed from hfRPE cells) blocks 
the VEGF-derived disruption of trans-epithelial resistance (TER). Neutralisation of 
PEDF with an anti-PEDF antibody (added on the apical surface of cells for 1 h) leads 
to TER breakdown attributed to VEGF (Ablonczy et al., 2011). 
 
1.5 The RPE and the blood-retinal barrier 
 
Epithelial  cells  such  as  the  RPE  have  a  well-structured  junctional  complex  to 
establish  a  barrier  function.  This  complex  includes  tight  junctions,  adherens 
junctions, gap junctions and desmosomes (Denker and Nigam, 1998, Meyer et al., 
2002). The major role of the tight junctions is to enable the RPE to regulate fluid 
flow  between  the  neuroretina  and  the  choriocapillaris  (Turowski  et  al.,  2004, 	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Rizzolo, 2014). The complexity of barrier function is exemplified by the fact that 
tight  junctions  involve  the  participation  of  approximately  40  different  proteins 
including claudins, Zonula occludens-1 (ZO-1) and occludin (Gonzalez-Mariscal et 
al., 2003). Upon formation of the tight junctions, RPE cells are induced to express 
various essential molecules including glucose transporters, which are necessary for 
trans-epithelial glucose transport (Ban and Rizzolo, 2000).   
 
The formation of fully structured tight junctions requires the association of three key 
different families of membrane proteins: occludins, claudins and zonula occludens 
(ZO) (Furuse et al., 1993, Jin et al., 2002). More importantly, ZO proteins have been 
identified as the backbone of tight junctions, with ZO-1 protein being described as 
the regulator of the degree of tightness of tight junctions (Mitic and Anderson, 1998, 
Wang et al., 2014). Cloning and sequencing of ZO proteins, demonstrated that they 
have three distinct PDZ domains, located on their N-termini, via which they can bind 
directly  to  the  C-termini  of  claudins  (Itoh  et  al.,  1993,  Itoh  et  al.,  1999).  This 
observation led to the hypothesis that ZO proteins could be the possible regulators of 
polymerisation of claudins at the site of tight junction formation in epithelial cells 
(Itoh et al., 1999). Knowing that the RPE is a claudin-19 dominant epithelium and 
that ZO-1 is an essential regulator of the tight junctional architecture, particularly 
close attention has been paid to these two junctional proteins in studies of RPE cell 
biology (Peng et al., 2011, Mitic and Anderson, 1998). 
 
1.5.1 Zona Occludens-1, ZO-1 
ZO-1, -2 and -3 are all members of the zonula occludens family of intracellular 
plaque proteins which have the capacity to interact with various barrier-forming, 
signaling  and  structural  proteins,  all  being  part  of  the  tight  junctional  complex 
(Fanning et al., 2012). ZO-1, with a molecular mass of approximately 220 kDa, has 
the ability to directly interact with, via its Src homology 3 (SH3) domain, the ZO-1-
associated nucleic acid binding protein (ZONAB) transcription factor, that regulates 
cell  proliferation  in  epithelial  cells  (Balda  et  al.,  2003,  Balda  and  Matter,  2000, 
Stevenson et al., 1986). The more polarised epithelial cells become the more ZO-1 
becomes  enriched  at  junctions  and  therefore,  via  ZONAB,  cell  proliferation  is 
arrested (Balda et al., 2003). Loss of ZO-1 leads to a delay in junction assembly as 	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was shown in polarised ZO-1
-/- mouse epithelial cells (Umeda et al., 2004).  
 
The ability of confluent ZO-1
-/- mouse epithelial cells to form tight junctions was 
monitored once these cells were transferred back to normal Ca
2+ medium (they were 
initially cultured in low Ca
2+ medium containing 5µM Ca
2+). ZO-1 deficient cells 
even after 10 h of incubation in the normal Ca
2+ medium demonstrated retarded 
recruitment of occludins and claudins, causing delays in tight junction assembly. 
This retardation in tight junction formation was completely rescued by exogenous 
expression  of  ZO-1,  indicating  the  necessity  of  ZO-1  in  the  formation  of  tight 
junctions (Umeda et al., 2004). 
 
1.5.2 Claudin-19 
 
Currently 24 different claudin proteins have been characterised, each of which is 
believed to exert a unique influence on the selectivity and permeability of epithelial 
tight junctions (Peng et al., 2011). The claudins form a family of transmembrane 
proteins which function as either heterodimers or oligomers in epithelial cells (Peng 
et al., 2011).  
 
Claudin-19 is encoded by the CLDN19 gene and it has been found to be expressed at 
high levels in the kidney and the eye (Konrad et al., 2006). Claudin-19 is a necessary 
component of tight junctions in human RPE cells and in kidneys since individuals 
lacking its expression suffer from severe visual impairment and from a condition 
known as familial hypomagnesemia with hypercalciuria and nephrocalcinosis, which 
is a tubular disorder accompanied by excessive renal magnesium and Ca
2+ excretion 
and chronic kidney failure (Konrad et al., 2006, Hou and Goodenough, 2010). These 
observations  suggest  a  significant  role  for  claudin-19  in  paracellular  ion  re-
absorption in the kidney and in the normal development of the retina, respectively 
(Konrad et al., 2006, Hou and Goodenough, 2010).   
 
Further  research  indicated  the  necessity  of  claudin-19  in  the  assembly  of  tight 
junctions  (Miyamoto  et  al.,  2005).  Examination  of  Schwann  cells  isolated  from 
claudin-19-deficient mice showed that formation of tight junctions was arrested. This 
arrest was associated with claudin-19 deficiency and therefore it was hypothesised 
that claudin-19 is a crucial component of the tight junctions, via which Schwann 	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cells can perform their electrophysiological sealing function (Miyamoto et al., 2005). 
 
1.6 RPE models of retinal disease 
Despite the wealth of information about RPE and retinal diseases, which has been 
obtained from in vivo studies in mouse models, there are limitations within such 
models  including  limited  availability  of  tissue,  differences  between  mouse  and 
human  and  long  delivery  times  which  can  affect  quality  of  the  tissue  and  high 
variability amongst samples. This has led to the use of in vitro cultures of isolated 
RPE cells from different species as an alternative strategy (Maminishkis et al., 2006). 
However, it should be noted that in vitro models also have their limitations and in 
some  cases  mammalian  RPE  cell  cultures  fail  to  maintain  key  phenotypic 
characteristics such as polarity, pigmentation and phagocytic ability (Turowski et al., 
2004).  
 
1.7 RPE cell lines as tools for studying retinal physiology 
A number of different cell culture models have been used in the past in order to 
examine RPE functionality in vitro, however every cell model has been demonstrated 
to have its advantages and limitations at the same time. 
 
1.7.1 Human fetal RPE 
Human fetal RPE cells (hfRPE) have been repeatedly used to unravel the molecular 
mechanisms  of  various  RPE-related  diseases.  hfRPE  cells  can  rapidly  re-develop 
pigmentation  once  they  are  cultured  in vitro,  they  can  form  well-organised  RPE 
monolayers,  with  apical  microvilli,  express  key  proteins  essential  for  RPE 
functionality and can retain their polarity with regards to the polarised expression of 
ion  channels  and  transporters  (Adijanto  et  al.,  2012,  Strunnikova  et  al.,  2010, 
Maminishkis et al., 2006, Flannery et al., 1990, Castorino et al., 2011). In addition, 
they  maintain  their  phagocytic  activity,  metabolise  retinol,  produce  and  secrete 
grown factors in a polarised fashion and they have the capacity to form strong tight 
junctions (Castorino et al., 2011, Flannery et al., 1990). 
 
Although  hfRPE  cells  represent  an  excellent  RPE  cell  culture  model,  they  have 
limitations. hfRPE cells are usually obtained in low numbers and they require several 
weeks of in vitro culture until they can reach a confluent state (Burke, 2008, Adijanto 	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et  al.,  2012).  Also,  hfRPE  cells  have  to  be  seeded  at  a  high  density  as  cell-cell 
contact is crucial in order to control their ability to proliferate. Finally, hfRPE cells 
have a very limited number of divisions and therefore they can only be used until 
passage 2 as usually after that they tend to lose their capacity to re-differentiate 
(Burke, 2008). 
 
1.7.2 ARPE-19 
 
Although hfRPE cells form authentic RPE monolayers in vivo ARPE-19 cells are the 
most widely used in vitro model, as they can be manipulated to resemble diseased or 
aged  RPE.  ARPE-19  cells,  which  are  an  immortalised  human  cell  line,  are 
commercially available, very easy to maintain, and provide an unlimited number of 
cells (Ablonczy et al., 2011, Maminishkis et al., 2006, Dunn et al., 1996). 
 
However,  ARPE-19  cells  have  limitations  as  a  model  for  RPE  function  in vitro. 
These cells are normally non-pigmented though they can regain melanosomes after 
many weeks of in vitro cell culture, they have variable cell shape (not hexagonal), 
they demonstrate low expression of RPE maturation markers such as RPE65 and 
they  have  relatively  poor  phagocytic  capacity,  most  likely  due  to  low  level  of 
expression of key regulators such as the aνβ5 integrin and MerTK (Ablonczy et al., 
2011). 
 
1.7.3 Primary porcine RPE cells 
 
Primary  porcine  cells  are  an  excellent  model  for  the  in  vitro  study  of  RPE 
functionality as not only do they retain their pigmented phenotype but they also keep 
their hexagonal shape. In addition, they quickly develop tight junctions and establish 
a  tight  monolayer  soon  after  plating.  On  the  other  hand,  their  isolation  is  time-
consuming,  they  are  generally  obtained  in  small  numbers  and  they  have  limited 
replicative potential which means they should be used before cell passage three. 
 
1.7.4 Human-induced pluripotent stem cell-derived RPE cells 
Human-induced pluripotent stem cell (hiPSC)-derived progenitors are increasing in 
popularity as they afford a means of obtaining many copies of progenitor cells which 
have a particular desired genetic profile as they originate from living patients (Gamm 
and Meyer, 2010). In the case of hiPSC-derived RPE cells, a large number of RPE 	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cells with a specific genetic profile linked to the retinal disease of interest could be 
obtained  and  maintained  in  vitro  (Park  et  al.,  2008).  hiPSC  from  patients  and 
generation  of  RPE  cells  allows  the  investigation  of  the  cellular  and  molecular 
mechanisms of a given disease without the need to genetically manipulate the RPE 
cells. Moreover, hiPSC-derived RPE cells maintain an authentic RPE phenotype in 
vitro (Kokkinaki et al., 2011). 
 
Although  hiPSC-derived  RPE  cells  could  be  a  very  promising  tool  for  the 
investigation of several retinal conditions, the process of obtaining RPE cells from 
their progenitors is very long, expensive and all clones need to be screened before 
they can be used for any in vitro studies, in order to ensure that they have retained 
the desired genetic profile (Krohne et al., 2012). 
 
1.7.5 RPE-J cell line 
RPE-J  cells  are  rat  RPE  cells  which  have  been  transfected  with  a  temperature-
sensitive mutant of the viral SV40 large T antigen. Transfection of these cells can 
only happen at a permissive temperature (33 
oC) (Chou, 1989). At 33 
oC RPE-J cells 
can be maintained indefinitely as an immortalised proliferative cell line, but upon 
transition  to  the  non-permissive  temperature  (40
oC)  they  become  highly 
differentiated and acquire their RPE phenotype (Jat and Sharp, 1989). 
 
RPE-J  cells  develop  strong  tight  junctions,  as  indicated  by  ZO-1  staining  and 
acquired TER values, they have good polarity with long apical microvilli and pre-
melanosomes accumulated towards their apical side (Nabi et al., 1993). Although 
RPE-Js become polarised, they demonstrate altered polarity of two essential proteins: 
the Na
+/K
+-ATPase ion pump and the N-CAM, which in vivo are exclusively located 
on the apical side of RPE (Nabi et al., 1993).  
 
The use of RPE-Js overcomes the dependence of experiments on primary RPE cells, 
however the process of culturing RPE-J cells with good epithelial properties requires 
several  rounds  of  cloning  and  selection,  as  well  as  dedicated  incubators  at  the 
restrictive and permissive temperatures. Also, that fact that key proteins might lose 
their polarised expression in vitro might indicate that these cells could lose some of 
their  RPE  characteristics.  Also,  taking  into  account  possible  differences  between 	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species, ARPE-19, hfRPE, hiPSC-derived RPE and porcine RPE cells could be more 
appropriate models than RPE-Js depending on the molecular events and biochemical 
pathways under investigation. 
 
1.8 Diseases of the RPE 
As previously mentioned the RPE performs a number of specialised functions, all 
necessary  for  the  maintenance  of  a  healthy  neural  retina.  Gene  mutations  and/or 
disturbance of the RPE monolayer can lead to a number of hereditary retinopathies 
such  as  Leber’s  congenital  amaurosis  (LCA),  Best’s  disease,  retinitis  pigmentosa 
(RP),  choroideraemia  and  age-related  macular  degeneration  (AMD),  all  of  which 
have in common a dysfunctional and/or disrupted RPE monolayer (Musarella and 
Macdonald, 2011, Koirala et al., 2013, Bonilha, 2008, Triantafylla et al., 2014, Black 
et al., 2014). 
 
1.9 Age-related macular degeneration (AMD): 
AMD is the leading cause of blindness (in industrialised nations), in people aged 
over  65.  As  AMD  progresses  the  central  part  of  the  retina,  called  the  macula, 
degenerates (Figure 4). The macula is a particularly important part of the retina as it 
is essential for fine detail and image resolution. In other words, a decline in central 
vision, due to progressive AMD, prevents individuals from recognising objects and 
performing everyday activities. The rate of AMD progression is variable between 
individuals (Klein et al., 2010) in that it can either progress slowly so that patients 
notice little change in their vision or progress rapidly which in turn may lead to 
severe vision loss in just a few years.  
 
Figure 4. Demonstration of a healthy macula and of a wet AMD-affected macula. Color fundus 
photograph of a normal human retina (left) and of a wet AMD-affected human retina (right), where a 
large fibrovascular scar covers the macular region (black arrow, right). Sourced and adapted from 
www.eyesite.org. 	 ﾠ 31	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1.10 Two forms of AMD 
There are two main forms of AMD (Figure 5) which describe its clinical progression. 
The early form is known as ‘atrophic’ AMD (also known as non-exudative) and the 
more  severe  form  which  arises  at  a  later  stage  in  a  minority  of  patients  is 
‘neovascular’ AMD (also known as exudative) (Anderson et al., 2002). Atrophic 
AMD generally progresses slowly and is mainly characterized by the formation of 
yellow  extracellular  insoluble  lipoproteinaceous  deposits,  between  the  RPE  and 
Bruch’s membrane, termed drusen (Anderson et al., 2002). Enhanced development 
of  drusen  formation  is  associated  with  the  later  stage  of  atrophic  AMD  called 
geographic atrophy (GA), where blind spots develop within the macula due to areas 
of  RPE  cell  loss  and  the  death  of  overlying  photoreceptors  (Klein  et  al.,  2008). 
Despite the fact that the exact mechanism of drusen formation is not fully understood 
previous  research  has  demonstrated  that  these  deposits  are  rich  in  a  number  of 
inflammatory proteins such as apolipoprotein E, amyloid P component, vitronectin 
and various complement proteins (e.g. C3b, C5 and C5b-9) (Anderson et al., 2002). 
Although there is no treatment available for the atrophic form, patients are given 
dietary supplements rich in antioxidants and zinc in an attempt to slow down the 
condition (Klein et al., 2008). 
 
In  contrast  to  the  atrophic  form  of  AMD,  the  neovascular  type  is  more  severe. 
Neovascular AMD, which occurs on a background of the atrophic form, accounts for 
approximately 10 % - 15 % of AMD and progresses rapidly (Guyer et al., 1986). 
There is evidence that unregulated RPE-driven VEGF production leads to choroidal 
neovascularisation  (CNV),  where  new  blood  vessels  start  to  emerge  from  the 
choroid, develop through Bruch’s membrane and finally extend into the sub-retinal 
space where they may leak and haemorrhage (Lopez et al., 1996, Green and Enger, 
2005).  	 ﾠ 32	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Figure 5. Comparison of the normal macula with a neovascular and an atrophic macula. (A) 
Schematic representation of the anatomy of a human eye, where the macula, the central part of the 
retina, is located at the back of the eye. (B) Comparison of a normal retina to an AMD-affected retina. 
In neovascular AMD blood vessels emerge from the choroid, expand through Bruch’s membrane and 
finally extend into the sub-retinal space where they may induce haemorrhage. In atrophic AMD, a less 
severe form of AMD, yellow lipoproteinaceous deposits (drusen) develop between bruch’s membrane 
and the RPE. Drusen might lead to apoptosis of the RPE and therefore compromise vision. Sourced 
and adapted from www.vision-and-eye-health.com. 
 
 
1.11 AMD and the RPE 
 
Age-related modifications of the RPE include a reduction in pigmentation (decrease 
in melanosomes), diminished cell density, decreased metabolic activity and enhanced 
secretion of pro-inflammatory cytokines (such as interleukin-6 and -8) (Mullins et 
al., 2000, Lueck et al., 2011). These changes are believed to be partly attributable to 	 ﾠ 33	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the accumulative effects of oxidative stress.  
 
1.12 Oxidative stress in AMD-affected RPE cells 
 
The production of reactive oxygen species (ROS) in the RPE could stem from the 
phagocytosis of POS (RPE cells are known for their high phagocytic activity), the 
high oxygen consumption and the absorbance of scattered light (Tate et al., 1995, 
Sripathi  et  al.,  2011).  The  inability  of  aged  RPE  cells  to  metabolise  the  ROS, 
produced from the above RPE functions, could result in ROS accumulation, which in 
turn  can  lead  to  oxidative  stress  and  therefore  RPE  cell  damage.  This  RPE 
degeneration has been shown to contribute towards AMD development (Sripathi et 
al., 2011).  
 
Elevated oxidative stress leads to intracellular accumulation of lipofuscin, which is a 
non-degradable  heterogeneous  mixture  of  proteins  and  insoluble  lipids  that 
accumulate over the years within the RPE (Sparrow et al., 2010). Lipofuscin in the 
presence of light is able to induce further ROS formation which impairs several of 
the  main  functions  of  the  RPE,  including  phagocytosis  of  POS  and  lysosomal 
degradation  (Holz  et  al.,  1999).  In  addition  to  lipofuscin,  aged-RPE  accumulate 
advanced  glycation  end-products  (AGEs)  which  can  also  be  found  in  drusen 
(Ishibashi et al., 1998). Once AGEs interact with their receptor (RAGE), which is 
expressed on RPE cells, in advanced AMD, the nuclear factor kappa B (NF-kB) is 
activated (Howes et al., 2004). Activation of this pro-inflammatory regulator may 
lead to the up-regulation of interleukin-6 (IL-6). IL-6 over-expression by RPE cells 
may in turn contribute to the development of CNV in neovascular AMD by autocrine 
stimulation of VEGF (Oskolkova et al., 2008, Paimela et al., 2007).  
 
Furthermore, elevated intracellular levels of ROS can induce mitochondrial damage 
such  as  structural  alterations  in  the  mitochondrial  membranes  and  mitochondrial 
DNA (mtDNA) damage resulting in insufficient ATP production. All these events 
can further enhance the accumulation of ROS and eventually lead to cell apoptosis 
(Tilleul et al., 2013, Wang et al., 2007). 
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1.13 Mitochondrial damage in AMD-affected RPE cells 
Mitochondria are the main source of energy in eukaryotic cells, and as RPE cells are 
highly metabolically active their cytoplasm contains a large number of mitochondria 
(Jarrett  et  al.,  2008).  The  inner  and  outer  mitochondrial  membranes  consist  of 
phospholipid  bilayers  with  various  integrated  proteins.  The  inner  membrane  is 
organized into cristae, which provide the surface area sufficient for ATP production 
(Jarrett  et  al.,  2008).  In  addition  to  supplying  cellular  energy,  mitochondria  are 
involved in a range of other processes, such as signalling, cell differentiation, cell 
death and control of the cell cycle (Nordgaard et al., 2008, Folmes et al., 2012). 
Mitochondria account for the mass production of ROS since approximately 90 % of 
the oxygen used by the cells is metabolised within these organelles via the electron 
transport  chain  (ETC)  (Van  Remmen  and  Richardson,  2001).  This  mitochondria-
specific ROS production is the result of oxidative phosphorylation during which, 
mitochondria transfer electrons from nicotinamide adenine dinucleotide (NADH) to 
electron transporters so as to produce ATP (Van Remmen and Richardson, 2001). 
In the event of electron leakage during this process O2
- can accumulate which in turn 
can affect the integrity of mitochondrial lipids, proteins and mtDNA (Brand et al., 
2004). Previous research has demonstrated the onset of mitochondrial dysfunction in 
AMD cases, where the matrix density and the overall number of mitochondria within 
RPE have been greatly reduced (Feher et al., 2006).  
Furthermore,  oxidative  stress-induced  mtDNA  damage  has  previously  been 
suggested to be one of the pathogenic mechanisms in AMD (Blasiak and Szaflik, 
2011). mtDNA (approximately 16.5 kb) is organised into a specific structure, termed 
the  nucleoid,  which contains various maintenance and repair proteins such as DNA 
polymerase γ (Wang and Bogenhagen, 2006). mtDNA is especially vulnerable to 
oxidative damage  because it lacks a number of histone and non-histone proteins and 
is an active site of ROS production (Wei, 1998). According to the mitochondrial 
theory of ageing, the co-localisation of ROS with the ETC during an organism’s 
lifespan plays a fundamental role in mitochondrial dysfunction due to damage of the 
mtDNA (Miquel et al., 1980, Liang and Godley, 2003). This damage can include 
point mutations, deletions and rearrangements in mtDNA which may play a role 
retinal disease (Liang and Godley, 2003). 	 ﾠ 35	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At this point it should be noted that in addition to ROS there are additional factors 
which increase oxidative stress in mitochondria including cigarette smoke, blue light 
and phagocytosis of photoreceptor outer segments (Figure 6) (Jarrett et al., 2008). 
All of these factors have the potential to challenge the integrity of mtDNA (increase 
mutagenesis),  which  is  particularly  vulnerable  since  mitochondrial  repair 
mechanisms are believed to be less effective than nuclear DNA (nDNA) mechanisms 
(Yakes and Van Houten, 1997, Jin et al., 2001). 
 
 
	 ﾠ  
Figure 6. mtDNA damage and retinal degeneration. Once a certain threshold of mtDNA instability 
is breached, energy production levels drop in mitochondria and therefore cell functionality is impaired 
and mitochondria initiate apoptosis. This event will eventually contribute to the initiation of retinal 
degeneration. Sourced and adapted from (Jarrett et al., 2008).   
 
 
 
1.14 The complement system 
 
The complement system is part of the innate immune system consisting of more than 
30 different proteins, which are present in blood plasma and on various cell surfaces 
(Krarup et al., 2008). The complement system not only provides immune defence by 
eliminating foreign particles and microorganisms but also plays a homeostatic role 
by regulating the degradation of damaged host cells such as apoptotic and necrotic 
cells (Krarup et al., 2008).  
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other cell types have been found to contribute to complement protein production 
including: endothelial, epithelial, and kidney cells (Morgan and Gasque, 1997). For 
instance it has previously been shown that apart from liver C2, C4 and factor B are 
produced in significant amounts in the human kidney as well (Feucht et al., 1989, 
Welch et al., 1996, Welch et al., 1993). However, circulation is not the only source 
of complement proteins. RT-PCR studies in the RPE/choroid (derived from C57BL/6 
mice)  demonstrated  that  specific  components  of  the  complement  system  can  be 
produced  locally  in  the  retinal  environment  (Luo  et  al.,  2011).  The  components 
identified by RT-PCR were: C1q, C1s, C1r, C2, C3, CFH and CFB, of which C3, 
upon  cytokine  treatment  (interferon-γ),  was  up-regulated  while,  CFH  was  down-
regulated (Luo et al., 2011). This finding, in combination with other studies could 
imply the significance of CFH to modulate local inflammation in the retina. In fact, it 
was previously reported that CFH expression levels in the retina were similar to CFH 
expression levels in the liver (Hageman et al., 2005). Several sequence variations in 
the CFH gene can lead to the onset of atypical hemolytic uremic syndrome and 
glomerulonephritis, both of them leading to kidney malfunction (Abrera-Abeleda et 
al.,  2006,  Remuzzi  et  al.,  2002).  There  have  been  cases  were  individuals  with 
atypical hemolytic uremic syndrome suffered from severe renal failure, indicating 
that  mutated  CFH  protein  levels  can  have  an  effect  on  retinal  health  as  well 
(Remuzzi et al., 2002). Whether these amounts were stemming from circulation or 
produced  locally  in  the  retina  remained  to  be  addressed.  Recently,  it  has  been 
demonstrated that patients receiving a liver transplant for 5 years or more, develop 
AMD (Khandhadia et al., 2013). However, Khandhadia et al., 2013 reported that 
AMD development in liver transplant patients is only associated with recipient rather 
than donor amounts of CFH conferring the Y402H mutation. That said, presence of 
AMD does not depend on the hepatic expression of CFH but it depends on its local 
intraocular expression instead (Khandhadia et al., 2013).  
 
 
1.15 Three activation pathways of the complement system 
 
Three distinct pathways are able to activate the complement system: the classical, 
alternative  and  the  lectin  pathway  (see  Figure  7).  Also,  recently  the  coagulation 
system has been demonstrated to activate complement independently of the afore-
mentioned  pathways  (Huber-Lang  et  al.,  2006).  Every  pathway  has  its  unique 	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mechanism  to  trigger  its  activation  but  all  lead  to  the  turnover,  by  enhanced 
enzymatic cleavage, of the most abundant complement protein, C3 into C3a and C3b 
(Kemper et al., 2008). C3b by attaching to target cell membranes tags the cell for 
either lysis by the assembly of lytic pores on the cell surface or for phagocytosis by 
immune cells (Kemper et al., 2008). In the case of target lysis the whole of the 
cascade  must  be  activated.  Target  lysis  is  achieved  through  the  assembly  of 
membrane attack complex (MAC). MAC assembly begins with the cleavage of C5 
molecules into C5a and C5b via C5 convertase. Then, C5b is associated with C6, C7, 
C8, and C9 complement proteins, to assemble the C5b-7, C5b-8, and finally MAC, 
C5b-9 complexes (Rus et al., 1996). 
  
 
Figure  7.  The  activation  pathways  of  the  complement  system.  Each  of  the  three  pathways 
(classical, lectin and alternative) leads to the formation of the terminal membrane attack complex. 
MASPs, MBL-associated serine proteases; MBL, mannan-binding lectin; CFH, complement factor H; 
CFI, complement factor I; SC5b-9, soluble C5b-9. 
 
1.16 The classical pathway 
 
The classical pathway is initiated by the activation of the C1 complex, which is 
constituted of C1q protein and the two proteases C1r and C1s (Dodds et al., 1978). 
C1q recognises antibody-antigen aggregates and upon binding it activates the C1r 	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protease, which in turn cleaves and activates the two C1s molecules to form the 
active C1s serine protease (Dodds et al., 1978). This C1s molecule is able to cleave 
the C4 and C2 complement components in order to form the C3 convertase (C4b2a) 
which then cleaves soluble C3 protein into C3a and C3b. The C3b molecule plays an 
essential  role  within  the  complement  cascade.  It  is  an  opsonin  that  marks  either 
foreign  particles  or  apoptotic  cells  to  be  phagocytosed.  Free  C3b  molecules  will 
either  bind  to  target  cells  or  to  C4b  to  form  the  C5  convertase  (C4b3b2a).  C5 
convertase  will  then  cleave  soluble  C5  protein  into  C5a  and  C5b  and  the  latter 
molecule may eventually drive MAC formation (Figure 8) (Wallis et al., 2010). 
 
During activation of the classical pathway C3b production may be amplified through 
the  alternative  pathway  due  to  the  formation  of  a  C3b-Factor  B  (CFB)  complex 
(Farries et al., 1988). Once this complex is formed, an additional factor, Factor D 
(CFD),  will  contribute  to  the  formation  of  another  C3  convertase,  C3bBb,  by 
processing (cleavage) any C3Bb complexes. This amplification step can lead to the 
clustering  of  multiple  C3b  molecules  on  a  target  cell  surface  and  therefore  will 
enhance the opsonisation of the pathogen for phagocytic cells (Farries et al., 1988). 
 
The classical pathway apart from its role in host defence could be involved in the 
pathogenesis of glaucoma, as immunohistochemical analysis of the glaucomatous 
retinas  of  mouse,  monkey  and  humans,  showed  that  C1q  was  significantly  up-
regulated (Stasi et al., 2006). This C1q up-regulation preceded the extensive death of 
retina ganglion cells (RGC), suggesting that the classical pathway could be directly 
associated with RGC degeneration in glaucoma (Ding et al., 2012, Stasi et al., 2006). 
Further research has demonstrated that C1q might be involved in the clearance of 
apoptotic cells from the retina. Thus, C1q was found to be gradually up-regulated in 
the retinas of mice lacking the rhodopsin gene (a model of RP) (Humphries et al., 
2012). As the degeneration progressed, these higher levels of C1q in Rho
-/- mice 
could  have  been  part  of  a  defence  mechanism  that  favoured  the  clearance  of 
apoptotic cells. Additionally, when C1q was eliminated in Rho
-/-C1q
-/- mouse retinas, 
the viability and functionality of cone photoreceptors became severely compromised 
(Humphries et al., 2012). Further investigation of inflamed retinas (mice and human) 
identified the accumulation of C1q within ocular tissues adjacent to inflammatory 
sites  (Murinello  et  al.,  2014,  Montalvo  et  al.,  2007).  In  particular, 	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immunofluorescence  analysis  of  human  retinas  derived  from  patients  with  early 
AMD, demonstrated the presence of C1q in the choriocapillaris but not in drusen 
deposits (Murinello et al., 2014). 
 
 
Figure 8. Mechanism through which classical pathway activation leads to cell lysis. When C1q 
(member of the C1q complex) binds to specific targets on a cell surface, C1s and C1r are activated. 
Then C1s contributes to the formation of C3 convertase (C4b2a) by cleaving C2 and C4 complement 
proteins.  C3  convertase  creates  C3b  (by  cleaving  C3),  which  in  turn  helps  the  assembly  of  C5 
convertase. This convertase will finally cleave C5 to C5b, which will lead to the formation of the final 
complement complex (Carroll and Sim, 2011). 
 
 
 
1.17 The lectin pathway 
The lectin pathway is characterised by lower levels of activation than the classical 
pathway as its key protein mediators, L-, H-, and M-ficolins, mannan-binding lectin 
(MBL) and collectin, are found at lower levels in the blood compared to C1q. These 
mediators  identify  pathogen-associated  molecular  patterns  (PAMPs)  such  as 
polysaccharides on the surface of pathogens (Krarup et al., 2008). Lectin pathway 
activation entails cleavage of MBL and ficolins by specific serine proteases termed: 
MBL-associated serine proteases (MASPs). These proteases form complexes with 
MBL or ficolins and once they bind to a cell surface, MASPs are auto-activated with 
the exception of MASP-3 (Zundel et al., 2004). Although much of the functionality 
of MASPs remains to be elucidated, it has been shown that the lectin pathway uses 
the same protein cascade to activate the complement system as the classical pathway, 
by forming the same C3 convertase C4b2a (Thiel et al., 1997).  
 
1.18 The alternative pathway  
As  reviewed  by  (Thurman  and  Holers,  2006)  one  unique  characteristic  that 	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distinguishes the alternative pathway from the classical one, is that the alternative 
pathway is continuously activated (at low levels) as it depends on the constantly low 
levels of C3 hydrolysis in plasma to C3(H2O) which is similar to the C3b molecule 
in  terms  of  structure  and  functionality.  C3(H2O)  is  able  to  form,  in  a  Mg
2+-
dependent-manner, a complex with CFB which in turn is cleaved by CFD, leading to 
the  formation  of  the  fluid  phase  C3  convertase:  C3(H2O)Bb.  This  C3(H2O)Bb 
protein complex, which is the equivalent of the classical pathway C3 convertase, 
cleaves C3 into C3a and C3b (as shown in Figure 9). These C3b molecules can be 
deposited on any available cell surface.  
 
Additionally, CFB is able to bind to the previously produced C3b molecules and be 
cleaved by CFD to form an additional (but this time surface-bound) C3 convertase of 
the alternative pathway termed C3bBb.  That way, the production of C3b molecules 
is enhanced and therefore leads to the so-called amplification loop of the alternative 
pathway.  
 
 
Figure 9. Mechanism of alternative pathway activation. During the alternative pathway activation 
two different forms of C3 convertases can be formed: the fluid phase C3 and the surface-bound one. 
Upon  formation  of  the  surface-bound  C3  convertase,  properdin  (P)  stabilises  this  convertase, 
maintaining the amplification loop. Cleaved C3 molecules (C3b) will contribute to the formation of 
C5 convertase (Carroll and Sim, 2011). 
 
 
 
 
 
 
 
 
1.19 Regulators of the alternative pathway – Complement factor H 
 
In order for the alternative pathway to be able to discriminate between host and 
pathogens it uses three major recognition proteins: Complement factor H (CFH), 
properdin and C3b (Pangburn et al., 2000). 
 
CFH is a large soluble glycoprotein which is capable of interacting with molecular 	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patterns on host cell surfaces, which can either be polyanionic and/or membrane-
bound  C3b  molecules  (Jokiranta  et  al.,  1996).  These  interactions  allow  CFH  to 
suppress  activation  of  the  alternative  pathway  on  host  surfaces  (Pangburn  et  al., 
2000). In cases where any of the three C3b binding sites, located at the N-terminus of 
CFH, are mutated surface-bound C3b molecules start to aggregate and therefore they 
lead to enhanced alternative pathway (AP) activation (Sharma and Pangburn, 1996). 
In more detail, Sharma et al., 1996 demonstrated that mutated forms of CFH lacking 
any of the three C3b binding sites, conferred a 6- to 8-fold reduction in the ability of 
CFH to bind C3b on sheep erythrocytes, indicating that all three sites contribute to 
the regulation of complement activation on erythrocytes. That way the development 
of complement-mediated pathology can take place because the complement system 
targets cell surfaces of host cells which lack protection from CFH (Pangburn et al., 
2000). 
 
1.20 Regulators of the alternative pathway – Properdin 
 
Properdin is a recently discovered pathogen recognition molecule. It has been shown 
to  recognise  bacteria  and  apoptotic  human  T-cells  and  promote  complement 
activation via the alternative pathway (Kemper et al., 2008, Spitzer et al., 2007). 
Overall, properdin is believed to promote the alternative pathway in three ways: by 
binding to and providing stability to the AP C3 convertase C3bBb, by binding to 
multiple  membrane-bound  C3b  molecules  which  enhances  the  production  of  the 
other  C3  convertases  (C3bBbP),  and  by  interacting  with  complement-activated 
surfaces independently of C3b (Spitzer et al., 2007). People lacking properdin are 
more prone to developing bacterial infections (meningococcal septicaemia has been 
reported) showing that it has an essential role in the innate immune system (Sjoholm 
et al., 1982). Although C3b is not classified as a recognition molecule, it has strong 
binding  preferences  towards  various  carbohydrates  and  for  specific  amino  acid 
hydroxyl groups localised on Threonine, Serine and Tyrosine residues of protein 
structures on cell surfaces (Sahu and Pangburn, 1995).  
 
1.21 The terminal complement complexes – Formation of C5b-7 
 
Once  attachment  of  C6  to  the  alpha-chain  of  C5b  takes  place,  C6  changes  its 
conformation which enables it to bind to the hydrophobic area of the lipid membrane 
bilayer  (formation  of  C5b-6)  (Rus  et  al.,  1996).  After  assembly  of  the  C5b-6 	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complex, soluble C7 can bind to the alpha-chain of C5b (part of the C5b-6 complex) 
and this interaction allows the C5b-7 complex to minimally span the lipid bilayer, 
stabilising the nascent terminal complement complex (TCC) on the cell surface (Hu 
et al., 1981).  
 
1.22 The terminal complement complexes – Formation of C5b-8 and C5b-9  
 
Upon formation of the C5b-7 complex, C8 binds to the beta-chain of C5b, in order to 
form  the  C5b-8  complex  (Stewart  et  al.,  1987).  Within  C5b-8,  the  C8αβγ 
heterotrimeric protein initiates the insertion event of the first C9 molecule via its 
alpha-chain, thus assembling the C5b-91 complex (Stewart et al., 1987). In contrast to 
C5b-9,  the  less  stable  C5b-8  is  less  capable  of  lysing  cells.  Thus  studies  have 
demonstrated that hemolysis of erythrocytes requires the assembly of multiple C5b-8 
complexes, because C5b-8 induces hemolysis at a slower rate than C5b-9 (Laine and 
Esser, 1989, Ramm et al., 1982). 
 
During the attachment of the first C9 molecule of the C5b-91 complex, C9 unfolds 
into  a  tubular  structure  so  as  to  allow  the  insertion  of  further  C9  monomers 
(approximately  16-18  molecules)  to  form  a  poly-C9  lytic  pore  (C5b-9n)  via  C9 
polymerisation  (Laine  and  Esser,  1989).  The  functional  diameter  of  a  C5b-9n 
complex ranges from 1nm to approximately 11nm, where the pore size is dependent 
on the number of attached C9 molecules (Ramm et al., 1985).  However, formation 
of a lytic pore is not always the final outcome of C5b-9 complex formation on the 
cell surface, with the exception of erythrocytes. Nucleated cells, including cases of 
RPE studies and K562 cells (erythroleukaemic cell line) have been shown to be more 
resistant towards complement-induced cell lysis (Anderson et al., 2002, Saar Ray et 
al., 2014).  
 
1.23 Membrane attack complex, C5b-9 
 
Activation of any of the three complement pathways leads to the formation of the 
final  multi-protein  complex  capable  of  inducing  cell  lysis  on  erythrocytes:  the 
membrane attack complex (MAC) or C5b-9 (Laine and Esser, 1989). Cleavage of C5 
triggers the chain reaction described above that leads to the assembly of the final 
complex C5b-9 (as shown in Figure 10) (Rus et al., 1996). C5b-9 refers to the trans-
membrane  pores,  on  the  cell  surface,  whose  assembly  requires  prior  sequential 	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formation of the rest of the TCC (Rus et al., 1996). Any soluble forms of the C5b-9 
complex tend to bind to vitronectin (also known as S-protein), leading to formation 
of the SC5b-9 complex (Podack and Muller-Eberhard, 1980). Vitronectin is a soluble 
plasma glycoprotein which acts as a negative regulator of the complement system by 
inhibiting MAC-induced cell lysis (Podack and Muller-Eberhard, 1979). 
 
Figure 10. Formation of the terminal membrane attack complex (MAC). Once C5 convertase 
forms, via activation of either of the three complement pathways, it cleaves C5 into C5a and C5b. C5b 
then binds to C6 and the C5b-6 complex is inserted in to the lipid bilayer of the cell membrane. 
Further binding of C7 and C8 will insert the newly formed C5b-8 complex deeper into the membrane. 
C8 acts as a binding site for the first C9 molecule, which in turn will attract more C9 molecules to 
form the multi-C9 sub-lytic pores (Tegla et al., 2011). 
 
 
 
1.24 The dual role of the C5b-9 complex 
 
Complement-mediated lysis is a ‘multi-hit’ process in which lysis of nucleated cells 
requires a large number of membrane-bound C5b-9 complexes (Koski et al., 1983). 
When there is limited complement present, C5b-9 can exert a protective effect on 
cells (Dashiell et al., 2000). Thus, these authors demonstrated that when complement 
C7 was added back to C7-depleted sera, a low level of C5b-9 complex formation 
promoted the proliferation of Schwann cells. Evidence suggests that the number of 
membrane-attached C5b-9 complexes determines whether the cellular response will 
be either lysis or survival and proliferation (Dashiell et al., 2000, Koski et al., 1983).   
 
 
1.25 C5b-9 complex-mediated cell lysis 
 
When C5b-9 complex formation increases, so that the rate of assembly exceeds the 
rate at which they can be removed from the cell surface, cell death is induced in 	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erythrocytes, regardless of cell-volume ratio (Koski et al., 1983). Originally it was 
believed  that  a  single  C5b-9  complex  was  able  to  lyse  an  erythrocyte  through 
osmosis (Rommel and Mayer, 1973). However, most cells (nucleate and anucleate) 
need the localisation of multiple C5b-9 complexes on their cell surfaces to become 
lysed via complement (Koski et al., 1983). C5b-9-mediated lysis is driven largely by 
an increase in intracellular Ca
2+ which in turn leads to mitochondrial dysfunction, 
which  in  turn  causes  loss  of  energy  production  (loss  of  ATP,  ADP  and  AMP) 
(Papadimitriou et al., 1991).  
 
 
1.26 Cell survival induced by C5b-9 
Sub-lytic quantities of C5b-9 are able to promote cell cycle activation via activation 
of signalling cascades, which inhibit apoptosis/necrosis (Figure 11) (Dashiell et al., 
2000). Research using various cell types (e.g. smooth muscle cells and Schwann 
cells), showed that cellular proliferation and protection from apoptosis is primarily 
based on signalling via heterotrimeric Gi proteins leading to downstream activation 
of phosphatidylinositol 3-kinase/Akt/FOXO1 (cell proliferation) and extracellular-
regulated kinase 1 (ERK1) (Niculescu et al., 1999, Dashiell et al., 2000). 
 
Additionally,  the  C5b-9  complex  stimulates  cellular  proliferation  by  sequentially 
activating the cyclin-dependent kinases (CDKs), CDK4 and CDK2, which are vital 
for the transition from G1 to the S-phase of the cell cycle (Niculescu et al., 1999). 
This cell cycle progression, as reported in rat oligodendrocytes and endothelial cells, 
is further supported by the activation (via phosphorylation) of the RGC-32 kinase by 
Akt, which in turn forms a complex with cyclin B1-CDC (Fosbrink et al., 2009, 
Badea et al., 1998).  
 
Evidence has also shown that sub-lytic doses of C5b-9 are able to prevent apoptosis 
by up-regulating FLIP, which leads to the inactivation of the pro-apoptotic proteins: 
Bad and caspase-8 (Cudrici et al., 2006). Taken together, these observations suggest 
that  low  level  exposure  to  C5b-9  complex  might  favour  cell  survival  and  tissue 
homeostasis. 
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Figure  11.  Signaling  from  the  C5b-9  complex  promotes  cell  proliferation  and  prevents 
apoptosis. Membrane-bound C5b-9 associates with membrane-bound Gi protein, activating Ras and 
Raf. Raf in turn, will activate MEK1 and ERK1. Additionally, C5b-9 activates PDK1 and AKT1 via 
PI3K. Activated PI3K up-regulates FLIP which inhibits activation of apoptosis-related caspase-8 and 
cleavage of Bid, while activated AKT1 prevents apoptosis by regulating FOXO and Bad. Sourced 
from Tegla et al., 2011.     
 
 
1.27 Complement regulators 
 
All three activation pathways of the complement system need to be tightly regulated 
to ensure that complement does not target healthy host cells. This can be achieved by 
both fluid-phase and membrane-bound regulatory proteins (Zipfel and Skerka, 2009) 
(full list of complement regulators is provided in Table 1). Currently, there are five 
known membrane-bound regulators: the C3b receptor (CD35), complement receptor 
of  the  immunoglobulin  superfamily  (CRIg),  membrane  cofactor  protein  (CD46), 
decay-accelerating factor  (DAF, also known as CD55) and CD59, also known as 
membrane inhibitor of reactive lysis (MIRL) (Pangburn et al., 2000). While all the 
above regulators inhibit C3/C5 convertases, only CD59 inhibits the terminal stage of 
C5b-9 formation by inhibiting the binding of C9 proteins to C5b-8 complex (Rollins 
and Sims, 1990). For this reason, many studies on C5b-9 complex formation include 
a step in which CD59 is blocked using an appropriate antibody. 
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1.28 Complement regulator CD59 
 
CD59  (also  known  as  protectin,  p18  and  MIRL)  is  structurally  related  to  the 
leukocyte antigen 6 (Ly-6) family of proteins (Davies et al., 1989) and its human 
gene is located on chromosome 11p13 (Meri et al., 1991). It is an 18-kDa membrane 
glycoprotein that controls the formation of the C5b-9 complex on autologous tissue 
(Tomlinson,  2006).  Thus,  CD59  located  on  the  cell  surface  of  host  cells,  via  its 
glycophosphatidyl inositol (GPI) anchor (Rudd et al., 1997), prevents the formation 
of the C5b-9 terminal complex by binding to the alpha-subunit of C8 in the C5b-8 
multi-protein  complex  and/or  to  the  C9b  fragment  of  the  final  C5b-9  complex, 
blocking the input of further C9 proteins (Tomlinson, 2006, Rollins and Sims, 1990, 
Davies et al., 1989). Due to its crucial role, CD59 has a very wide expression profile 
and has been found to be present on most circulating blood cells, endothelial and 
epithelial cells, and spermatozoa (Davies et al., 1989). Additionally, CD59 can be 
present in a soluble form (either through direct release from the cell surface or due to 
enzymatic cleavage of the GPI anchor) where it is found in body fluids including 
urine and amniotic fluid (Qin et al., 2005).  
 
CD59  serves  several  functions  in  addition  to  complement  regulation.  The 
identification of two forms of CD59 in the mouse has shown that this glycoprotein 
exerts  complement-dependent  (CD59a)  and  complement-independent  functions 
(CD59b) (Qin et al., 2005). Lack of CD59a (one of the two forms found in the 
mouse)  leads  to  haemolytic  anaemia,  in  which  mice  develop  a  mild  paroxysmal 
nocturnal haemoglobinuria (PNH)-like phenotype (Holt et al., 2001). A complement-
independent function of CD59b (the second form found in the mouse) was found in 
the  testis  where  studies  demonstrated  that  in  CD59b
-/-  mice,  sperm  viability  and 
morphology  were  compromised  (Qin  et  al.,  2005).  Although  this  phenotype  was 
related to the absence of CD59b, it developed in a complement-independent fashion 
as there was no evidence for increased accumulation of C5b-9 complex, and also 
removal of C3 did not inhibit CD59b
-/- mice from developing sperm abnormalities 
(Baalasubramanian et al., 2004). Other complement-independent activities of CD59 
include  signaling  events  within  B-,  T-  and  Natural  Killer  (NK)-cells, 
lipopolysaccharide (LPS) signaling and regulation of apoptosis (Sivasankar et al., 
2007, Korty et al., 1991, Yamamoto et al., 2003, Marcenaro et al., 2003, Donev et 	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al., 2006). 
 
The regulated expression of CD59 is of high importance since CD59 over-expression 
has been linked to tumour growth (Li et al., 2013). On the other hand its absence can 
lead  to  severe  haemolytic  anaemia  (Motoyama  et  al.,  1992).  It  is  possible  that 
exploring the multiple interactions between CD59 and its complement ligands will 
help  enable  the  development  of  CD59-dependent  therapeutics  for  treating 
inflammatory conditions such as PNH (Yamashina et al., 1990). 
 
1.29 Decay-accelerating factor 
Decay-accelerating  factor  (DAF),  also  known  as  CD55,  is  a  70-kDa 
glycophosphatidylinositol-anchored glycoprotein and is a member of the Regulators 
of Complement Activation (RCA) family of proteins (Nishikawa et al., 1998). As its 
name suggests, its primary role is to regulate the activity of C3 and C5 convertases 
(classical  and  alternative  pathway,  respectively),  by  accelerating  their  decay 
(Brodbeck et al., 2000). DAF is expressed by various cell types such as endothelial 
and epithelial cells (Post et al., 1990). DAF accelerates the decay of C3 convertases, 
C4b2a and C3bBb, by binding to C4b or C3b respectively (Medof et al., 1984). 
Individuals lacking DAF expression accumulate C3b molecules (as C3 convertase 
activity  is  not  regulated)  and  develop  PNH,  which  is  a  condition  that  leads  to 
intravascular hemolysis and platelet activation. This suggests a primary role for DAF 
in protecting host-cells from complement activation (Hillmen et al., 1992). 
 
1.30 Complement receptor 1-related protein/gene y 
Complement  receptor  1-related  protein/gene  y  (Crry)  is  a  key  regulator  of  the 
complement system expressed exclusively on rodent (mouse, rat) cell membranes but 
not in human (Caragine et al., 2002). Crry is the structural and functional analog of 
DAF and the membrane cofactor protein (MCP) negative regulators of complement 
system (Caragine et al., 2002). MCP protein in humans has been found to exert a 
critical role in inhibiting complement-induced tissue injury as it can be significantly 
up-regulated  in  a  number  of  diseases  such  as  glomerulonephritis,  ischemic  acute 
kidney injury and acute renal allograft rejection (Endoh et al., 1993, Miao et al., 
2014). Examination of Crry in rodents would help to elucidate the mechanisms of 
MCP action in humans (Miao et al., 2014). 	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Chronic kidney diseases have been correlated with deterioration of renal function due 
to  structural  damage  in  the  tubulointerstitium  (Schainuck  et  al.,  1970).  Blocked 
expression of Crry in rat mesangial cells via oligodeoxynucleotides (ODNs) led to 
enhanced complement-mediated cell lysis, while in vivo, Crry knockdown (ODN-
mediated) in rats suffering from proteinuria, led to the enhanced accumulation of the 
C5b-9 complex and C3 protein (Hori et al., 1999). This observation indicated the 
importance of Crry in restricting complement activation and therefore inhibiting cell 
damage (Hori et al., 1999). 
 
Further research re-confirmed the necessity for Crry expression on the basolateral 
surface of murine renal tubular epithelial cells (TECs) (Renner et al., 2010). Thus, 
exposure  of  the  basolateral  surface  of  TECs  (derived  from  Crry
-/-fB
-/-  mice)  to 
complement-component  serum  led  to  enhanced  complement  activation  compared 
with TECs from wild-type mice (Renner et al., 2010). 
 
1.31 Complement and AMD 
 
Research  has  demonstrated  the  association  of  multiple  risk  factors  with  AMD, 
including  family  history,  smoking,  age,  high  blood  pressure  and  inflammation. 
Specifically in recent years, genetic studies have revealed the role of the complement 
system in AMD (Smith et al., 2001) where polymorphisms in multiple complement 
genes either increase or decrease the risk of AMD development (Kunchithapautham 
et al., 2012). 
 
Indeed,  polymorphisms  in  complement  activators  such  as  CFB,  complement 
inhibitors (complement factor H, complement 1 inhibitor C1) and other proteins of 
the complement cascade (complement factors 2 and 3) have all been shown to be 
related to AMD (Table 2) (Gold et al., 2006, Kunchithapautham et al., 2012).  
 
The  first  genetic  evidence  for  the  complement  system  being  associated  with  the 
development of AMD was the discovery of the Y402H polymorphism in the CFH 
gene. This causes tyrosine to be substituted for histidine at amino acid position 402 
within the CFH protein and greatly increases the risk of AMD development (Haines 
et al., 2005, Hageman et al., 2005, Gold et al., 2006). Additionally, CFH is a member 	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of  the  RCA  gene  cluster  and  is  therefore  linked  with  other  genes  to  create  a 
haplotype  that  harbors  polymorphisms  that  determine  AMD  susceptibility.  For 
instance,  deletion  of  the  CFHR1  (Complement  Factor  H-related  1)  and  CFHR3 
members of the above gene cluster reduces the risk of AMD development (Hageman 
et al., 2006). 
 
AMD is a very complex genetic disease as other highly penetrant missense mutations 
have  recently  been  identified  in  other  loci,  which  may  increase  or  decrease 
susceptibility (van de Ven et al., 2013). Genotyping of multiple samples derived 
from AMD patients led to the recognition of rare missense variants that increase the 
risk of advanced AMD. Such variants are substitution of Lysine to Glutamine at 
position  155  (Lys155Gln)  in  the  C3  protein,  substitution  of  Proline  to  Serine  at 
position 167 (Pro167Ser) in C9, and substitution of Glycine to Arginine at position 
119 (Gly119Arg) in complement factor I (CFI). Further investigation of some of the 
above variants showed that the allele of C3 encoding Lys155Gln increased resistance 
to proteolytic inactivation by CFH and CFI (Seddon et al., 2013). Therefore, this loss 
of C3 protein regulation led to the enhanced activation of the alternative pathway 
(Seddon et al., 2013). With regards to the allele of CFI encoding Gly119Arg, it has 
been demonstrated that the Gly119Arg mutant protein is expressed to a lesser extent 
than the wild-type protein and therefore C3b degradation was less evident in the 
plasma and sera of AMD patients carrying that mutation (van de Ven et al., 2013). 
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1.32 Aims of the project 
A strong association between the complement system and AMD has been established 
as  mutations  in  genes  encoding  complement  inhibitors/activators  can  promote  or 
prevent  the  initiation  of  AMD.  Also,  it  has  been  shown  that  C5b-9  is  found  in 
samples  from  AMD  patients  (mainly  on  the  basal  surface  of  RPE  and/or  drusen 
deposits). Therefore, it was essential to develop optimal conditions for the in vitro 
formation of C5b-9 on the basal surface of RPE cells in order to investigate whether 
this complex would induce any physiological changes to the RPE monolayer. 
 
By determining which cell culture model is the most appropriate for our studies, it 
was  desirable  to  investigate  not  only  the  elimination/formation  rate  of  C5b-9 
complex on the basal surface of RPE cells but also to examine the mechanism/s of its 
elimination. The next milestone of the project was to examine whether C5b-9 can 
induce  any  changes  in  the  characteristics  of  RPE  cells  such  as:  TER,  actin 
cytoskeleton, the expression of junctional proteins and the expression of some of the 
negative regulators of the complement system.  
 
Since  it  has  recently  been  suggested  that  complement  activation  could  affect 
mitochondrial numbers and/or stability in a number of various cell lines including 
primary human lung epithelial cells and Ehrlich ascites tumor cells, it was intriguing 
to investigate whether the direct exposure of pRPE cells to basal amounts of C5b-9 
would  affect  mitochondrial  numbers  and/or  stability  (Papadimitriou  et  al.,  1991, 
Papadimitriou  et  al.,  1994,  Triantafilou  et  al.,  2013).  As  Feher  et  al.,  2006 
demonstrated that RPE cells from patients with advanced AMD suffered from low 
mitochondrial  numbers  and  altered  mitochondrial  structure,  compared  to  control 
samples,  it  was  hypothesized  that  complement  could  implement  changes  in 
mitochondria in the context of AMD.  
 
The  final  aim  of  this  project  was  to  investigate  whether  C5b-9  would  affect  the 
process of POS phagocytosis by examining not only the binding and internalization 
of outer segments, but also by examining the activation levels of three phagocytosis-
related kinases: p-MerTK, p-FAK and p-Src. 
 
 	 ﾠ 53	 ﾠ
 
 
 
 
 
 
 
 
 
 
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠ
Materials & Methods 
         (Chapter 2) 	 ﾠ 54	 ﾠ
	 ﾠ
2. Materials and Methods 
2.1 Cell lines 
Two  different  cell  lines  were  used  to  optimise  and  perform  experiments  in  this 
project:  ARPE-19  cells  (an  immortalised  human  cell  line)  and  primary  porcine 
retinal pigment epithelial cells (pRPE). 
 
2.1.1 Cultivation of ARPE-19 cells 
The  ARPE-19  cell  line  (provided  from  ATCC,  number  CRL-2307)  has  been 
extensively used in vitro. ARPE-19 cells were cultured at 37 ºC with 5 % carbon 
dioxide (CO2), using Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, 
D5796) with 10 % foetal bovine serum (FBS, Gibco, 07F0423K) and 100 U/ml of 
penicillin/streptomycin (Gibco, 1469713). Media was changed twice per week. 
 
At full confluence, cells were detached from their flasks by administering 0.02 % 
trypsin (Gibco, 15400-054). First, cells were washed twice with phosphate buffered 
saline (PBS), then trypsin was added and cells were incubated at 37 ºC for 3 min. 
Trypsinisation was stopped by adding FBS and cells were collected by centrifugation 
at 1,000 rpm for 3 min at room temperature.  
 
2.1.2 Storing (freezing) and thawing of ARPE-19 cells 
ARPE-19 cells were stored in cryo-tubes in 75 % of DMEM (10 % FBS, 100 U/ml 
of  penicillin/streptomycin)  and  25  %  dimethylsulfoxide  (DMSO,  Sigma-Aldrich, 
472301). Cells were initially frozen at -80 ºC overnight before being transferred to -
196 ºC in liquid nitrogen tanks.  
 
Thawing  of  cells  was  accomplished  by  rapidly  warming  the  cryo-vials  and  then 
transferring the cells into 10 ml of pre-warmed DMEM (10 % FBS, 100 U/ml of 
penicillin/streptomycin).  Cells  were  centrifuged  at  1,000  rpm  for  3  min  at  room 
temperature. The cell pellet was then re-suspended in fresh media and cells were 
plated in T25 flasks (Nunc flasks, Thermo Scientific, 178905) at 37 ºC with 5 % 
CO2.  
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2.1.3 Collection of pRPE cells 
Porcine eyes were freshly delivered from a slaughter house (via First Link, UK) and 
kept on ice, both during transportation and before processing in the lab. Once the 
bulbi were detached from the surrounding muscle tissue, they were disinfected using 
PBS and videne surgical scrub (Williams Medical Supplies, D748980). They were 
then placed at 4 ºC for 30 min in PBS and penicillin/streptomycin (1 mg/ml). Then 
the bulbi were cut underneath the ora serrata. The anterior part (including the lens 
and  vitreous)  was  discarded,  while  the  posterior  part  (neuroretina  and  RPE)  was 
processed. Prior to the RPE isolation, the neuroretina was detached from the RPE 
monolayer, cut at the optic nerve and finally homogenised in 48 % sucrose solution, 
pH 7.0 and KCl buffer (0.3 M KCl, 10 mM HEPES, 0.5 mM CaCl2 and 1 mM 
MgCl2).  Isolation  of  the  RPE  cells  was  performed  by  adding  10x  trypsin-EDTA 
(Gibco, UK) for 20 min at 37 ºC to or into the posterior part of each eye. Then, RPE 
cells were detached and isolated by repetitive pipetting. Trypsinisation was stopped 
by the addition of DMEM and 10 % FBS. RPE cells were collected for in vitro 
culturing  after  centrifugation  at  2,000  rpm  for  3  min.  The  cell  pellet  was  re-
suspended  in  fresh  DMEM  containing  10  %  FBS  and  100  U/ml  penicillin/ 
streptomycin.  Finally,  pRPE  cells  were  placed  in  6-well  plates  (Nunclon 
DeltaSurface, Thermo Scientific, 140675) at a cell density of approximately 1 x 10
5 
cells/well. 
 
2.1.4 Isolation and storage of photoreceptor outer segments (POS) 
Neuroretinas were processed in order to extract the POS. Falcon tubes containing 
KCl buffer (0.3M KCl, 10 mM HEPES, 0.5 mM CaCl2 and 1 mM MgCl2) and 48 % 
sucrose  at  pH  7.0  were  used  to  add  and  therefore  homogenise  the  isolated 
neuroretinas. Falcon tubes containing the homogenised neuroretinas were shaken for 
2 min and their contents were placed into 1.5 ml Eppendorf tubes. These tubes were 
then centrifuged at 7,000 rpm for 5 min. The supernatant, which contained the outer 
segments was filtered through sterile gauze (cheese cloth) and diluted 1:1 with KCl 
buffer (no sucrose). This mixture (buffer and POS) was centrifuged at 7,000 rpm for 
7 min. Pellets were washed using 1 ml of PBS and centrifuged again at 7,000 rpm for 
7  min.  Pellets  were  re-suspended  in  serum-free  DMEM  with  100  U/ml 
penicillin/streptomycin. Aliquots of 200 µl were prepared and stored at -80 ºC. 
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2.1.5 In vitro culturing of pRPE cells 
Upon isolation, pRPE cells were cultured in a separate incubator under the same 
conditions as specified in section 2.1.1. Cells were washed once with sterile PBS 
before adding fresh media. 
 
2.1.6 Cultivation of pRPE cells in trans-well inserts 
In order to make both surfaces (apical and basolateral) of pRPE cells accessible to 
various treatments (binding of POS on the apical surface, C5b-9 complex assembly 
on  the  basal  surface),  pRPE  cells  were  cultured  on  12-well  polyester  trans-well 
inserts (Transwell® polyester membrane cell culture inserts, 12 mm Transwell, 0.4 
µm pore polyester membrane insert, catalogue No. 734-1579, Corning, UK). Also, 
cultivation  of  pRPE  cells  in  trans-wells  allowed  cells  to  polarise  correctly  and 
therefore mimic their morphology in the mammalian eye in vivo. Cells were grown 
using  fresh  DMEM  containing  10  %  FBS  and  100  U/ml  penicillin/streptomycin. 
Once they reached a confluent state, the amount of FBS was reduced to 1 %. As a 
general practise cells were maintained in trans-well inserts for 7 – 21 days prior to 
experimentation. To ensure the formation of a properly formed monolayer of pRPE 
cells within the trans-well plates, the TER was measured. 
 
2.2 Measurement of TER 
TER measurement allows the confirmation of a fully formed intact monolayer of 
pRPE  cells  grown  in  trans-well  plates.  When  cells  reach  a  confluent  state  and 
establish strong tight junctions, TER values increase correspondingly. Recording of 
stable TER measurement is therefore a good indication that an authentic monolayer 
of  cells  has  formed  (approximately  two  weeks  after  plating  on  trans-wells). 
Furthermore, a dense monolayer ensures that proteins and reagents added to one side 
will  only  be  able  to  access  the  cell  surface  on  that  side.  All  TER  values  were 
corrected by subtracting the TER value obtained from a blank insert which did not 
contain any cells. Then, the corrected TER values were multiplied by the surface 
area of the insert to acquire the resistance of the entire area that cells occupy (Ω/cm
2) 
(Garcia-Diaz and Essig, 1985). All TER measurements were performed using an 
epithelial voltometer (Figure 12) (World Precision Instruments, Inc.). 	 ﾠ 57	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Figure 12. TER measurement in a 12-trans-well plate using an STX2 manual electrode. A. STX2 
manual electrode. B. Epithelial voltometer (EVOM). Images acquired from (Sonoda et al., 2009)  and 
www.pharmaceutical-int.com, respectively. 
 
 
2.3 Permeability assay 
In  addition  to  TER  measurements,  permeability  assays  may  be  used  to  further 
monitor the integrity of pRPE cells grown in trans-well plates. Inserts were washed 
twice with sterile PBS, then 1 mg/ml of either low or high molecular weight (3-5 
kDa  and  70  kDa,  respectively)  dextran  (fluorescein  isothiocyanate-dextran, 
rhodamine B isothiocyanate-dextran, Sigma-Aldrich, FD4 and R9379, respectively) 
was added to the insert in DMEM (serum-free). At specified time points, 20 µl of 
media were collected from the outer well. The 20 µl aliquots were replaced with 20 
µl  of  DMEM  to  prevent  artificial  effects  of  volume  changes.  The  fluorescence 
intensity  of  the  aspirated  samples  was  measured  at  520  nm  (for  fluorescein 
isothiocyanate-dextran) or at 590 nm (for rhodamine B isothiocyanate-dextran) with 
a  Safire  plate  reader.  The  above  protocol  was  adjusted  from  (Matter  and  Balda, 
2003). 
 
2.4 Cell viability assay 
The viability of RPE cells (both ARPE-19 and pRPE) was examined using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT)  in  the  MTT  assay 
(Sigma-Aldrich, M2128) according to (Mosmann, 1983). In this assay, mitochondrial 
dehydrogenases of living cells cleave the tetrazolium ring of MTT and blue formazan 
crystals start to form. In contrast, dead cells do not develop formazan crystals as 	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mitochondrial  dehydrogenases  are  not  active.  Formazan  crystals  were  allowed  to 
form by adding 180 µl of DMEM and 20 µl of MTT solution (5 mg thiazolyl blue / 1 
ml PBS) at 37 ºC to cells plated on a 96-well micro-plate (Nunc Plates, Thermo 
Scientific, 167008). After 3 h crystals were dissolved by adding 100 µl of DMSO. 
The optical density (OD) of the supernatants was measured in a spectrophotometer at 
a  wavelength  of  490  nm.  Every  individual  MTT  cell  viability  assay  included  a 
positive  control  (untreated  cells)  and  a  negative  control  (cells  treated  with  1  % 
Triton-X 100 for 10 min, prior to the MTT assay). 
 
2.5 In vitro formation of the C5b-9 multi-protein complex 
To induce formation of the C5b-9 complex on the apical and/or basal surface of both 
cell types (ARPE-19 and / or pRPE cells) four different approaches were applied in 
order to achieve a uniform and reproducible pattern of C5b-9 complex formation. 
Each protocol is described here separately where they are referred to as methods A, 
B,  C  and  D  respectively.  Method  DT  refers  to  the  in vitro  formation  of  C5b-9 
complex on the basal surface of pRPE cells, grown on trans-well plates. 
 
Purified  complement  component  proteins  referenced  below  were  purchased  from 
Complement Technology, USA, unless stated otherwise. A summary of the different 
protocols is shown in Table 2. 
 
2.5.1 Method A, C5b-9 complex induction with normal human serum  
Studies of the C5b-9 complex frequently use normal human serum (NHS) as a source 
of complement proteins (Johnson et al., 2011, Lueck et al., 2011). To induce in vitro 
assembly  of  the  C5b-9  complex  using  NHS,  ARPE-19  cells  (passage  26)  were 
cultured  on  glass  coverslips  at  37  °C  /  5  %  CO2,  for  approximately  10  days. 
Confluent  cells  were  then  washed  twice  with  sterile  PBS.  To  block  one  of  the 
negative regulators of C5b-9 complex formation, cells were pre-incubated with a 
purified rabbit anti-human CD59 antibody (1.34 mg/ml, generous gift of Prof. M. P. 
Morgan, Cardiff University) for 1 h at 37 
oC / 5 % CO2 in DMEM. ARPE-19 cells 
were then washed once with sterile PBS and incubated in 20 % NHS in DMEM 
(Sigma-Aldrich, H4522) overnight at 37 
oC / 5 % CO2. As a control, ARPE-19 cells 
were  treated  as  mentioned  above  except  that  the  NHS  was  heat  inactivated  by 
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2.5.2 Method B, C5b-9 complex induction with C5-depleted human serum 
ARPE-19 cells (passage 26) were cultured on glass coverslips for approximately 10 
days after becoming confluent. Cells were washed twice with sterile PBS prior to 
incubation with the purified rabbit anti-human CD59 antibody for 1 h at 37 
oC / 5 % 
CO2 in DMEM. The cells were then washed once with sterile PBS and incubated 
overnight with 60 µg/ml of purified complement protein 5 (C5, A120) and 30 % C5-
depleted human serum (A320) in DMEM at 37 
oC / 5 % CO2. As a control, ARPE-19 
cells were pre-treated with the anti-CD59 antibody (as described above), washed 
once  with  PBS  and  treated  with  30  %  of  C5-depleted  human  serum  in  DMEM 
overnight at 37 
oC / 5 % CO2. 
 
Method B was also performed without blocking the CD59 negative regulator with 
the rabbit anti-human CD59 antibody. 
 
2.5.3  Method  C,  C5b-9  complex  induction  with  C5b-6,  C7  proteins  and  C5-
depleted human serum,  
In order to increase the amount of C5b-9 complex formation in vitro, it was tested 
whether  adding  C5b-6  complex  (A122)  and  C7  (A124)  protein  to  C5-depleted 
human serum was able to enhance the levels of the C5b-9 complex. C5b-6 and C7 
complement proteins are essential for the formation of the C5b-7 complex, which in 
turn allows the binding of C8 and C9 (Stewart et al., 1987). 
 
ARPE-19 cells (passage 26) were cultured on glass coverslips for approximately 10 
days.  Once  cells  were  confluent,  they  were  washed  twice  with  sterile  PBS  and 
incubated  overnight  with  the  C5b-6  complement  complex  (C5b-6,  0.2  mg/ml), 
complement protein 7 (C7, 60 µg/ml) and 30 % C5-depleted human serum in DMEM 
overnight at 37 
oC / 5 % CO2. As a control, ARPE-19 cells were incubated only with 
30 % C5-depleted human serum and complement protein 7 (C7, 60 µg/ml) in DMEM 
overnight at 37 
oC / 5 % CO2. 
 
Method C was also performed in the presence of 1 mg/ml propidium iodide (PI, 
Sigma  Aldrich,  UK).  The  addition  of  PI  was  to  investigate  whether  the  C5b-9 
complex forms a functional pore on ARPE-19 cells.  
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It should be noted that at a later stage method C was also applied to pRPE cells 
grown on glass coverslips, as studies were progressing. 
 
2.5.4 Method D, C5b-9 complex induction with purified complement proteins  
Confluent pRPE cells (passage 1) grown on glass coverslips were incubated with 0.2 
mg/ml of C5b-6 complex, 60 µg/ml of C7, 50 µg/ml of C8 (A125) and 60 µg/ml of 
C9 (A126) purified complement proteins in DMEM overnight at 37 
oC / 5 % CO2. 
This method of C5b-9 complex formation was initially tested on the apical surface of 
pRPE  cells.  As  a  control  pRPE  cells  were  incubated  with  C5b-6  complex  (0.2 
mg/ml), C7 (60 µg/ml) and C8 (50 µg/ml) purified complement proteins in DMEM 
overnight at 37 
oC / 5 % CO2.  
 
2.5.4.1 Method D applied in trans-well inserts (method DT)  
As is discussed in the first results chapter (Section 3.7), method D was judged to be 
the most efficient in inducing large and stable amounts of C5b-9 complex on the 
apical surface of pRPE cells, thus method D was selected as the method of choice for 
all future experiments. However, in order to more accurately reproduce the in vivo 
C5b-9 complex formation, it was necessary to modify the procedure to allow the 
complex to form on the basal surface of pRPE cells instead of the apical. For this 
reason, pRPE cells were allowed to form a confluent monolayer on trans-well inserts 
(as described in section 2.1.6 and shown schematically in Figure 13).  
 
Cells were washed once with sterile PBS and incubated with 500 µl of DMEM on 
the apical surface. On the basal surface cells were treated with 500 µl of DMEM 
containing C5b-6 complex (0.2 mg/ml), C7 (60 µg/ml), C8 (50 µg/ml) and C9 (60 
µg/ml) purified complement proteins (Figure 13). Cells were incubated for 1 h, 4 h, 8 
h, 24 h and 48 h at 37 
oC / 5 % CO2, unless stated otherwise.  As a control, C9 was 
omitted, thus cells were treated with C5b-6 complex (0.2 mg/ml), C7 (60 µg/ml) and 
C8 (50 µg/ml) purified complement proteins only.  	 ﾠ 61	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Figure 13. Schematic representation of complement studies in trans-well inserts. C5b-9 complex 
formation on the basal surface of pRPE cells at 37 
oC / 5 % CO2, for 1 h, 4 h, 8 h, 24 h and 48 h, 
unless stated otherwise. 
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           Table 2. Summary of the protocols for the in vitro C5b-9 complex formation. 
 
 
2.6 Inhibition of C5b-9 endocytosis using dynasore  
Basal C5b-9 complex was formed in vitro according to method DT (Section 2.5.4.1). 
In order to block the endocytosis of the C5b-9 complex, media was supplemented 
with 200 µg/ml of dynasore hydrate (Sigma-Aldrich, D7693) for 24 h (unless stated 
otherwise) at 37 
oC / 5 % CO2. The next day, cells were washed once with sterile 
Method  Treatment  Controls 
A  Pre-treatment: α-CD59 antibody 
(1.34 mg/ml) in DMEM for 1 h. 
Then, 20 % NHS overnight. 
Pre-treatment: α-CD59 antibody 
(1.34 mg/ml) in DMEM for 1 h. 
Then 20 % heat-inactivated NHS, 
overnight. 
B  Pre-treatment: α-CD59 antibody 
(1.34 mg/ml) in DMEM for 1 h. 
Then, C5 (150 µg/ml) + 30 % C5-
depleted human serum, overnight.  
Pre-treatment: α-CD59 antibody 
(1.34 mg/ml) in DMEM for 1 h. 
Then, 30 % C5-depleted human 
serum, overnight.  
C  C5b-6 complex  (0.2 mg/ml) + C7 
(60 µg/ml) + 30 % C5-depleted 
human serum, overnight  
C7 (60 µg/ml) + 30 % C5-depleted 
human serum, overnight.  
D  C5b-6 complex (0.2 mg/ml) + C7 
(60 µg/ml) + C8 (50 µg/ml) + C9 
(60 µg/ml) in DMEM, overnight. 
C5b-6 complex (0.2 mg/ml) + C7 
(60 µg/ml) + C8 (50 µg/ml) in 
DMEM, overnight. 
DT  Apical Chamber: 
DMEM (500 µl), overnight. 
Basal Chamber: 
C5b-6 complex (0.2 mg/ml) + C7 
(60 µg/ml) + C8 (50 µg/ml) + C9 
(60 µg/ml) in DMEM (500 µl), 
overnight. 
Apical Chamber: 
DMEM (500 µl), overnight. 
Basal Chamber: 
C5b-6 complex (0.2 mg/ml) + C7 
(60 µg/ml) + C8 (50 µg/ml),   
in DMEM (500 µl), overnight. 	 ﾠ 63	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PBS and were either lysed for western blotting or fixed for immunofluorescence or 
electron microscopy.  
   
2.7 Outer segment phagocytosis by C5b-9-treated pRPE cells  
To investigate whether the C5b-9 complex influences retinal phagocytosis (binding, 
internalisation  and/or  degradation  of  POS),  C5b-9  was  assembled  on  the  basal 
surface of pRPE cells (Method DT) and at a later stage pRPE cells were fed with 
POS on their apical side according to the following protocol: POS were counted and 
used in a final concentration of 10
7 POS / ml. Then POS were sonicated for 10 min at 
room temperature and centrifuged at 13,000 rpm at room temperature for 1 min. The 
supernatant was discarded while the pellet was dissolved in 850 µl of 10 mM sodium 
phosphate buffer pH 7.2, 100 µl of 1 M sodium bicarbonate pH 9.0 and 5 µl (5 %) of 
alexa fluor 555 (Life Technologies, A-20009). The Eppendorf tube containing the 
POS was covered in foil and placed in the rotor for 1 h at room temperature. The 
outer segments were then centrifuged at 13,000 rpm for 1 min at room temperature, 
the supernatant was discarded and the pellet was re-suspended in 1 ml of DMEM. 
This washing step was repeated 3 times. After washing, POS were diluted in DMEM 
and 1 % FBS  (500 µl) and added to the apical chamber of the trans-well insert of 
confluent pRPE cells for 1 h at 37 
oC / 5 % CO2, to allow the POS to bind to the 
apical  cell  surface.  One  hour  prior  to  the  addition  of  POS  500  µl  of  DMEM 
containing complement proteins (as described in Method DT, Section 2.5.4.1) was 
added to the basal compartment to allow basal formation of the C5b-9 complex. As a 
control, these conditions were replicated but with C9 omitted from the complement 
protein mix (Figure 14).  One hour after the addition of POS the apical cell surface 
was washed 3 times with PBS to remove unbound POS. Then cells were either fixed 
with ice-cold methanol (100 %) and processed for immunofluorescence staining or 
returned to culture medium and incubated overnight at 37 
oC / 5 % CO2 (Section 
2.9).  	 ﾠ 64	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Figure 14 Schematic representation of phagocytosis in C5b-9-treated pRPE cells. At 0 h C5b-9-
treated pRPE cells were fed apically with fluorescent POS for 1 h. After 1 h, cells were washed with 
sterile PBS and were fixed with pure ice-cold methanol. Alternatively, once cells were washed, at 1 h, 
were then maintained at 37 
oC / 5 % CO2 overnight. At 24 h most of the C5b-9 complex is absent 
from the basal surface of cells.  
 
 
 
2.8.1 SDS – PAGE and western blotting 
In  order  to  investigate  whether  the  C5b-9  complex  affects  the  activation  of  the 
downstream  effectors  of  POS  phagocytosis,  pRPE  cells  were  exposed  to  POS 
according to the following protocol: one hour prior to the addition of POS on the 
apical surface of pRPE cells, 500 µl of DMEM containing complement proteins (as 
described in Method DT, Section 2.5.4.1) was added to the basal compartment to 
allow formation of the C5b-9 complex. In the meantime, POS were prepared at a 
concentration of 10
7 / ml, sonicated for 10 min at room temperature and centrifuged 
at 13,000 rpm at room temperature for 1 min. After washing, POS were diluted in 
DMEM containing 1 % FBS. At 1 h after C5b-9 complex formation, 500 µl POS was 
added to the apical chamber (Figure 15). For control cells the same procedure was 
followed, however C9 protein was not included in the media on the basal chamber. 	 ﾠ 65	 ﾠ
At the completion of each time point, cells were washed once with sterile PBS and 
then lysed in sample buffer, as described in Section 2.10. 
All primary and secondary antibodies used for the above studies are listed in Tables 
3 and 4, respectively. 
 
Figure 15. Schematic of  the  in vitro  phagocytosis  in complement-treated pRPE cells. C5b-9-
treated cells were fed with POS apically at 37 
oC / 5 % CO2 for different time-points, and then lysed 
and processed for SDS-PAGE and western blotting. 
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2.8.2 Cell lysis 
Upon completion of an individual treatment, the pRPE monolayer in 12-well trans-
well inserts was washed once with sterile PBS and lysed with 200 µl of 2 % w/v 
sodium  dodecyl  sulfate  (SDS),  25  %  w/v  glycerol,  0.5  M  Tris,  154.52  g/mol 
dithiothreitol (DTT) and 0.2 % w/v bromophenol blue at room temperature.  
 
2.8.3 Sodium dodecyl sulfate-polyAcrylamide gel electrophoresis (SDS)-PAGE 
Following cell lysis, proteins were resolved by SDS-PAGE according to the method 
of (Laemmli, 1970). SDS denatures proteins and gives them all a negative charge. 
The ratio of mass and charge leads to protein separation according to the overall size 
of the protein. The DTT (one of the components of the sample buffer, described in 
section  2.10)  reduces  the  disulfide  bonds  of  proteins  so  that  they  separate  as 
monomers.  The  protein  extract  was  loaded  in  the  stacking  gel  (20  µl  of  protein 
extract was loaded per well per sample). Upon initiation of electrophoresis, proteins 
were separated within pre-cast gradient gels (NuPage
® 4-12 % Bis-Tris gradient gels, 
Life  Technologies,  WG1402BX10).  Electrophoresis  was  performed  at  150  V  for 
approximately 1.5 h at room temperature until the dye front reached the bottom of 
the gel. 
 
2.8.4 Western blotting 
Following SDS - PAGE, a blot sandwich was prepared to transfer the proteins from 
the  gradient  gel  to  a  polyvinyl  difluoride  (PVDF)  membrane  (GE  Healthcare, 
G3126136). The preparation of the sandwich blot was the following: sponge > two 
filter  papers  >  gradient  gel  >  PVDF  membrane  >  two  filter  papers  >  sponge.  It 
should be noted that, before the assembly of the sandwich blot, all parts were soaked 
with pure distilled H20, 10x Tris-glycine (0.25M Tris and 1.92 M Glycine) pH 8.4 
(GeneFlow, EC-880) and pure methanol. Transfer of the proteins from the gradient 
gel  to  the  PVDF  membrane  was  completed  in  a  blotting  chamber  (XCell4 
Surelock
TM Midi-Cell) at 12 V overnight at 4 
oC. The next day, the membranes were 
washed twice with 0.05 % Tween-20 (Sigma-Aldrich, P1379) in Tris-buffered saline 
(TBS) and blocked with 5 % milk powder in TBS-T (0.05 % Tween-20 + TBS) for 1 
h at room temperature. Blocking with milk saturates any free binding sites on the 
membrane  and  therefore  reduces  background.  After  blocking,  membranes  were 
incubated with a primary antibody (Table 3, section 2.8.1)  (depending on the protein 	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of  interest).  Primary  antibodies  (1:1000  dilution,  unless  stated  otherwise)  were 
diluted in 5 % BSA in TBS-T at 4 
oC overnight. Following the primary antibody 
incubation, membranes were washed 3 times with TBS-T (15 min each wash) and 
the secondary antibody was added (1:1000 dilution) in 5 % milk in TBS-T for 1 h at 
room  temperature  (Table  4,  section  2.8.1).  After  the  one-hour  incubation  period, 
membranes were washed for at least 5 h with TBS-T. Finally, protein bands were 
visualised by chemiluminescence using ECL western blotting detection reagents (GE 
Healthcare, IRPN2209) at room temperature. Then, the membranes were transferred 
into cling-film and exposed to a Kodak Biomax XAR X-ray film in the dark room. 
All protein bands of interest were normalised to GAPDH, a house-keeping protein 
and quantified by densitometric analysis using ImageJ (NIH, freeware). 
 
2.9 Confocal microscopy and image analysis 
Cells were washed twice with sterile PBS and then fixed either with pure ice-cold 
methanol (5 min) or with 4 % paraformaldehyde (PFA, Sigma-Aldrich, 15,812-7) for 
30 min at room temperature. Fixation was stopped by washing the cells thoroughly, 
three times with PBS at room temperature. Cells were then permeabilised with PBS 
containing 0.01 % Triton-X 100 (Sigma, T-8787) (PBS-T) for 15 min. To reduce 
background staining, the cells were blocked with 1 % bovine serum albumin (BSA, 
Sigma, A7906) in PBS-T for 1 h at room temperature. After blocking, cells were 
incubated with a primary antibody (depending on the protein of interest). All primary 
antibodies  (Table  3,  section  2.8.1)  were  diluted  1:50  in  1  %  BSA  and  PBS-T 
overnight at 4 ºC.  
 
The  next  day,  cells  were  washed  three  times  with  PBS  at  room  temperature  to 
remove non-bound primary antibody. Then a secondary antibody (Table 4, section 
2.8.1), FITC- or TRITC-conjugated, was applied at 1:100 dilution for 1 h at room 
temperature.  When  examination  of  the  cytoskeleton  (F-actin)  was  required, 
rhodamine phalloidin (1:2000 dilution, Life Technologies, R415) was added together 
with the secondary antibody. To stain cell nuclei, 10 min before the removal of the 
secondary antibody, DAPI (4’, 6-diamidino-2-phenylindole) was added at 1 mg/ml. 
At  this  stage,  it  should  be  noted  that  all  samples  were  protected  from  light  as 
fluorophore-conjugated antibodies and DAPI are light sensitive. Excess secondary 
antibody  was  removed  with  three  PBS  washes  at  room  temperature.  Cells  were 	 ﾠ 70	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coated with mounting media (Mowiol) and analysed by confocal microscopy using a 
Leica  SP2  confocal  microscope.  This  approach  allowed  the  acquisition  of  three-
colour images and / or z-stacks via sequential scanning of the three main colour 
channels:  DAPI  (blue),  FITC  (green)  and  TRITC  (red).  Each  channel  covers 
different areas of the colour spectrum depending on the emission spectrum. DAPI’s 
maximum emission wavelength is at 461 nm and therefore gives a blue colour. For 
the FITC channel a 488-green fluorescent dye was used with a maximum emission 
wavelength at 488 nm and for the FITC channel a 555-red fluorescent dye was used 
with  an  emission  wavelength  at  555  nm.  These  dyes,  as  mentioned  above,  were 
conjugated with the secondary antibody. To acquire 3D images of z-sections, data 
were processed using the Imaris
® 3D reconstruction software.  
 
2.10 Statistical Analysis 
Data are shown as mean value and standard error. Student’s t-test was performed to 
establish the significance of statistical differences between two groups.  
 
2.11 Cryo-immunoelectron microscopy  
Cryo-immunoelectron microscopy (Cryo-EM) was used to examine the subcellular 
localisation of the C5b-9 complex in pRPE cells, by gold particle-labelled anti-C5b-9 
antibody, as described below. 
 
Formation of the C5b-9 complex was performed on the basal surface of pRPE cells 
(Method DT, section 2.5.4.1) for 4 h and 24 h (± 200 µg/ml dynasore hydrate, as in 
Section 2.6). As a control, C5b-8-treated pRPE cells were used (Method DT, section 
2.5.4.1). 
 
After the above treatments, pRPE cells were prepared for cryo-EM by incubating 
them in 4 % PFA in 0.1 M phosphate buffer pH 7.4 and then embedding them in 12 
% gelatine. After infusion with 2.3 M sucrose, 90-nm sections were cut at -120 
oC 
and  collected  in  1:1  2.3  M  sucrose  /  2  %  methylcellulose.  Sections  were  then 
immunolabelled  by  incubating  them  with  the  anti-C5b-9  antibody  (Dako,  UK) 
followed by 10 nm-gold-tagged protein A (UMC, Utrecht), as described  ((Slot et al., 
1991)). Analysis of the C5b-9 complex localisation in pRPE cells was performed 
using  ImageJ.  The  number  of  gold  particles  counted  was  normalised  to  the 	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cytoplasmic area counted per cell, excluding the area covered by the nucleus. The 
cryo-EM studies were performed in collaboration with Dr. Thomas Burgoyne (UCL 
Institute of Ophthalmology, UK). 
 
2.12  Electron-microscopy (EM) for mitochondrial analysis 
In order to assess whether the basal C5b-9 complex affects mitochondrial integrity 
(by measuring mitochondrial number and morphology) the following samples were 
used:  non-treated  pRPE  cells,  cells  incubated  with  DMEM  +  DMSO  for  24  h 
(vehicle), DMEM  with 200 µg/ml dynasore hydrate (24 h), C5b-8-treated cells (24 
h),  C5b-9-treated  cells  (24  h)  and  C5b-9-treated  cells  with  200  µg/ml  dynasore 
hydrate (24 h). C5b-9 complex formation was performed according to Method DT 
(Section 2.5.4.1). 
 
Upon completion of the treatments cells were fixed with 2 % w/v PFA / 2 % w/v 
glutaraldehyde for 2 h before incubating them in 1.5 % w/v osmium tetroxide / 1.5 % 
w/v  potassium  ferricyanide  for  1  h.  Cells  were  dehydrated  using  increasing 
concentrations  of  ethanol  (70  %,  90  %  and  100  %  v/v  ethanol)  followed  by 
propylene oxide before embedding in epon resin. 70 nm sections were cut using a 
Leica  UC7  ultra-microtome  and  imaged  on  a  JEOL  1010  transmission  electron 
microscope.  The  EM  studies  were  performed  in  collaboration  with  Dr.  Thomas 
Burgoyne (UCL Institute of Ophthalmology, UK). 
 
 
Mitochondria counting in pRPE cells was undertaken using ImageJ. The number of 
mitochondria counted was normalised to the cytoplasmic area per cell, excluding the 
area covered by the nucleus. 
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3. Results  
 
3.1 Membrane attack complex formation on ARPE-19 cells 
 
The membrane attack complex (MAC), which is also referred to as C5b-9, is a multi-
protein complex that is formed upon activation of the complement pathway (Laine 
and Esser, 1989). It can cause permeability of the target cell membrane and may 
therefore result in cell lysis (Laine and Esser, 1989). The aim of this part of the study 
was to determine if the formation of C5b-9 could be mimicked in vitro by treating 
ARPE-19  cells  with  normal  human  serum  (NHS).  To  accomplish  this,  ARPE-19 
cells  (passage  26)  were  cultured  on  glass  coverslips  at  37  °C  /  5  %  CO2,  for 
approximately 10 days. Confluent monolayers were then washed twice with sterile 
PBS. In order to block the major negative regulator of C5b-9 formation, cells were 
first incubated with a purified rabbit anti-human CD59 antibody (1.34 mg/ml) for 1h. 
The cells were washed once with sterile PBS and incubated in 20 % NHS overnight 
(Table 2, Method A). To detect C5b-9, immunofluorescence staining was performed 
using an antibody that reacts with the poly-C9 neo-epitope of the C5b-9 complex. 
For controls, ARPE-19 cells were treated as described above, except that the NHS 
was heat inactivated (HI-NHS) by incubation at 58 °C for 1 h (Table 1, Method A) in 
order to denature the complement proteins.  
 
C5b-9 complex formation was observed on ARPE-19 cells (Figure 16). However, it 
was  not  possible  to  analyse  the  precise  location  of  the  complex,  with  regard  to 
whether it was on the cell surface or cytoplasmic. Furthermore, the pattern of C5b-9 
complex formation was not uniform, some cells stained positively for C5b-9, while 
other cells showed weak or no C5b-9 staining. In control cells treated with HI-NHS 
no C5b-9 complex formation was observed, confirming that the heat denaturation of 
the serum complement proteins had been successful (Figure 16-B). 
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Figure 16. C5b-9 complex formation on ARPE-19 cells. (A-C) In control cells treated with HI-
NHS, staining with C5b-9 antibody (green) showed that there was absence of C5b-9 complex. DAPI 
(blue) was used to observe cell nuclei. (D-F) ARPE-19 cells treated overnight with 20 % NHS. The 
C5b-9 staining (green) reveals patchy formation of the C5b-9 complex. Images A, B, C, D, E and F 
were derived from two independent experiments. Scale bar represents approximately 50 µm. 
 
 
3.2 An alternative method to induce C5b-9 complex formation on ARPE-19 cells 
 
In order to demonstrate that C5b-9 complex formation was indeed due to assembly 
of the individual C5b, C6, C7, C8 and C9 complement proteins, we next examined 
the effect of eliminating one of these five proteins (Hu et al., 1981, Stewart et al., 
1987). To achieve this, as described in section 3.1, ARPE-19 cells were cultured on 
glass  coverslips  for  approximately  10  days.  Cells  were  then  washed  twice  with 
sterile PBS prior to incubation with the purified rabbit anti-human CD59 antibody 
(1.34 mg/ml), for 1 h in DMEM. The cells were then washed once with sterile PBS 
and  incubated  overnight  either  with  30  %  C5-depleted  NHS  in  DMEM 
supplemented  with  150  µg/ml  purified  C5  protein,  or  with  C5-depleted  NHS  in 
DMEM alone (control) (Table 2, Method B). To detect C5b-9 complex formation, 
immunofluorescence staining was performed using the anti-C5b-9 specific antibody 
(Section 3.1). The results showed the presence of C5b-9 on the ARPE-19 cells but 
again it was not possible to define its precise location (cell surface or cytoplasmic), 
(Figure 17-A, C). Again, the pattern of C5b-9 formation was not uniform, as some 	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cells  stained  strongly  for  C5b-9,  while  other  cells  showed  weak  or  no  C5b-9 
staining.  In  the  case  where  C5  protein  was  depleted  from  the  NHS,  no  C5b-9 
staining was observed, confirming that the C5 protein is crucial for in vitro C5b-9 
complex assembly (Figure 17-B).  
 
 
Figure 17. C5 is required for C5b-9 formation on ARPE-19 cells. (A) ARPE-19 cells were positive 
for  C5b-9  (white  arrows)  when  incubated  overnight  with  30  %  C5-depleted  NHS  in  DMEM 
supplemented with 150 µg/ml purified C5 protein. (B) Absence of C5b-9 staining on ARPE-19 cells 
incubated overnight with 30 % C5-depleted NHS in DMEM alone. (C) Higher magnification of an 
ARPE-19 cell stained positive for C5b-9 complex. Images A, B and C represent two independent 
experiments. Scale bars represent approximately 50µm (A and B) and 20µm (C), respectively. 
 
 
To gain greater insight into the localisation of the C5b-9 in these experiments, we 
next  performed  3D  reconstructions  of  z-sections  from  a  C5b-9-treated  ARPE-19 
monolayer,  treated  as  described  earlier  (Table  2,  Method  B).  Image  stacks  were 
obtained on a Leica SP2 confocal microscope. Using Imaris
® for the 3D rendering, 
C5b-9-positive staining (green) was observed on the apical surface of the ARPE-19 
cells  (Figure  18-A,  B),  suggesting  that  the  C5b-9-specific  staining  observed  in 
Figures 16 and 17 was also on the apical cell surface. However, when compared to 	 ﾠ 76	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the F-actin staining (Figure 18-A) it was still difficult to determine precisely whether 
or not some of the C5b-9 is cytoplasmic. It is possible that 10 days in culture is not 
sufficient  to  allow  ARPE-19  cells  to  form  a  properly  polarised,  tightly-packed 
monolayer. 
 
 
 
 
 
Figure 18. Cross-section of C5b-9-treated ARPE-19 cells cultured for 10 days. (A) C5b-9 staining 
(green) shows that C5b-9 is formed on the apical surface of ARPE-19 cells. (B) The yellow line 
indicates the location of the cross-section in (A). (A, B, C) F-actin (red) shows that stress fibres 
developed on both apical and basal sides. However, no C5b-9 staining was observed on the basal side 
of cells (C). Blue represents DAPI staining. Scale bars represent approximately 15µm (A) and 40µm 
(B, C).  Images A, B and C were derived from two independent experiments. Image acquired using 
Imaris
® software. 
 
 
3.3 C5b-9 is formed on the apical surface of ARPE-19 cells 
 
As previously discussed, ARPE-19 cells grown for 10 days were not suitable for the 
examination of C5b-9 complex localisation in detail, as cells within that amount of 
time  did  not  form  a  sufficiently  mature  (with  relation  to  pigment  development), 
well-organised  monolayer.  To  address  this  point  and  to  determine  the  cellular 	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localisation of the C5b-9 complex in more detail, 3D reconstructions of z-sections 
were derived from ARPE-19 cells that were cultured for approximately 15 weeks 
instead  of  10  days.  This  15-week  period  enabled  ARPE-19  cells  to  develop 
significantly greater depth that more closely resembled that seen in RPE cells in 
vivo, and which therefore provided a better insight into the localisation of the C5b-9 
complex. ARPE-19 cells treated as in Method B were fixed and stained using the 
C5b-9 antibody. Volumetric rendering using Imaris
® clearly revealed C5b-9 (Figure 
19-A,  B,  green  staining)  on  the  apical  surface  of  ARPE-19  cells,  immediately 
adjacent to the F-actin staining (red). Interestingly the C5b-9 complex appeared to 
induce structural changes to the actin cytoskeleton (white arrow, Figure 19-A). It 
might  be  possible  that  this  structural  change  is  an  early  indication  of  C5b-9 
endocytosis.  
 
 
Figure  19.  Cross-section  of  C5b-9-treated  ARPE-19  cells  cultured  for  15  weeks.  (A,  B)  The 
images show C5b-9 staining (green) on the apical surface of the cells in relation to the F-actin staining 
(red) and the position of nuclei (blue). C5b-9 complex formation seemed to distort the apical actin 
cytoskeleton (white arrow). The yellow line (B) indicates the location of the cross-section (A). (C) At 
the basal side of ARPE-19 cells abundant stress fibres are visible but no C5b-9 staining was observed, 
confirming that the complement proteins were unable to cross the monolayer. Scale bars represent 
approximately 10µm. Images A, B and C were derived from two independent experiments. Image 
acquired using Imaris
® software.   	 ﾠ 78	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3.4 C5b-9 complex formation without blocking CD59 
 
Up to this point, prior to treatment with either NHS or C5 protein in C5-depleted 
human serum, ARPE-19 cells were incubated with a rabbit polyclonal anti-CD59 
blocking antibody. The reason for performing this pre-treatment was to increase the 
formation of the C5b-9 complex in vitro, as CD59 is known to block the binding of 
C9 molecules to C5b-8 complex, thereby inhibiting the assembly of a fully formed 
C5b-9 complex, (Rollins and Sims, 1990, Davies et al., 1989, Tomlinson, 2006). 
Here  it  was  investigated  whether  C5b-9  complex  formation  would  occur  in  the 
absence  of  this  pre-treatment  stage.  To  this  end,  ARPE-19  cells  were  incubated 
(either pre-treated or non-treated with the anti-CD59 antibody), with 150 µg/ml C5 
protein in 30 % C5-depleted human serum (Section 2.5.2).  
 
Immunofluorescence  analysis  showed  that  C5b-9  complex  formation  occurred 
without the need to block its negative regulator, CD59 (Figure 20). Additionally, 
comparison of the cells pre-treated with the anti-CD59 antibody (Figure 20-C) with 
cells that did not receive the pre-treatment (Figure 20-D), revealed that both samples 
developed  qualitatively  similar  amounts  of  C5b-9  staining  (green).  As  a  control, 
ARPE-19 cells were incubated overnight only with 30 % C5-depleted human serum. 
No C5b-9-specific staining was observed in either sample (Figure 20-A, B). These 
results suggest that there was no need to use the anti-CD59 blocking antibody in 
these experiments, and therefore this step was eliminated from all future studies. One 
possible explanation for this observation might be that there is a threshold limit, 
above which, CD59 is not able to block the assembly of fully formed C5b-9 complex 
on the cell surface. It is possible that the concentration of complement proteins used 
in these applied methods of in vitro C5b-9 complex formation surpassed CD59’s 
blocking activity. 
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Figure 20. Induction of C5b-9 complex formation without blocking its negative regulator, CD59. 
(A, B) No C5b-9-positive staining (green) was detected in ARPE-19 cells incubated overnight only 
with  30  %  C5-depleted  human  serum,  regardless  of  whether  they  received  the  anti-CD59  pre-
treatment  or  not,  respectively.  (C,  D)  C5b-9  staining  (green)  was  observed  in  both  experimental 
settings: ARPE-19 cells treated with the blocking antibody and ARPE-19 cells that did not receive the 
pre-treatment, respectively. C5b-9 was assembled by incubating the cells overnight with C5 protein 
and 30 % C5-depleted human serum. Images A, B, C and D were derived from one independent 
experiment. Scale bar represents approximately 50µm. 
 
3.5 Assembled C5b-9 complex rarely induces cell permeability in ARPE-19 cells 
 
Next  we  asked  whether  C5b-9  complex  formation  would  have  an  effect  on  cell 
integrity by making the cells permeable. In bacterial cells and anucleate cells such as 
red blood cells, C5b-9 induces lysis by forming a pore in the cell membrane (Koski 
et al., 1983). In order to test cell permeability, ARPE-19 cells (passage 26) growing 
on glass coverslips for approximately 4 weeks, were treated overnight with C5b-6 
complement complex, complement protein 7 (C7), 30 % C5-depleted human serum 
and propidium iodide (PI) (Table 2, Method C). PI is a small fluorescent molecule, 
able  to  access  the  cytoplasm  and  nucleus  via  permeabilised  membranes.  Once  it 	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binds to the DNA of the target cell it can be observed by fluorescence microscopy. 
Here, a positive control was used where 0.01 % Triton-X 100 was administered to 
ARPE-19 cells for 5 min to induce permeability (Figure 21). Immunofluorescence 
analysis of C5b-9-treated and negative control cells (Figure 21) demonstrated that 
there  was  no  staining  for  PI.  Therefore,  although  C5b-9  complex  has  been 
extensively linked to cell lysis (Laine and Esser, 1989) this was not observed in these 
experiments  in  these  cells.  The  rationale  for  using  C5b-6  complexes  and  extra 
amounts of C7 purified protein (C7 is also present to the C5-depleted human serum) 
was  to  increase  the  possibility  of  obtaining  higher  amounts  of  in  vitro  C5b-9 
complex. Furthermore, qualitative analysis of DAPI staining of control vs treated 
cells suggested that the cells were viable (Figure 21). Section 3.6 validates these 
findings via cell viability assays. 
 
Figure 21. Effects of C5b-9 complex formation on permeability of ARPE-19 cells. C5b-9 complex 
formation  was  induced  by  treating  ARPE-19  cells  overnight  with  C5b-6  purified  complement 
complex, C7 protein and C5-depleted human serum (Ai-iii). Control cells were incubated overnight 
with C7 protein and C5-depleted human serum (Bi-iii). Cells were treated with 0.01% Triton X-100 to 
induce cell permeability (red staining) (Ci-iii). While ARPE-19 cells showed positive staining for C5b-
9 (green), there was an absence of PI staining (red), suggesting that C5b-9 complex formation does 
not form a pore in the cell membrane. Control cells showed an absence of PI staining as expected. 
Scale  bar  represents  approximately  50µm.  Images  A(i-iii),  B(i-iii)  and  C(i-iii)  were  derived  from  one 
independent experiment. 	 ﾠ 81	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Although the results in Figure 21 demonstrate that C5b-9 does not appear to create 
functional pores in RPE cell membranes, permeability was observed in occasional 
cells (Figure 22). ARPE-19 cells positive for C5b-9 complex were also positive for 
PI and the cell nucleus also appeared to be smaller as compared to other cell nuclei, 
suggesting that in rare instances (approximately 4 ARPE-19 cells developed PI and 
C5b-9-specific  staining  within  a  population  of  112  ARPE-19  cells,  which  only 
developed  DAPI  staining)  C5b-9  formation  may  induce  cell  permeability  and 
possibly apoptosis in ARPE-19 cells.  
 
 
 
 
 
Figure 22. Cell permeability induced by the C5b-9 complex. Most ARPE-19 cells appear to be 
healthy as they develop normal nuclear staining (blue) with the exception of an occasional C5b-9-
positive  cell.  Green  staining  represents  the  formation  of  C5b-9  on  a  single  ARPE-19  cell  after 
overnight incubation with C5b-6, C7 complement protein and 30 % C5-depleted human serum. The 
red  nucleus  depicts  a  permeabilised  C5b-9-positive  cell,  stained  positive  for  propidium  iodide. 
Overall, the figure shows the contrast in cell integrity between a complement-affected cell and the 
surrounding unaffected ARPE-19 cells. These data represent one independent experiment. Scale bar 
represents 20µm. 	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3.6 C5b-9 does not affect RPE cell viability 
 
C5b-9 complex formation is associated with lysis and therefore cell death in various 
cell types including erythrocytes (Rommel and Mayer, 1973, Koski et al., 1983).  
Therefore, the MTT cell viability assay was used to examine whether apical C5b-9 
complex formation on ARPE-19 cells could lead to cell death. Also, the MTT assay 
was used as an alternative method to demonstrate that C5b-9 complex does not affect 
viability as previously shown by immunofluorescence analysis. 
 
During  this  assay,  cells  were  treated  as  described  in  Table  2,  Method  C.  Three 
different controls were used: ARPE-19 cells treated with 1 % Triton X-100 to induce 
cell  death  (positive  control),  untreated  ARPE-19  cells  incubated  in  DMEM,  and 
ARPE-19 cells incubated overnight with C7 protein and 30 % C5-depleted human 
serum  (Table  2,  Method  C).  Figure  23  reveals  that  C5b-9-treated  cells  have 
approximately the same levels of cell viability as the control and untreated samples. 
These data confirm that in this experimental model C5b-9 complex formation does 
not cause RPE cell death. Each bar represents the average absorbance measured at 
490 nm, from three wells (triplicates) under the same condition. Data were expressed 
as mean ± SEM. 
 
	 ﾠ 
 
 
 
 
 
 
 
 
   
 
 
 
 
Figure 23. C5b-9 complex formation does not affect ARPE-19 cell survival. MTT cell viability 
assay measuring the levels of cell death on ARPE-19 cells treated overnight with C5b-6 and C7 
complement proteins in 30 % C5-depleted human serum. Three different controls were used: ARPE-
19 cells treated with 1 % Triton X-100 to induce cell death (positive control), untreated ARPE-19 
cells incubated in DMEM, and ARPE-19 cells (control) incubated overnight with C7 protein and 30 % 
C5-depleted human serum. Each bar represents the average absorbance measured at 490 nm, from one 
independent experiment using three wells (triplicates) per condition. Data were expressed as mean ± 
SEM. 
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     3.7 C5b-9 complex formation on primary porcine RPE cells 
 
To exclude the possibility that the observations so far might be specific to ARPE-19 
cells, primary porcine RPE cells (pRPE) were used as an alternative cell type to 
further investigate C5b-9 complex formation. In many ways pRPE cells are a better 
model to examine the effects of C5b-9 complex on the RPE in vitro, as these cells 
exhibit good retention of their epithelial phenotype following isolation from pig eyes. 
 
Two methods were used to induce C5b-9 complex formation on confluent pRPE 
cells.  In  the  first  method  (MAC-A)  cells  were  incubated  overnight  with  C5b-6 
complex, C7 protein and 30 % C5-depleted human serum (Table 2, Method C). In 
the second method (MAC-B) cells were incubated overnight with C5b-6 complex, 
C7, C8 and C9 purified complement proteins in DMEM (Table 2, Method D). For 
this experiment two different negative controls were used: control-A and control-B. 
In control-A pRPE cells were incubated only with C7 protein and 30 % C5-depleted 
human serum, while in control-B, pRPE cells were incubated with C5b-6, C7 and C8 
proteins in DMEM (Methods C and D, respectively).  
 
As shown in Figure 24, these two methods yielded different effects with regard to 
C5b-9  complex  formation.  C5b-9  complex  formation,  when  using  the  MAC-A 
method, was not uniform (Figure 24, Bi-iii). On the other hand, after performing the 
MAC-B method, C5b-9 complex formation was not only more evenly distributed but 
also  relatively  more  C5b-9  complex  was  observed  (Figure  24,  Di-iii).  Moreover, 
immunofluorescence  staining  of  F-actin  (red)  demonstrated  the  apparent 
development of abundant stress fibres upon application of the MAC-B method as 
compared to the MAC-A method (Figure 24, Bii, Dii, respectively). 	 ﾠ 84	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Figure  24.  C5b-9  complex  formation  on  the  apical  surface  of  porcine  RPE  cells  using  two 
methods. Method C (MAC-A) leads to a variable pattern of C5b-9 complex formation (Bi, Biii, green 
staining), while method D (MAC-B) creates a more specific and intense staining specific for the C5b-
9 complex (Di, Diii, green staining). The MAC-B method leads to the formation of abundant stress 
fibres (Dii, Diii, red staining), while actin filaments appear more circumferential in method MAC-A 
(Bii, Biii, red staining).  Images A(i-iii), B(i-iii), C(i-iii) and D(i-iii) represent one independent experiment.   
Scale bar represents approximately 50µm.  
 
 
 
 
 	 ﾠ 85	 ﾠ
 
3.8 C5b-9 complex formation on the basal aspect of pRPE cells 
 
Thus far, the formation of the C5b-9 complex had only been investigated on the 
apical surface of ARPE-19 and pRPE cells, as both cell lines were growing on glass 
coverslips  and  therefore  only  the  apical  surface  was  accessible  to  complement 
proteins. But with the method of in vitro C5b-9 complex formation now optimised, 
further studies were carried out on pRPE cells grown on transwell cell culture plates, 
where  both  aspects  (apical  and  basal)  of  pRPE  cells  were  accessible  to  various 
treatments.  
 
It is well established that in vivo, AMD patients develop C5b-9 complex formation 
on  the  basal  surface  of  the  retinal  pigment  epithelium  and/or  Bruch’s  membrane 
(Anderson et al., 2002). Therefore we decided to continue these studies using C5b-9 
formation on the basal surface of pRPE cells, by using culture well inserts. pRPE 
cells were cultured (passage 1) in 12-transwell plates and after approximately two 
weeks when the RPE monolayer developed a stable trans-epithelial resistance, C5b-9 
complex was assembled in vitro as described in Table 2, Method DT. The C5b-6 
complex, C7, C8 and C9 purified complement proteins were added in DMEM, to the 
basal chamber of the trans-well. As a control, only C5b-6, C7 and C8 proteins were 
added in DMEM, to the basal chamber of the trans-well. In the apical chamber (in all 
samples, including the control) only DMEM was added. In a first set of experiments 
three  different  time-points  were  used  (1  h,  5  h  and  24  h)  for  C5b-9  complex 
formation, in order to examine how rapidly C5b-9-positive staining developed as 
judged by immunofluorescence analysis. Imaris
® software was used to examine both 
the apical and basal surface of cells. Immunofluorescence demonstrated the presence 
of substantial C5b-9 complex formation on the basal surface of pRPE cells within 1 h 
(Figure 25-Bii). Basal levels of C5b-9 complex increased further by 5 h (Figure 25-
Cii), while at 24 h (Figure 25-Dii) C5b-9 complex levels had decreased significantly. 
The pattern of basal C5b-9 complex accumulation was also quantified by measuring 
the  fluorescence  intensity  specific  to  C5b-9  using  Imaris
®.  The  apical  surface  of 
pRPE  cells  (in  all  samples,  including  the  control)  remained  negative  for  C5b-9 
staining demonstrating the integrity of the monolayer throughout (Figure 25-Ai, Bi, 
Ci and Di). Four different areas per sample were quantified. As described earlier in 
Section 3.7 on the 24 h sample (Figure 24-Dii), abundant stress fibres developed as 	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observed by F-actin staining (red staining). This observation is in accordance with 
results in Figure 25, where C5b-9 complex was allowed to form for 24 h on the basal 
surface of pRPE cells (Figure 25-Di, Dii). The C5b-9 complex formation/elimination 
rate from the basal surface of pRPE cells over time will be examined in more detail 
in the next chapter. 
 
 
 
Figure 25. C5b-9 complex assembly on the basal surface of pRPE cells. C5b-9 (green staining) 
was detected via immunofluorescence when C5b-6, C7, C8 and C9 complement proteins were added 
in DMEM to the basal surface of pRPE for different time-points (Bii, Cii and Dii). At 1 h (Bii) C5b-9 
complex was visible (green), and staining increased further at 5 h (Cii), while at 24 h (Dii) C5b-9-
positive staining decreased significantly. Staining for F-actin (red) demonstrated the development of 
abundant stress fibres at 24 h (Di and Dii). The apical surface in all samples remained C5b-9-negative 
(Ai, Bi, Ci and Di). As a control pRPE cells were used, where C5b-6, C7 and C8 proteins were added 
in DMEM on the basal surface for 24 h (Aii). (E) Each bar represents the average of the C5b-9-related 
fluorescence intensity as measured from four independent areas per sample from one independent 
experiment,  using  Imaris
®  software.  Data  were  expressed  as  mean  ±  SEM.  Scale  bar  represents 
approximately 20µm.  	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3.9 C5b-9 complex formation does not affect the viability of pRPE cells 
 
Overnight formation of C5b-9 (Table 2, method D) did not appear to induce the 
death  of  pRPE  cells  (Figure  26),  as  was  observed  previously  for  ARPE-19  cells 
(Figure  23).  Again,  for  the  MTT  assay  three  different  controls  were  used:  cells 
treated with 1 % Triton X-100 (for 10 min) to induce cell death (positive control), 
untreated cells were pRPE cells incubated in DMEM, and negative control cells were 
cells that were incubated overnight with C5b-6, C7 and C8 purified complement 
proteins in DMEM.  
 
The MTT cell viability assay demonstrated that C5b-9-treated pRPE cells (C5b-9 
sample) had approximately the same levels of cell survival when compared to the 
untreated cells and the negative control.  
 
Figure 26. C5b-9 complex formation does not reduce the viability of primary porcine RPE cells. 
MTT cell viability assay was performed to measure survival of primary porcine RPE cells treated with 
C5b-6, C7, C8 and C9 complement proteins in DMEM, overnight at 37 
oC / 5 % CO2 (C5b-9). Three 
different controls were used: cells treated with 1 % Triton X-100 for 10 min to induce cell death 
(positive control), pRPE cells incubated in DMEM (untreated) and cells that were incubated overnight 
with C5b-6, C7 and C8 purified complement proteins in DMEM (control). Each bar represents the 
average  absorbance  measured  at  490  nm,  from  one  independent  experiment  using  three  wells 
(triplicates) per condition. Data were expressed as mean ± SEM. 
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3.10 Discussion  
 
•  Assembling the C5b-9 complex in vitro 
 
Optimising the conditions for the in vitro assembly of C5b-9 on the apical and/or the 
basal surface of RPE cells was an essential first step in defining a model in which to 
examine  the  interplay  between  the  complement  system  and  the  retinal  pigment 
epithelium. Testing and finally establishing method DT (as shown in Table 2) as the 
optimal  approach,  allowed  us  to  overcome  potential  inconsistencies  in  C5b-9 
complex formation and to better control the in vitro conditions. Additional control 
was derived from the fact that a serum-free environment guaranteed that any effects 
observed were solely due to the presence of C5b-9 and not due to the presence of 
various other factors being present within human sera (NHS or C5-depleted serum). 
 
The initial approach to inducing C5b-9 complex on the apical surface of ARPE-19 
cells, by administering 20 % NHS overnight, did not yield consistent effects (Figure 
16). The pattern of C5b-9 formation was not uniform, as some cells were stained 
positively for the C5b-9 complex, while others showed weak or no C5b-9-positive 
staining (Figure 16-F). Complement-competent NHS has previously been shown to 
be capable of inducing C5b-9 complex formation in two different cell models: hfRPE 
cells (Johnson et al., 2011) and ARPE-19 cells (Lueck et al., 2011). Johnson et al., 
(2011), demonstrated that 10 % NHS in serum-free media was capable of inducing 
uniform staining specific to C5b-9 on the basal surface of hfRPE cells. In addition, 
Lueck et al., (2011) by using ascending concentrations of NHS observed the in vitro 
formation of C5b-9 complex on the apical surface of ARPE-19 cells. This C5b-9 
complex formation was accomplished by incubating ARPE-19 cells with 5-20 % 
NHS for 1 h. Therefore, in order to achieve high levels of C5b-9 complex formation, 
elements of the two different protocols described above, were combined by using 
20% complement-competent NHS for 24 h instead of 1 h.  
 
In  combination  with  the  above  protocol,  in  order  to  investigate  whether  the 
prolonged use of NHS can induce complement activation and/or lysis, we performed 
a pilot experiment where ARPE-19 cells were treated with 20 % NHS for 1d, 2d, 5d 
and 7d. As a control ARPE-19 cells were incubated with 20 % HI-NHS, using the 
same timepoints. While low levels of C5b-9 formation were identified at 24 h, these 	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levels were significantly decreased by day 5, while at day 7, C5b-9 was not present 
any  more.  Similar  results  were  observed  when  CNV  was  induced  by  laser-
photocoagulation in C57BL/6 mice. Immunofluorescence analysis using flat mounts, 
demonstrated  that  C5b-9  formation  was  up-regulated  on  days  1  and  3  post-laser 
injury, however C5b-9 levels were significantly down-regulated on days 5 and 7 
(Lyzogubov  et  al.,  2010).  Overall,  Method  A  combined  with  the  above  pilot 
experiment  indicated  not  only  that  ARPE-19  cells  survived  from  the  prolonged 
presence of complement but also it demonstrated once again that the NHS did not 
yield high levels of C5b-9 complex. 
 
However, as this protocol did not yield useful results it was necessary to further 
refine the experimental conditions. To this end ARPE-19 cells were incubated with 
purified C5 protein and 30 % C5-depleted human serum (Figure 17-A). However, 
immunofluorescence  analysis  demonstrated  a  similar  pattern  of  C5b-9  complex 
formation to that seen in Figure 16-F (where cells were treated only with 20 % 
NHS). C5-depleted human serum has previously been demonstrated to be capable of 
leading to C5b-9 complex assembly, when C5 protein was added back to the media 
(Johnson et al., 2011). C5 protein, essential for the assembly of C5b-9 complex, is 
synthesised primarily in the liver and its concentration in human plasma (derived 
from normal donors) ranges from 72 to 171 µg/ml (Gupta and Sarin, 1984, Sjoholm, 
1975, Strunk et al., 1988). Therefore, in order to mimic the in vivo concentration of 
C5 protein in the circulation, C5 purified complement protein was used at 150 µg/ml. 
Examining the possibility Method B to sufficiently enable C5b-9 formation without 
compromising cell viability we performed a pilot study during which ARPE-19 cells 
were incubated with purified C5 protein and 30 % C5-depleted human serum on their 
apical cell surface for 1d, 3d, 5d and 7d. As a control, ARPE-19 cells were treated 
only with 30 % C5-depleted human serum on their apical cell surface for the same 
amount of time as above. Propidium iodide was present in the media at all times, in 
order to investigate whether the assembled C5b-9 could induce cell lysis or not. 
Immunofluorescence  analysis  demonstrated  that  Method  B  produced  again  low 
levels of C5b-9 on the apical surface of ARPE-19 cells at day 1, while most of the 
C5b-9-specific staining was absent by day 3. In addition to this observation, it should 
be  noted  that  PI  did  not  stain  cell  nuclei  and  therefore  implicating  that  C5b-9 
complex did not affect cell survival. Overall, Method B combined with the above 	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pilot experiment indicated the need to develop a more advanced protocol for the in 
vitro formation of C5b-9 complex. 
 
Despite these refinements it was evident that neither of these methods (Method A 
and B, Table 2) was ideal for the in vitro formation of C5b-9 complex, as only 
minimal and patchy C5b-9-specific staining was observed. One explanation could be 
that  the  ARPE-19  cells,  used  in  both  conditions,  were  only  grown  in vitro for 
approximately 10 days, and therefore the cells did not have sufficient time to form a 
well-organised  and  more  authentic  RPE  monolayer.  Within  this  monolayer  there 
may have been cells whose surface was less accessible to the complement proteins 
and serum in order for the C5b-9 complex to cover wider areas and therefore to 
develop  a  more  uniform  staining.  The  absence  of  a  fully  differentiated  RPE 
phenotype was confirmed by 3D image reconstruction of ARPE-19 cells grown for 
10 days in vitro (Figure 18). In particular, the F-actin staining indicated that cell 
height  was  not  uniform  (Figure  18-A).  In  general,  ARPE-19  cells  need  longer 
periods to form a monolayer with RPE characteristics (Turowski et al., 2004). This 
is partly reflected by the fact that the ARPE-19 cell line is only able to reach low 
TER values of 30-45 Ω/cm
2. Even when ARPE-19 cells are grown in vitro for a 
longer period such as six months, there is usually little improvement in the TER 
(Luo et al., 2006).  
 
Luo et al., (2006) and Ahmado et al., (2011) reported that in addition to exhibiting 
low TER values, F-actin appears to be far less organised in immature cultures of 
ARPE-19  cells  compared  to  cells  which  have  been  grown  for  more  than  fifteen 
weeks  (Ahmado  et  al.,  2011).  After  approximately  three  months  ARPE-19  cells 
develop a more epithelial-like phenotype where actin filaments appeared to be more 
circumferential. This observation was confirmed in this study where ARPE-19 cells, 
grown for approximately 15 weeks exhibited abundant basolateral stress fibres, and 
an apical layer of F-actin in the region where one would expect to observe microvilli 
in vivo (Figure 19).  	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Methods A and B demonstrated the need to use more mature ARPE-19 cells and 
therefore  the  optimisation  of  the  conditions  for  C5b-9  complex  formation  was 
continued by using ARPE-19 cells grown on glass coverslips for 4 weeks instead of 
10 days. These cells were treated with a mixture of purified complement proteins 
and serum in order to increase the amount of C5b-9 complex in vitro. Extra C7 was 
added as this is a crucial protein for the formation of the C5b-7 complex. It is mainly 
produced from the liver and bone marrow and its concentration varies from 50-70 
µg/ml in human serum (Hammer et al., 1981, Naughton et al., 1996). Substitution of 
purified C5 from the C5b-6 complex eliminated the step where C5 protein in the 
media had to be cleaved to C5a and C5b molecules (Rawal and Pangburn, 1998). 
C5b  production  is  the  initial  event  in  the  formation  of  the  C5b-9  complex 
(Silversmith  and  Nelsestuen,  1986).  Although  immunofluorescence  analysis 
revealed the presence of stronger C5b-9-specific staining, again there was a sub-
population of cells that did not develop C5b-9-positive staining at all (Figure 21-
Aiii).  
 
As 4-week-old ARPE-19 cells did not radically improve the end result of C5b-9 
complex formation, pRPE cells were used instead, as these are known to retain their 
hexagonal phenotype and also to form a tight monolayer in vitro. The advantages of 
using  pRPE  as  a  cell  model  were  discussed  in  more  detail  in  Section  1.7.3. 
Furthermore, as NHS and C5-depleted human serum contain a variety of growth 
factors and other growth modulating molecules, it was decided to develop a more 
reductionist version of the above protocol by omitting serum. Incubating pRPE cells 
with C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM led to 
a uniform staining pattern specific to C5b-9 across the apical surface of the pRPE 
monolayer (Figure 24-Diii). Addition of purified C8 and C9 proteins in these in vitro 
conditions was essential. C8 is composed of three subunits (α, β and γ) which bind to 
the first C9 molecule on the C5b-8 complex. Its concentration in human plasma 
varies  between  50-80  µg/ml  (Manni  and  Muller-Eberhard,  1969,  Schreck  et  al., 
1998). C9 is the final component of the C5b-9 complex and its concentration in 
human  serum  ranges  from  40  to  70  µg/ml  (Hammer  et  al.,  1981,  Podack  and 
Tschopp, 1982). 
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 In addition, comparison of MAC-A method (also known as method C) with MAC-B 
method (also known as method D) showed that the latter protocol appeared to induce 
the  formation  of  abundant  F-actin  stress  fibres  (Figure  24-Bii,  -Dii,  respectively). 
Stress  fibres  are  needle-shaped  bundles  of  actin  filaments  which  contain  various 
actin-associated  proteins  (Katoh  et  al.,  1998).  These  F-actin  stress  fibres  have 
previously been found to be regulated by RhoA, a member of the Rho family of 
small GTPases that mediate actin remodelling via activation of several signalling 
pathways (Zhang et al., 2007, Etienne-Manneville and Hall, 2002). Interestingly, the 
expression level of RhoA has previously been shown to be modulated by C5b-9 in 
rat glomerular epithelial cells (GECs) in vitro (Zhang et al., 2007). These authors 
showed that when rat GECs were cultured with NHS either for a short period (40 
min) or for a long period (18 h), complement increased the activity of RhoA (GTP-
bound form of RhoA protein levels were elevated compared to control samples). 
Further studies shown that this C5b-9-induced RhoA activation is partly attributed to 
the C5b-9-induced activation of the Erk pathway, upstream of RhoA (Mouawad et 
al., 2014).  
 
Previous immunohistochemical studies from eyes derived from AMD donors had 
shown that in vivo, C5b-9 is localised at the basal surface of RPE cells (Johnson et 
al., 2000, Anderson et al., 2002). To attempt to reproduce this in culture pRPE cells 
were grown on trans-well plates in order to permit assembly of C5b-9 on the basal 
surface of these cells. Addition of the mix of purified complement proteins at the 
basal chamber led to the rapid formation of C5b-9 complex on the basal surface of 
pRPE cells. C5b-9 levels were increased at 5 h (Figure 25-Cii) but were significantly 
reduced  by  24  h    (Figure  25-Dii).  These  results  show  that  pRPE  cells  have 
mechanisms that enable them to remove C5b-9, and the possible reasons for this 
observation will be addressed in the next chapter. 
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•  C5b-9 complex formation without blocking CD59 
 
The  immunofluorescence  analysis  in  Figure  20  demonstrated  that  is  possible  to 
assemble C5b-9 without the need to block its negative regulator, CD59. Comparison 
of the cells pre-treated with the anti-CD59 antibody (Figure 20-C) with cells that did 	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not  receive  the  pre-treatment  (Figure  20-D),  showed  that  both  developed  similar 
amounts of C5b-9-positive staining. 
 
CD59  is  one  of  the  membrane-bound  negative  complement  regulators,  which  is 
expressed by several cell types including endothelial and epithelial cells (Nose et al., 
1990, Meri et al., 1991). Its primary role is to inhibit the incorporation of multiple C9 
molecules on the membrane-bound C5b-8 complex, by binding tightly to the C8 
protein of this complex (Morgan, 1999). However, a single C9 protein may bind to 
C5b-8 even in the presence of CD59 and therefore permit the formation of small 
C5b-9 complexes in which C8 and C9 are in a ratio of 1:1.5 instead of 1:3.5 (Meri et 
al., 1990). Within these ‘small’ C5b-9 complexes CD59 is believed to mediate only a 
partial unfolding of the bound C9 protein and therefore, ‘bigger’ C5b-9 complexes 
(C5b-912) cannot be assembled. This reduces the possibility of cells suffering from 
ion leakage, which in turn is capable of inducing cell death (Rollins and Sims, 1990). 
 
Despite the above observations that CD59 in principle inhibits the formation and 
therefore the lytic activity of C5b-9 there are cases of various neurodegenerative 
diseases  where  complement  attack  was  believed  to  be  responsible  for  the 
degeneration of neurons and glial cells, regardless of the presence of CD59 (as well 
as C1 inhibitor, clusterin, MCP and DAF) (Singhrao et al., 1999, Yasojima et al., 
1999). It may therefore be that there is a threshold limit above which CD59 cannot 
inhibit the formation of multiple C5b-9 complexes. The results in Figure 20 are in 
line with this notion, as Method B clearly provides enough complement proteins to 
promote the assembly of C5b-9 complex on the ARPE-19 cells. The concentrations 
of  the  complement  component  proteins  would  therefore  appear  to  overcome  the 
inhibitory activity of CD59. 
 
•  The C5b-9 complex does not affect cell viability 
 
Despite the presence of the terminal complex ARPE-19 cells remained viable, as 
judged by various criteria. Immunofluorescence analysis showed that PI was not able 
to access the nuclei, with only rare exceptions observed in these studies. In general, 
DAPI staining revealed a normal morphology of the nuclei for the majority of the 
ARPE-19 cells examined. It should be noted that the C5b-9 complex has an average 	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pore diameter of 90-100 Å, which is large enough to admit the passage of ions and is 
also large enough to enable PI to access the cytoplasm of ARPE-19 cells (Zalman 
and  Muller-Eberhard,  1990).  Cell  viability  was  further  confirmed  by  performing 
MTT assays on C5b-9-treated ARPE-19 and pRPE cells.  
 
Decades ago it was demonstrated that C5b-9 can induce lysis of erythrocytes and 
lysis of various types of nucleated cells including cell lines such as Molt4 and U937, 
derived from human T lymphocytes and histiocytes, respectively (Koski et al., 1983). 
While initially it was believed that erythrocytes may be lysed by a single C5b-9 
complex, this hypothesis (‘one-hit’ theory) was later challenged by the observation 
that approximately 850 C5b-9 complexes are required to lyse an erythrocyte. This 
number was derived from the measured number of C7 protein molecules required to 
induce cell lysis (Rommel and Mayer, 1973, Bauer and Valet, 1983). Perhaps lysis of 
nucleated cells such as RPE, requires an even higher number of C5b-9 complexes 
due to their bigger size, or perhaps nucleated cells have mechanisms to resist C5b-9 
attack regardless of the amount of complex that forms. Normally red blood cells are 
approximately 6-8 µm in diameter while, RPE cells are approximately 15 µm (Aarts 
et al., 1983, Roorda et al., 2007).  
 
The  fact  that  complement-mediated  cell  lysis  is  not  a  simple  process,  as  was 
previously  thought,  is  supported  by  the  observation  that  nucleated  cells,  upon 
immune  attack,  can  increase  lipid  synthesis  in  their  cell  membranes  to  protect 
themselves  from  being  permeabilised  (Schlager  et  al.,  1978).  Currently,  it  is  not 
known  whether  bound  C5b-9  stimulates  ARPE-19  cells  to  alter  their  metabolic 
activity in order to enrich their complement-attacked membranes with extra lipid 
molecules.  
Overall,  our  data  are  consistent  with  the  findings  of  Johnson  et  al.,  (2011)  who 
showed that the presence of C5b-9 on the basal surface of hfRPE cells did not affect 
cell  viability.  The  cells  used  here  (ARPE-19  and  pRPE)  retained  their  viability, 
despite exposure to C5b-9, which is consistent with the observation that in AMD 
patients the RPE can remain viable for many years. 
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4. RPE cell responses to C5b-9 complex assembly  
4.1 C5b-9 formation/elimination from the basal surface of RPE cells 
As shown in section 3.8, C5b-9 is detectable on the basal surface of pRPE cells 
within  1  h  of  adding  the  purified  proteins,  while  at  24  h  levels  of  C5b-9  were 
significantly  decreased.  To  acquire  a  better  understanding  of  the 
formation/elimination  of  the  C5b-9  complex  and  also  to  further  validate  the 
observations from Figure 25 the study was extended by including additional time 
points.  pRPE  cells  were  cultured  in  12-well  trans-well  plates  and  once  they  had 
formed a confluent monolayer C5b-9 complex formation was developed as described 
in method DT (section 2.5.4.1). Thus, C5b-6, C7, C8 and C9 purified complement 
proteins were added in DMEM, on the basal chamber of the trans-well and incubated 
overnight. As a control C9 was omitted. Five different time points were applied (1 h, 
4 h, 8 h, 24 h and 48 h) to study the formation/elimination of C5b-9 complex via 
immunofluorescence. High levels of C5b-9-positive staining were detected within 1 
h  on  the  basal  RPE  cell  surface  (Figure  27-Bii).  These  high  C5b-9  levels  were 
maintained at 4 h (Figure 27-Cii), but started to decline by 8 h (Figure 28-Aii). The 
level of C5b-9-positive staining was further reduced at 24 h (Figure 28-Bii) and by 48 
h it was almost absent from the basal surface of the pRPE cells (Figure 28-Cii). 
Control cells (cells treated with C5b-6 + C7 + C8 proteins) did not develop any 
staining specific to the α-C5b-9 antibody on their basal surface, as expected. To 
quantify  these  observations,  the  fluorescence  intensity  specific  to  C5b-9  was 
measured  using  Imaris
®  from  three  independent  experiments  (four  different  Z-
sections per sample per experiment). The apical surface of all samples remained 
negative for C5b-9-specific staining (Figure 27-Ai, Bi, Ci and Figure 28-Ai, Bi and 
Ci) demonstrating the integrity of the monolayer throughout. These results show that 
RPE  cells  have  mechanism(s)  for  eliminating  C5b-9,  probably  to  mitigate  any 
harmful  effects  if  C5b-9  were  to  remain  at  the  cell  surface.  The  next  section 
examines the role of endocytosis in this process. 
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Figure 27. C5b-9 complex formation on the basal surface of pRPE cells.  As a control, pRPE cells 
were incubated with DMEM apically (Ai) and with C5b-6, C7 and C8 proteins in DMEM basally, for 
4 h (Aii). pRPE cells were treated only with DMEM on their apical surface for 1 h and 4 h (Bi and Ci, 
respectively). C5b-6, C7, C8 and C9 purified complement proteins were added in DMEM media on 
the basal surface of pRPE cells for 1 h and 4 h (Bii and Cii, respectively). C5b-9 complex formation 
(green staining) was detected via immunofluorescence. High levels of C5b-9-positive staining were 
detected for both time points (1 h and 4 h) on the basal surface of the cells. The apical surfaces of all 
samples (including the control) were incubated with DMEM only and therefore they did not develop 
any C5b-9-positive staining (Ai, Bi and Ci). Red staining corresponds to F-actin, blue staining to 
DAPI. Scale bar represents approximately 20µm. 
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Figure 28. C5b-9 complex formation/elimination on the basal surface of pRPE cells.  The images 
show a continuation of the experiment in Figure 26 at later time points. In combination with data from 
Figure 26, C5b-9 levels declined at 8 h on the basal surface of pRPE cells (Aii) and a further reduction 
was  observed  at  24  h  (Bii).  Hardly  any  C5b-9-positive  staining  was  detected  at  48  h  (Cii).  The 
histogram (G) provides a quantitative readout of the staining intensity of the C5b-9 complex on the 
basal surface of pRPE cells as a function of time. Each bar represents the average of the C5b-9-related 
fluorescence intensity as measured from twelve independent areas stemming from three samples, from 
three independent experiments, using Imaris
® software. Data expressed as mean ± SEM, ***P<0.001. 
Red staining corresponds to F-actin, blue staining to DAPI. Scale bar represents approximately 20µm. 
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4.2 Endocytosis of C5b-9 by RPE cells 
To test whether the elimination of C5b-9 from the basal surface of pRPE cells could 
be attributed, at least partly, to endocytosis, dynasore monohydrate was used to block 
the endocytic pathway. Dynasore is able to block both types of endocytosis (clathrin-
mediated  and  caveolae-mediated)  as  it  acts  as  a  non-competitive  inhibitor  of 
dynamins I, II and III by blocking their GTPase activity in a dose-dependent manner 
(Macia et al., 2006, Henley et al., 1998). More specifically, in clathrin-mediated 
endocytosis it has been shown that dynasore is capable of inhibiting endocytosis of 
transferrin in HeLa cells without interfering with membrane protein biosynthesis at 
the same time (Macia et al., 2006). 
 
The  aim  of  an  initial  pilot  experiment  was  to  demonstrate  that  dynasore  blocks 
endocytosis of transferrin on the apical surface of pRPE cells. Transferrin is an 80-
kDa glycoprotein essential for iron transportation from the bloodstream to various 
cells  types,  including  RPE  cells  (Baudouin  et  al.,  1992).  The  transferrin-iron 
complex binds to transferrin receptors on the surface of cells, gets internalised and 
therefore delivers iron to cells, essential for their growth and proliferation (Baudouin 
et al., 1992). 
 
Confluent pRPE cells (passage 1) grown in 12-well trans-well plates were incubated 
with 200 µg/ml of dynasore monohydrate in DMEM on the apical chamber for 24 h. 
Prior  to  the  completion  of  this  incubation  period,  without  changing  the  media, 
fluorescently tagged transferrin (5 mg/ml, Alexa Fluor
® 555) was added to the apical 
chamber  for  30  min.  Cells  were  then  methanol-fixed  and  stained  (according  to 
method 2.9) with a mouse monoclonal anti-ezrin antibody, in order to label the apical 
surface of pRPE cells (Figure 29-A). Immunofluorescence staining of the apical cell 
surface provided a clear indication of whether transferrin became internalised or not. 
As a vehicle control, pRPE cells were incubated only with DMEM, containing 0.65 
% DMSO that was used to dissolve dynasore on the previous sample. In both vehicle 
control  and  dynasore-treated  cells  DMEM  was  used  in  the  basal  chamber. 
Immunofluorescence analysis confirmed dynasore’s ability to block the endocytosis 
of  transferrin  (red  staining)  on  the  apical  surface  (green  staining)  of  pRPE  cells 
(Figure 29-Ci). Transferrin levels were significantly lower on the apical surface of 	 ﾠ 100	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the vehicle control (Figure 29-Bi), indicating that bound transferrin was successfully 
internalised. Figures 29-Cii and Bii show the same result from a basal perspective. 
Imaris
®  was  used  to  quantify  these  observations  by  measuring  the  fluorescence 
volume specific to transferrin in treated and untreated cells (Figure 30). Analysis of 
the apical surfaces of both the vehicle control and the dynasore-treated cells was 
performed (Figure 30-Ai and Bi respectively), while Figures 30-Aii and Bii show the 
same apical surfaces viewed from their cytoplasmic sides. Figure 30-Aiii (vehicle) 
and  Figure  30-Biii  (dynasore-treated  cells)  show  optical  sections  proximal  to  the 
apical cell surface. Data from Figure 29 and 30 were derived from one independent 
experiment. This study shows that dynasore can be used as an effective endocytosis 
inhibitor in order to block endocytosis in pRPE cells. 
 
Figure 29. Dynasore blocks endocytosis of transferrin in pRPE cells. The apical surface of cells 
(green staining) was labelled using an antibody to ezrin. Red staining corresponds to fluorescently 
tagged  transferrin  Alexa  Fluor
®  555  (A).  As  vehicle  control,  cells  were  incubated  with  DMEM 
containing DMSO (Bi). The basal surface of cells was incubated only with DMEM (Bii). On the apical 
surface of cells, 200 µg/ml of dynasore monohydrate was added in DMEM for 24 h. Before the end of 
this incubation period, transferrin was added for 30 min (Ci). The basal surface of cells was incubated 
only with DMEM for 24 h (Cii). Comparison of dynasore-treated cells (Ci, Cii) with vehicle control 
(Bi, Bii) demonstrates dynasore’s ability to block endocytosis of transferrin. Blue staining corresponds 
to DAPI. Scale bars represent approximately 20µm. 	 ﾠ 101	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Figure 30. Quantification of transferrin endocytosis on the apical surface of pRPE cells.  As 
vehicle control,  cells  were  incubated  with  DMEM  containing  DMSO  for  24  h  (Ai-iii). The apical 
surface of all cells (green staining) was labeled using an antibody specific to ezrin. Top view of the 
apical surface of the vehicle control cells (Ai). Aii provides an inner view of the apical surface of the 
vehicle control cells. Aiii  depicts an optical section proximal to the apical surface. On the apical 
surface of cells, 200 µg/ml of dynasore monohydrate was added in DMEM for 24 h. Before the end of 
this incubation period, transferrin was added to the same media for 30 min (Bi-iii). Bi shows the top 
view of the apical surface of the dynasore-treated cells. Bii provided an inner view of the apical 
surface of the dynasore-treated cells. Biii depicts an optical section proximal to the apical surface. The 
histogram (C) demonstrates the blockage of transferrin internalisation in dynasore-treated pRPE cells. 
Each bar is derived from the measurement of fluorescence volume specific to transferrin derived from 
four  independent  z-sections  per  sample  from  one  independent  experiment  using  Imaris
®.  Data 
expressed as mean ± SEM. Blue staining corresponds to DAPI. Scale bar represents approximately 
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4.3 The C5b-9 complex is eliminated via endocytosis  
 
It  has  previously  been  shown  that  various  cell  types  such  as  neutrophils, 
oligodendrocytes, platelets and tumour cells protect themselves from C5b-9-induced 
lysis  via  membrane  vesiculation  (Pilzer  and  Fishelson,  2005b).  Membrane 
vesiculation involves the processes of exo-, ecto- and/or endo-cytosis (Pilzer et al., 
2005a, Lakkaraju et al., 2014). Therefore, it was investigated whether the observed 
elimination of C5b-9 from the basal surface of pRPE cells was attributed, at least in 
part, to endocytosis. 
 
pRPE cells were grown on 12-well trans-well plates and the C5b-9 complex was 
allowed to form in vitro as described in method DT (section 2.5.4.1) in the absence or 
presence of dynasore. As a control C5b-6, C7 and C8 proteins were added to the 
basal chamber of the trans-well, for 4 h. To the apical chamber (in all samples, 
including the control) only DMEM was added. Two time points (4 h, 24 h) were 
selected, as we had already shown (Section 4.1) that at 4 h there were high levels of 
C5b-9 complex on the basal surface of pRPE cells while at 24 h these levels were 
significantly lower. Immunofluorescence was used to determine whether dynasore 
administration  maintained  C5b-9  levels  at  24  h.  Figure  31  demonstrates  the 
accumulation of C5b-9 (green staining) on the basal surface of pRPE cells at 4 h, and 
its  elimination  at  24  h.  However,  in  cells  treated  with  the  aforementioned 
complement  proteins  and  dynasore  for  24  h,  C5b-9  staining  remained  at  similar 
levels to those observed at 4 h (Figure 31-Diii). C5b-8-treated cells did not develop 
staining for C5b-9. These studies show that dynasore inhibits the elimination of C5b-
9, confirming that the major mechanism of C5b-9 complex removal in RPE cells is 
via endocytosis.  	 ﾠ 103	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Figure  31.  Dynasore 
blocks  endocytosis  of 
C5b-9 by pRPE cells. On 
the apical chamber of all 
samples (Ai, Bi, Ci and Di) 
only  DMEM  was  added. 
As  a  control  C5b-6,  C7 
and  C8  proteins  were 
added  in  DMEM  to  the 
basal  chamber  of  the 
trans-well,  for  4  h  (Aii). 
C5b-6,  C7,  C8  and  C9 
purified  complement 
proteins  were  added  in 
DMEM  to  the  basal 
chamber of the trans-well, 
for 4 h and 24 h (Bii and 
Cii,  respectively).  Also, 
pRPE  cells  were 
incubated  (basal  surface) 
with C5b-6 complex, C7, 
C8  and  C9  purified 
complement  proteins  in 
DMEM with 200 µg/ml of 
dynasore,  for  24  h  (Dii). 
Dynasore  not  only 
blocked  endocytosis  of 
the C5b-9 complex (green 
staining) at 24 h (Diii) but 
also  sustained  C5b-9 
levels  similar  to  those 
seen at 4 h (Biii). Without 
dynasore,  the  C5b-9 
complex was endocytosed 
(Ciii).  C5b-8  treated  cells 
did  not  develop  staining 
specific  to  the  α-C5b-9 
antibody  (Aiii).  The 
histogram  (E)  provides  a 
quantitative readout of the 
above  findings.  Each  bar 
represents  the  average  of 
the  C5b-9-related 
fluorescence  intensity  as 
measured  from  twelve 
independent  areas  from 
three samples, from three 
independent  experiments, 
using  Imaris
®.  Data 
expressed as mean ± SEM 
***P<0.001. Red staining 
corresponds  to  F-actin, 
blue  staining  to  DAPI. 
Scale  bar  represents 
approximately 20µm.	 ﾠ
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4.4 Cellular localisation of the C5b-9 complex in pRPE cells 
To  further  investigate  the  processing  of  C5b-9  by  RPE  cells  immuno-electron 
microscopy was used to examine the subcellular localisation of the C5b-9 complex in 
more detail.  
 
The  C5b-9  complex  was  allowed  to  form  in  vitro  on  confluent  pRPE  cells  as 
described in method DT (section 2.5.4.1) in the presence or absence of dynasore for 
times indicated in the legend of Figure 32. At the end of the experiment cells were 
processed according to the cryo-EM method, described in Section 2.11. 
 
In cells treated for 4 h with C5b-9, gold particles indicated the presence of the C5b-9 
complex (yellow arrows) on the basal surface of pRPE cells, possibly within basal 
in-foldings (Figure 32).  At 24 h in C5b-9-treated cells, almost no gold particles were 
detected on the basal surface of the cells, however gold particles were identified in 
the cytoplasm of pRPE cells. This is an indication that most of the C5b-9 complex 
was already internalised and most likely degraded in lysosomes, as only a few gold 
particles were detected. However, when cells were treated with complement proteins 
and dynasore for 24 h, a plethora of gold particles was located at the basal surface of 
pRPE cells. This accumulation of gold particles at 24 h is consistent with the arrest 
of C5b-9 endocytosis due to the presence of dynasore. It should be noted that some 
low level background gold labeling was evident in the control sample (blue arrows). 
Figure  32  provides  further  evidence  that  dynasore  maintains  C5b-9  on  the  basal 
aspect of pRPE cells by blocking endocytosis. Figure 32 demonstrates that at 4 h 
despite the majority of the C5b-9 complex residing on the basal surface there is some 
already internalised, though this declines by 24 h. Each bar from both histograms 
(Figure 32) represents the average number of gold particles counted in pRPE cells 
from eight different sections, from one immuno-gold experiment. Counting of the 
gold particles was performed with ImageJ freeware.  
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Figure 32. Localisation of C5b-9 in pRPE cells by immune-electron microscopy. As a control 
C5b-6, C7 and C8 proteins were added in DMEM, to the basal chamber of the trans-well, for 4 h. In 
test samples, C5b-6 complex, C7, C8 and C9 purified complement proteins were added in DMEM to 
the basal chamber of the trans-well ± 200 µg/ml dynasore for 24 h..At 4 h in C5b-9-treated cells, most 
gold particles (yellow arrows) resided on the basal surface of the cells. At 24 h, most of these gold 
particles were eliminated and only a few were identified as internalised due to their distant location 
from the basal surface. At 24 h, in cells treated with complement proteins and dynasore, many gold 
particles  were  located  on  the  basal  surface.  The  histograms  show  that  no  significant  levels  of 
internalised gold particles were detected apart from 4 h. Each bar from both quantification charts 
represents the average number of gold particles counted in pRPE cells from eight different sections, 
from  one  experiment.  Counting  of  the  gold  particles  was  performed  with  ImageJ  freeware.  Data 
expressed as mean ± SEM. Scale bars represent approximately 420nm. The processing of samples for 
immune-electron  microscopy  was  performed  by  Dr.  Thomas  Burgoyne,  UCL  Institute  of 
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4.5 The effect of C5b-9 on trans-epithelial resistance in pRPE cells 
 
These studies show that RPE cells tolerate C5b-9 remarkably well, with virtually no 
evidence of cell death, and that the complex is eliminated from the cell surface at 
least  in  part  by  endocytosis.  Next  we  started  to  investigate  whether  the  C5b-9 
complex might affect any of the numerous functions of RPE cells. First we examined 
the  barrier  properties  of  the  pRPE  monolayer,  since  this  is  a  key  physiological 
feature  of  all  mammalian  epithelia.  This  was  assessed  by  measuring  the  TER 
(Section 2.2) and permeability of the pRPE monolayer with low and high molecular 
weight fluorescent markers (Section 2.3). 
 
4.5.1 TER measurements in C5b-9-treated pRPE cells 
For this study confluent pRPE cells were grown in 12-well trans-well plates. C5b-9 
was allowed to form on the basal surface of these cells as described previously for 1 
h, 4 h, 8 h and 24 h and TER was measured at each time point using an EVOM with 
a  STX2  manual  electrode  (section  2.2).  When  pRPE  cells  were  transferred  from 
serum-containing media (1 % FBS in DMEM) to serum-free conditions (DMEM) 
TER  increased  slightly.  Therefore,  cells  were  incubated  for  1  h  in  serum-free 
conditions in order to allow them to adjust to their new environment, and to allow the 
TER to stabilise as well. Two different controls were used: pRPE cells growing in 
DMEM  (both  apical  and  basal  chambers)  and  C5b-8-treated  cells.  Basal  C5b-9 
complex formation led to a small but significant increase in TER at 1 h that remained 
stable until 24 h (Figure 33). Basal assembly of C5b-8 induced a similar effect on 
TER, however the magnitude of the increase was smaller. The results show that C5b-
9  induced  a  significantly  higher  increase  in  TER  (~90  Ω/cm
2  to  ~130  Ω/cm
2, 
p<0.001) than either the switch to serum-free medium or C5b-8 (p<0.05). In Figure 
32 each bar represents the average TER values obtained from twelve wells from 
three independent experiments. 	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Figure 33. Basal C5b-9 complex assembly increases TER in pRPE cells. For C5b-8 formation, 
C5b-6 complex, C7 and C8 proteins were added in DMEM, to the basal chamber of the trans-well for 
1 h, 4 h, 8 h and 24 h. C5b-9 complex was allowed to form on the basal surface of these cells by 
adding C5b-6 complex, C7, C8 and C9 purified complement proteins. The C5b-9 complex induced a 
higher TER increase than C5b-8 or DMEM alone. This effect was observed from 1 h through to 24 h. 
Each  bar  represents  the  average  TER  values  obtained  from  twelve  wells  from  three  independent 
experiments. Data expressed as mean ± SEM, ***P<0.001, *P<0.05. 
 
 
 
The same effects were observed when C5b-8 and C5b-9 complexes were formed on 
the apical surface of pRPE cells (Figure 34), and again, the increase was greater in 
C5b-9-treated  cells  than  in  DMEM-treated  and  C5b-8-treated  cells.  Each  bar 
represents the average TER values obtained from four wells from one independent 
experiment.  
 
Taken  together,  these  experiments  show  that  the  in vitro  assembly  of  the  C5b-9 
complex leads to an increase in the TER in pRPE cells, regardless of whether it 
forms on the apical or basal surface. 
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Figure 34. Apical C5b-9 complex formation increased TER in pRPE cells. C5b-8 and C5b-9 
complexes were formed on the apical surfaces of pRPE cells as described in the legend of Figure 32. 
Apical C5b-9 complex induced higher TER increase than apical C5b-8 complex and serum-free alone. 
This effect was observed from 1 h until 24 h. Each bar represents the average TER values obtained 
from four wells from one independent experiment. Data expressed as mean ± SEM. 
 
 
 
4.5.2 Effect of C5b-9 on permeability in pRPE cells 
 
Results from the previous section (4.5.1) demonstrate that C5b-9 assembly on pRPE 
cells  leads  to  an  increase  in  TER.  To  investigate  monolayer  integrity  using  an 
alternative approach, low and high molecular weight dextrans were applied to the 
media  (as  described  in  Section  2.3).  Using  both  low  and  high  molecular  weight 
dextrans can provide insight into the extent of barrier permeability, since the low 
molecular weight dextran will penetrate smaller spaces more rapidly. In this study in 
vitro C5b-9 complex formation was applied only to the basal surface of pRPE cells. 
 
When  low  molecular  weight  dextran  (fluorescein  dextran)  was  introduced  to  the 
system (Figure 35), no significant difference was detected in permeability between 
the C5b-8- and C5b-9-treated pRPE monolayers. At 4 h until 8 h, permeability in 
C5b-9-treated cells was slightly lower compared to the permeability of serum-free-
treated cells, however this effect did not last until 24 h, where the system appeared to 
be  saturated,  as  all  samples  (serum-free-,  C5b-8-  and  C5b-9-treated  cells) 	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demonstrated similar permeability to the empty well. Each bar represents the average 
value from four wells from one independent experiment.  
 
 
Figure 35. Permeability assessment of C5b-9-treated pRPE monolayers. C5b-9 was allowed to 
form on the basal cell surface by adding C5b-6 complex, C7, C8 and C9 purified complement proteins 
in DMEM for 1 h, 4 h, 8 h and 24 h. Permeability was monitored by adding 1 mg/ml of low molecular 
weight fluorescein dextran to the apical chamber. Sampling was taken from the basal chamber. No 
significant  difference  was  detected  in  permeability  between  the  C5b-8-  and  C5b-9-treated  pRPE 
monolayers. At 4 h until 8 h, permeability in C5b-9-treated cells was slightly lower compared to the 
permeability of serum-free-treated cells, however this effect did not last until 24 h, where the system 
appeared  to  be  saturated,  as  all  samples  (serum-free-,  C5b-8-,  C5b-9-treated  cells)  demonstrated 
similar permeability to the empty well. Each bar represents the average value from four wells from 
one independent experiment. Data expressed as mean ± SEM. 
 
In order to confirm the findings from Figure 35, permeability was checked again 
with the low molecular weight dextran only at 4 h. As shown previously (Figure 27), 
between 1-4 h there is maximum basal C5b-9 complex deposition in pRPE cells. 
Therefore, it was tested whether fluorescein dextran will demonstrate lower or higher 
permeability of the C5b-9-treated monolayer (by 4 h there are high levels of C5b-9 
basal  deposition)  compared  with  the  permeability  of  the  serum-free-  and  C5b-8-
treated monolayers. Despite the increase in the TER in C5b-9-treated cells at 4 h 
(compared to serum-free-treated cells, Figure 36-A), fluorescein dextran failed to 
demonstrate similar results when permeability was checked at 4 h as well (Figure 36-
B).  Each  bar  represents  the  average  value  derived  from  four  wells  from  one 
independent experiment (Figure 36-A, -B). 	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Figure  36.  Simultaneous  measurement  of  TER  and  permeability  in  pRPE  cells.  Before 
monitoring permeability of C5b-9-treated pRPE cells, TER was checked at 1 h, 4 h, 8 h and 24 h (A).  
Permeability was tested using a 3-5 kDa fluorescein dextran (administered to the apical chamber, that 
remained in the media until 4 h. Samples were taken from the basal compartment at 4 h (B). No 
difference was detected between serum-free-, C5b-8- and C5b-9-treated pRPE monolayers (B). Each 
bar represents the average value derived from four wells from one independent experiment. Data 
expressed as mean ± SEM. 
 
 
 
Using low molecular weight dextrans provides a very sensitive method of detecting 
differences  in  permeability  between  the  three  different  conditions  applied.  For 
comparison, higher molecular weight dextran was also used (rhodamine B-dextran, 
70 kDa). Sampling of rhodamine B-dextran also demonstrated that the differently 
treated pRPE monolayers retained their integrity to a similar extent (Figure 37), with 
all test samples exhibiting much lower values than the empty well at all time points 	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examined. Despite recording lower values for the C5b-9-treated cells, which would 
be consistent with the data obtained using TER measurements, these did not reach 
statistical significance in this set of experiments. Each bar in Figure 37 represents the 
average value obtained from eight wells from two independent experiments. 
 
Figure  37.  Permeability  analysis  of  C5b-9-treated  pRPE  monolayers  using  high  molecular 
weight dextran. C5b-9 was allowed to form on the basal cell surface by adding the C5b-6 complex, 
C7, C8 and C9 purified complement proteins in DMEM for 1 h, 4 h, 8 h and 24 h. Permeability was 
monitored by adding 1 mg/ml of high molecular weight rhodamine B dextran (70 kDa) to the apical 
chamber. Measurement of fluorescence in the lower chamber demonstrated that the differently treated 
pRPE monolayers retained their integrity, as the fluorescence values were much lower than those 
obtained from the empty well, at all time points examined. However, no significant differences in 
permeability  were  detected  between  serum-free-,  C5b-8-  and  C5b-9-treated  pRPE  cells.  Each  bar 
represents the average values from eight wells from two independent experiments. Data expressed as 
mean ± SEM. 
 
 
 
4.6 Does the C5b-9 complex affect levels of junctional proteins? 
 
To further investigate possible causes for the aforementioned C5b-9-induced TER 
increase in pRPE cells, the expression of two abundant junctional proteins in RPE 
cells (claudin-19 and ZO-1) was examined. ZO-1, is part of the junctional complex, 
and by binding to ZONAB, can control proliferation in epithelial cells (Balda et al., 
2003, Balda and Matter, 2000, Stevenson et al., 1986, Fanning et al., 2012). The 
better the monolayer RPE cells have formed the more ZO-1 becomes enriched at 
junctions  and  therefore  cell  proliferation  is  inhibited  (Balda  et  al.,  2003). 
Additionally, claudin-19 is a key component of the tight junctions in human RPE 	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cells and also in the kidney, having a crucial role in paracellular ion re-absoption in 
both tissues (Konrad et al., 2006, Hou and Goodenough, 2010).  
 
The aim of this experiment was to find out whether C5b-9 assembly leads to an 
increase  in  expression  of  any  key  junctional  proteins  that  would  provide  a 
mechanistic explanation for the rise in TER described earlier. However, western blot 
analysis  did  not  reveal  any  significant  changes  in  protein  expression  of  either 
claudin-19 or ZO-1 (Figure 38) in any of the various conditions. Each bar in Figure 
38 represents the average values derived from three wells from three independent 
experiments. 
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Figure 38. Exposure to C5b-9 does not alter expression of claudin-19 or ZO-1 in pRPE cells. The 
C5b-9 complex was allowed to form on the basal surface of pRPE cells by adding C5b-6, C7, C8 and 
C9 purified complement proteins in DMEM for 1 h, 4 h, 8 h and 24 h. Cells were extracted and whole 
cell lysates were analysed by SDS-PAGE and western blotting. Expression levels of both claudin-19 
(A) and ZO-1 (B) remained relatively constant throughout. Blots were scanned and densitometric 
analysis yielded the respective histograms. Each bar represents the average values derived from three 
wells from three independent experiments. Data expressed as mean ± SEM. 
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4.7 Claudin-19 expression in C5b-9-treated pRPE cells 
Although western blotting did not reveal any significant changes in protein levels of 
claudin-19 upon treatment of pRPE cells with C5b-9 (section 4.6) it was possible that 
changes in the subcellular localisation of claudin-19 might be consistent with the 
effect  on  TER.  To  address  this  possibility  immunofluorescence  analysis  was 
performed on pRPE cells exposed to basal C5b-9 for 1 h (Figure 39). The results 
show that there was no difference in the pattern of claudin-19 staining in serum-free- 
(Figure  39-Bi),  C5b-8-  (Figure  39-Ci)  and  C5b-9-treated  cells  (Figure  39-Di). 
However, simply switching pRPE cells to serum-free medium has a striking effect on 
its own. Thus, under normal culture conditions, claudin-19 was mainly punctate and 
cytoplasmic with only faint staining at the cell junctions (Figure 39-A), whereas in 
serum-free conditions it became tightly localised to the cell junctions and almost 
undetectable in the cytoplasm. This observation is consistent with the small increase 
in TER observed in pRPE cells in serum-free medium (Figure 33) but cannot account 
for the more significant rise in TER in cells exposed to C5b-9. In Figure 39, this 
analysis was extended to cells at 4 h, 8 h and 24 h respectively. The images show 
that while there was little discernable change from 1-8 h, at 24 h there was a clear 
reappearance of punctate cytoplasmic staining for claudin-19, with a corresponding 
decrease in enrichment at the cell junctions. It should be mentioned however, that 
C5b-9-treated pRPE cells at 4 h developed stronger staining for claudin-19 compared 
to serum-free- and C5b-8-treated cells.  
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Figure 39. Immunofluorescence analysis of claudin-19 in C5b-9-treated pRPE cells. In the apical 
chamber  of  all  samples  only  DMEM  was  added.  Two  different  controls  were  used:  pRPE  cells 
growing  with  DMEM  in  both  apical  and  basal  chambers,  and  C5b-8-treated  cells.  For  C5b-8 
formation, C5b-6 complex, C7 and C8 proteins were added in DMEM, on the basal chamber of the 
trans-well, for 1 h, 4 h, 8 h and 24 h. C5b-9 complex was allowed to form on the basal surface of 
pRPE cells by adding C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM, for 1 
h, 4 h, 8 h and 24 h. Untreated cells (A) were pRPE cells grown in 1 % FBS in DMEM. No changes in 
claudin-19 expression (green staining) between serum-free- (Bi-iv), C5b-8- (Ci-iv) and C5b-9-treated 
cells  (Di-iv)  were  observed.  However,  C5b-9-treated  pRPE  cells  at  4  h  (Dii)  developed  stronger 
staining for claudin-19 compared to serum-free- (Bii) and C5b-8-treated cells (Cii).  The transition 
from 1 % FBS to serum-free conditions seemed to affect expression of claudin-19. Blue staining 
represents DAPI. Scale bar represents approximately 15µm. 
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4.8 ZO-1 expression in C5b-9-treated pRPE cells  
In a parallel study to that just described for claudin-19, the cellular expression of ZO-
1  was  examined  in  pRPE  cells  exposed  to  C5b-9,  using  immunofluorescence  in 
conjunction with confocal microscopy (Figure 40). The results show that there was 
no difference in the pattern of ZO-1 staining in serum-free- (Figure 40-Bi-iv), C5b-8- 
(Figure  40-Ci-iv) and  C5b-9-treated  cells  (Figure  40-Di-iv).  In  contrast  to  findings 
presented in Figure 39, switching pRPE cells from 1 % FBS to serum-free conditions 
did not alter the pattern of ZO-1 staining. 
 
 
 
 
Figure 40.  Immunofluorescence analysis of ZO-1 in C5b-9-treated pRPE cells.  To  the apical 
chamber  of  all  samples  only  DMEM  was  added.  Two  different  controls  were  used:  pRPE  cells 
growing in DMEM, on both apical and basal chambers and C5b-8-treated cells. For C5b-8 formation, 
C5b-6 complex, C7 and C8 proteins were added in DMEM, on the basal chamber of the trans-well, for 
1 h, 4 h, 8 h and 24 h. C5b-9 complex was allowed to form on the basal surface of pRPE cells by 
adding C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM, for 1 h, 4 h, 8 h and 
24 h.  Untreated cells (A) were pRPE cells grown in 1 % FBS in DMEM. No changes in ZO-1 
expression (red staining) between, untreated (A) serum-free- (Bi-iv), C5b-8- (Ci-iv) and C5b-9-treated 
cells (Di-iv) were reported. Blue staining represents DAPI. Scale bar represents approximately 15µm. 
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4.9 C5b-9 endocytosis and TER in pRPE cells  
 
Results in this chapter showed that dynasore arrests endocytosis of C5b-9 on the 
basal surface of pRPE cells (section 4.3). Therefore, it was questioned whether the 
endocytosis and degradation of C5b-9 is important in linked in any way to the effects 
observed  on  TER.  To  answer  this  question,  pRPE  cells  were  incubated  with 
complement proteins and dynasore monohydrate, simultaneously, for 1 h, 4 h, 8 h 
and  24  h.  At  the  end  of  each  incubation  time,  TER  was  measured  according  to 
method 2.2. 
 
As shown in Figure 41, basal C5b-9 complex deposition induced an increase in TER 
from 1 h until 24 h, as expected. However, when pRPE cells were incubated with 
complement proteins and dynasore, the TER remained unchanged, suggesting that 
endocytosis of C5b-9 from the cell surface might indeed mediate or contribute to the 
observed change in TER. Dynasore on its own did not affect TER values when pRPE 
cells were incubated with the reagent alone in DMEM.  
 
Figure  41.  Maintenance  of  C5b-9  on  the  cell  surface  blocks  the  rise  in  TER.  On  the  apical 
chamber of all samples only DMEM was added. As a control pRPE cells were incubated in DMEM 
with 200 µg/ml of dynasore (basal chamber) alone. Basal deposition of C5b-9 induced a TER increase 
from  1  h  until  24  h.  However,  TER  values  remained  unchanged  when  cells  were  treated  with 
complement proteins and dynasore at the same time. Dynasore alone did not affect TER. Each data 
point  represents  the  average  value  of  twelve  wells  from  three  independent  experiments.  Data 
expressed as mean ± SEM, ***P<0.001. 
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4.10 Does inhibition of C5b-9 endocytosis affect expression levels of claudin-19 
and ZO-1 junctional proteins? 
 
Having  shown  that  the  prolonged  presence  of  the  C5b-9  complex  on  the  basal 
surface of pRPE cells blocks the rise in TER, we next examined whether C5b-9 + 
dynasore down-regulates the expression of claudin-19 and ZO-1 (Figure 42). 
 
Western  blotting  of  whole  cell  lysates  from  control  and  C5b-9-treated  cells  ± 
dynasore revealed no significant changes in the protein levels of either claudin-19 or 
ZO-1.  
 
Figure 42. Prolonged presence of C5b-9 complex does not affect claudin-19 and ZO-1 protein 
levels in pRPE cells. To the apical chamber of all samples only DMEM was added. Four different 
controls were used: pRPE cells growing in 1 % FBS in DMEM media (Untreated), cells incubated 
with DMEM + DMSO (Vehicle), cells incubated with DMEM + 200 µg/ml of dynasore (Dynasore) 
and C5b-8-treated cells. For C5b-8 formation, C5b-6 complex, C7 and C8 proteins were added in 
DMEM, on the basal chamber of the trans-well. C5b-9 was formed on the basal surface of pRPE cells 
by adding C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM ± 200 µg/ml of 
dynasore. Cells were extracted and whole cell lysates were analysed by SDS-PAGE and western 
blotting. No changes were detected in the protein levels of claudin-19 and ZO-1 relative to GAPDH 
loading control.  
  
 
4.11 Does inhibition of C5b-9 endocytosis affect the localisation of claudin-19? 
 
Although western blotting showed that protein bands of claudin-19 and ZO-1 were 
unaffected by C5b-9, when endocytosis of the complex was blocked by dynasore, it 
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subcellular  localisation  of  these  proteins.  To  investigate  this  possibility 
immunofluorescence  analysis  was  performed  to  cells  treated  with  C5b-9  in  the 
presence and absence of dynasore. 
 
In  untreated-cells  (Figure  43-Ai-ii),  vehicle  control  (Figure  43-Bi-ii),  dynasore- 
(Figure 43-Ci-ii) and C5b-8-treated cells (Figure 43-Di-ii) the pattern of claudin-19 
protein expression was broadly similar. Cells treated with C5b-9 complex for 4 h 
(Figure  43-Ei-ii)  demonstrated  a  much  stronger  and  more  specific  staining  for 
claudin-19 protein at the cell junctions. This observation is in line with results from 
Figure 39-Dii, where cells treated with C5b-9 for 4 h, demonstrated a stronger and 
more specific pattern of claudin-19 staining. On the other hand, claudin-19 staining 
in C5b-9-treated cells for 24 h (Figure 43-Fi-ii) and C5b-9 + dynasore-treated cells for 
24 h (Figure 43-Gi-ii) was similar to that in all four control samples. 	 ﾠ 120	 ﾠ
 
Figure 43. Claudin-19 expression in pRPE cells in which C5b-9 complex endocytosis has been 
arrested. To the apical chamber of all samples only DMEM was added. Four different controls were 
used: pRPE cells growing in 1 % FBS DMEM (Ai-ii), cells incubated with DMEM + DMSO (Bi-ii), 
cells incubated with DMEM + 200 µg/ml of dynasore (Ci-ii) and C5b-8-treated cells (Di-ii). For C5b-8 
formation, C5b-6 complex, C7 and C8 proteins were added in DMEM, on the basal chamber of the 
trans-well, for 4 h. In pRPE cells, C5b-9 complex was allowed to form on the basal surface by adding 
C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM for 4 h (Ei-ii). Also, pRPE 
cells were incubated with C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM ± 
200 µg/ml of dynasore for 24 h (Fi-ii and Gi-ii, respectively). Claudin-19 protein levels (green staining) 
remained stable, except from C5b-9-treated cells for 4 h, where claudin-19-specific staining appeared 
to be stronger and more specific. Blue staining represents DAPI. Scale bar represents approximately 
15µm. 
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4.12 Does C5b-9 complex formation influence expression of CD59 and DAF? 
As CD59 and DAF are two well-characterised negative regulators of the complement 
system  (Tomlinson,  2006,  Brodbeck  et  al.,  2000),  it  was  examined  whether 
expression of either of these two membrane-bound regulators is altered in response 
to  the  in vitro assembly  of  C5b-9  complex  in  pRPE  cells.  Western  blot  analysis 
revealed no significant changes in protein levels of DAF (Figure 44A) or CD59 
(Figure 44B) in the various conditions. 
 
Figure 44. C5b-9 assembly does not affect protein expression of CD59 and DAF. On the apical 
chamber  of  all  samples  only  DMEM  was  added.  Two  different  controls  were  used:  pRPE  cells 
growing in DMEM (serum-free conditions) on both apical and basal chambers, and C5b-8-treated 
cells. For C5b-8 formation, C5b-6 complex, C7 and C8 proteins were added in DMEM, on the basal 
chamber of the trans-well, for 1 h, 4 h, 8 h and 24 h. C5b-9 was allowed to form on the basal surface 
of these cells by adding C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM, for 
1 h, 4 h, 8 h and 24 h. Cells were extracted and whole cell lysates were analysed by SDS-PAGE and 
western blotting. Western blotting did not reveal any alteration in protein expression of both DAF (A) 
and CD59 (B) complement negative regulators between the different conditions relative to GAPDH 
loading  control.  Histograms  of  band  intensities  were  generated  by  densitometric  scanning  of  the 
western blots, with normalisation to the loading controls. Each bar represents the average values 
derived from three wells from three independent experiments. Data expressed as mean ± SEM. 	 ﾠ 122	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4.13 Does prolonged presence of C5b-9 complex affect protein levels of DAF and 
CD59 complement negative regulators? 
 
To extend the studies in Section 4.12 it was tested whether the combination of C5b-9 
+ dynasore would have any effect on the expression of DAF and CD59. Blot analysis 
revealed no alterations in the protein levels of both CD59 and DAF (Figure 45).  
 
Figure 45. Prolonged presence of C5b-9 complex does not affect CD59 and DAF protein levels in 
pRPE cells. To the apical chamber of all samples only DMEM was added. Four different controls 
were used: pRPE cells growing in 1 % FBS DMEM media (Untreated), cells incubated with DMEM + 
DMSO (Vehicle), cells incubated with DMEM + 200 µg/ml of dynasore and C5b-8-treated cells. For 
C5b-8 formation, C5b-6 complex, C7 and C8 proteins were added in DMEM to the basal chamber of 
the trans-well for 24 h. C5b-9 was formed on the basal surface of pRPE cells by adding C5b-6, C7, C8 
and  C9  purified  complement  proteins  in  DMEM  ±  200  µg/ml  of  dynasore  for  24  h.  Cells  were 
extracted and whole cell lysates were analysed by SDS-PAGE and western blotting. No changes were 
detected in the protein levels of CD59 and DAF relative to GAPDH loading control.  
 
 
 
4.14 Effect of the C5b-9 complex on pRPE cell mitochondria  
 
RPE  cells  are  highly  metabolically  active  and  in  order  to  function  properly  it  is 
essential  that  their  cytoplasm  is  rich  in  mitochondria  (Jarrett  et  al.,  2008). 
Mitochondrial  dysfunction  has  been  linked  to  AMD,  as  previous  research 
demonstrated  that  mitochondria  derived  from  RPE  cells  from  AMD  patients  are 
reduced in numbers, suffer from mtDNA mutations, have altered morphology and 
have changes in their content of proteins essential for protein trafficking (Feher et al., 
2006, Nordgaard et al., 2008).  
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The aim of this experiment was to investigate whether C5b-9 affects mitochondria in 
pRPE  cells.  For  the  purpose  of  this  experiment  Mitotracker
® Red  CMXRos  was 
administered. Mitotracker
® labels mitochondria within live cells (Chazotte, 2011). 
On the basal surface of confluent pRPE cells grown in 12-well trans-well plates, 
C5b-9 complex was allowed to form in the presence and absence of dynasore for 24 
h.  On  the  apical  chamber  of  all  samples,  where  only  DMEM  was  added, 
Mitotracker
® Red CMXRos was added in the media for 30 min. Then cells were 
washed with sterile PBS, fixed with 4 % PFA and processed for immunofluorescence 
(Section 2.9). 
 
Fluorescence analysis of the Mitotracker
®-specific staining (red staining), in Figure 
46, demonstrated that C5b-9 complex alone at 24 h (Figure 46-Di,iii) did not cause 
any  discernable  changes  to  gross  mitochondria-associated  fluorescence,  when 
compared with either of the control samples (Figure 46-Ai,iii, -Bi,iii, -Ci-,iii). However, 
when endocytosis of C5b-9 complex was blocked with dynasore for 24 h (Figure 46- 
Ei,iii)  the  Mitotracker
®-specific  staining  was  greatly  reduced.  The  histogram 
quantifies (Figure 46-F) the Mitotracker
® staining from one independent experiment 
(three different Z-sections per sample per experiment). This observation suggests 
that the prolonged presence of C5b-9 complex on the basal surface of pRPE cells 
reduces either mitochondrial numbers and/or mitochondrial integrity. 
 
However, the precise mechanism of how Mitotracker
® accesses the cytoplasm of live 
RPE cells and how it recognises metabolically active mitochondria is currently not 
well understood. Therefore, in order to validate findings from Figure 46 the same 
studies were performed, but this time using a marker for an integral mitochondrial 
protein. 
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Figure  46.  Prolonged 
presence  of  C5b-9 
reduces  Mitotracker
® 
staining in pRPE cells. 
To the apical chamber of 
all samples only DMEM 
was  added.  Three 
different  controls  were 
used:  pRPE  cells 
incubated with DMEM + 
DMSO  (Ai-iii),  cells 
incubated with DMEM + 
200  µg/ml  of  dynasore 
(Bi-iii)  and  C5b-8-treated 
cells  (Ci-iii).  For  C5b-8 
formation,  C5b-6 
complex,  C7  and  C8 
proteins  were  added  in 
DMEM,  on  the  basal 
chamber  of  the  trans-
well  for  24  h.  In  pRPE 
cells,  C5b-9  complex 
was allowed to form on 
the  basal  surface  by 
adding  C5b-6  complex, 
C7, C8 and C9 purified 
complement  proteins  in 
DMEM for 24  h  (Di-iii). 
Also,  pRPE  cells  were 
incubated  with  C5b-6 
complex, C7, C8 and C9 
purified  complement 
proteins  in  DMEM  + 
200  µg  ml  of  dynasore 
for  24  h  (Ei-iii). 
Mitotracker
®  Red 
CMXRos  (red  staining) 
was added in the media 
of  all  samples,  30  min 
before  cells  were  fixed. 
C5b-9  complex 
formation at 24 h (Di,iii) 
did  not  affect 
mitochondrial  staining 
when compared to any of 
the  control  samples 
(Ai,iii,  Bi,iii,  and  Ci,iii) 
according  to  the 
Mitotracker
®  staining. 
However,  when 
endocytosis of C5b-9 complex was arrested, mitochondrial staining was greatly reduced (Ei,iii). The 
histogram (F) quantifies the above observations. Each bar represents the average fluorescence volume 
specific to the Mitotracker
® staining derived from three z-sections per sample from one independent 
experiment. Data expressed as mean ± SEM. Blue staining represents DAPI. Scale bar represents 
approximately 15µm.	 ﾠ
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4.15 C5b-9 complex reduces Tim23 staining in pRPE cells 
 
The aim of this study was to validate the findings from Section 4.14. The interplay 
between  C5b-9  complex  formation  and  mitochondrial  integrity  was  examined  by 
staining mitochondria for Tim23. Tim23 is a mitochondrial translocase, a member of 
the TIM23 complex, essential for protein import in mitochondria (Donzeau et al., 
2000).  Tim23  spans  the  inner  and  outer  mitochondrial  membranes  in  order  to 
function and therefore its stability in mitochondria makes Tim23 an ideal protein for 
these studies (Donzeau et al., 2000). 
 
To perform these studies, confluent pRPE cells (passage 1) were used. In untreated 
cells (Figure 47-Ai-ii), vehicle control (Figure 47-Bi-ii), dynasore- (Figure 47-Ci-ii) and 
C5b-8-treated cells (Figure 47-Di-ii) Tim23 staining remained constant. Cells treated 
with C5b-9 for 24 h (Figure 47-Ei-ii) also demonstrated similar intensity of Tim23-
staining  to  the  above  controls.  On  the  other  hand,  Tim23  staining  in  C5b-9  + 
dynasore-treated  cells  (Figure  47-Fi-ii)  was  greatly  reduced,  consistent  with  the 
Mitotracker
® staining in Figure 46. Quantification (Figure 47-G) of these images 
confirms  that  blocking  endocytosis  of  C5b-9  leads  to  a  significant  (P<0.001) 
reduction  in  Tim23  staining. Each  bar  represents  the  fluorescence  specific  to  the 
Tim23
 staining from three independent experiments (four different Z-sections per 
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Figure 47. C5b-9 complex reduces Tim23 staining in pRPE cells. To the apical chamber of all 
samples only DMEM was added. Four different controls were used: pRPE cells growing in 1 % FBS 
DMEM (Ai-ii), cells incubated with DMEM + DMSO (Bi-ii), cells incubated with DMEM + 200 µg/ml 
of dynasore (Ci-ii) and, C5b-8-treated cells (Di-ii). For C5b-8 formation, C5b-6 complex, C7 and C8 
proteins were added in DMEM, on the basal chamber of the trans-well for 24 h.  pRPE cells were 
incubated with C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM ± 200 µg/ml 
of dynasore for 24 h (Ei-ii and Fi-ii, respectively). Tim23 protein levels (green staining) were similar in 
all  samples,  except  for  C5b-9  +  dynasore-treated  cells  (Fi-ii),  where  Tim23-specific  staining  was 
greatly reduced. The histogram quantifies these observations (G). Each bar represents the fluorescence 
specific  to  the  Tim23
 staining  from  three  independent  experiments  (four  different  Z-sections  per 
sample per experiment). Data expressed as mean ± SEM, ***P<0.001. Blue staining corresponds to 
DAPI. Scale bar represents approximately 15µm. 
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4.16 The C5b-9 complex reduces mitochondria numbers in pRPE cells 
 
Although immunofluorescence analysis of Tim23 and Mitotracker
® staining suggests 
that the prolonged presence of the C5b-9 complex (induced by dynasore) decreases 
the mitochondrial content of pRPE cells, these studies do not give any information 
about actual mitochondria numbers.  
 
To investigate whether the C5b-9 complex on the basal surface of pRPE cells affects 
the  number  of  mitochondria,  electron  microscopy  (EM)  was  performed  (Section 
2.12) in order to permit mitochondria counting.  
 
EM  analysis  provided  ultra-structural  information  about  general  RPE  cell 
morphology and mitochondria numbers (Figure 48, 49). Overall, pRPE cells under 
all  control  conditions  retained  a  normal  phenotype.  However,  pRPE  cells  treated 
with complement proteins and dynasore for 24 h demonstrated clear abnormalities, 
with  cells  containing  large  vacuolar  structures  and  fewer  mitochondria. 
Quantification  of  mitochondria  in  these  samples  confirmed  a  reduction  in 
mitochondria number in cells treated with C5b-9 + dynasore, and also in cells treated 
with C5b-9 alone (Figure 50). 
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Figure 48. Effect of C5b-9 on mitochondria numbers in pRPE cells. To the apical chamber of all 
samples only DMEM was added. Four different controls were used: pRPE cells growing in 1 % FBS 
DMEM media, cells incubated with DMEM + DMSO, cells incubated with DMEM + 200 µg/ml of 
dynasore and C5b-8-treated cells. For C5b-8 formation, C5b-6 complex, C7 and C8 proteins were 
added in DMEM, on the basal chamber of the trans-well for 24 h. pRPE cells were incubated with 
C5b-6 complex, C7, C8 and C9 purified complement proteins in DMEM ± 200 µg/ml of dynasore for 
24  h.  C5b-9  +  dynasore-treated  cells  developed  a  less  healthier  phenotype.  C5b-9-  and  C5b-9  + 
dynasore-treated  cells  displayed  a  decline  in  mitochondria  numbers.  Scale  bars  represent 
approximately 1.5µm. Nu, Nucleus ; PG, Pigment Granule. Yellow boxes refer to high power images 
in Figure 48. Sample processing for EM was performed by Dr. Thomas Burgoyne, UCL Institute of 
Ophthalmology. 
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Figure  49.  High  power  images  of  mitochondria  from  pRPE  cells.  High  power  images  of 
mitochondria from pRPE cells treated with DMEM ± 200 µg/ml of dynasore alone, C5b-9 and C5b-9 
+ dynasore for 24 h, as described in detail in the legend of Figure 47. The structure of mitochondria 
(blue arrow) appeared to be adversely affected from the simultaneous presence of C5b-9 + dynasore 
when compared to mitochondria structure of pRPE cells treated either with C5b-9 or dynasore alone. 
Scale bars represent approximately 1.5µm. Nu, Nucleus; PG, Pigment Granule. Sample processing for 
EM was performed by Dr. Thomas Burgoyne, UCL Institute of Ophthalmology. 
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Figure  50.  C5b-9  reduces  mitochondria  numbers  in  pRPE  cells.  The  histogram  provides 
quantitative analysis of the images in Figure 47. C5b-9- and C5b-9 + dynasore-treated cells reported a 
decline  in  mitochondria  numbers.  Each  bar  in  the  histogram  represents  the  average  number  of 
mitochondria counted in pRPE cells from five different sections, from one independent experiment. 
Data expressed as mean ± SEM. Counting of mitochondria was performed with ImageJ freeware. 
 
 
4.17 Western blot analysis of Tim23 and cytochrome C in C5b-9-treated pRPE 
cells 
 
Immunofluorescence analysis (Section 4.15) of Tim23 protein suggested that C5b-9 
reduces expression of this protein in the presence of dynasore. To investigate this 
further, the protein levels of Tim23 and cytochrome C were examined by western 
blotting in pRPE cells exposed to C5b-9 + dynasore. Cytochrome C is attached to the 
inner membrane of mitochondria where it promotes electron transfer (Sanghera and 
Pinheiro, 2000). Its release from mitochondria indicates the initiation of apoptosis, 
during which, permeability of the outer and inner membranes increases and therefore 
leads to mitochondrial swelling and rupture (Ott et al., 2002). 
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Western blot analysis did not reveal any significant expression changes either in 
Tim23 or cytochrome C protein levels (Figure 51).  These results suggest that whilst 
C5b-9  in  the  presence  of  dynasore  causes  loss  of  mitochondrial  enrichment  of 
Tim23, the protein is still present at normal levels in the RPE cells. 
 
Figure 51. Western blot analysis of Tim23 and cytochrome C in C5b-9-treated pRPE cells. To 
the apical chamber of all samples only DMEM was added. Four different controls were used: pRPE 
cells growing in 1 % FBS DMEM (Untreated), cells incubated with DMEM + DMSO (Vehicle), cells 
incubated with DMEM + 200 µg/ml of dynasore and C5b-8-treated cells. For C5b-8 formation, C5b-6 
complex, C7 and C8 proteins were added in DMEM, on the basal chamber of the trans-well for 24 h. 
pRPE cells were incubated with C5b-6 complex, C7, C8 and C9 purified complement proteins in 
DMEM ± 200 µg/ml of dynasore for 24 h. Cells were extracted and whole cell lysates were analysed 
by SDS-PAGE and western blotting (A). Blots were scanned and densitometric analysis yielded the 
respective histograms (B). No significant changes either in Tim23 or cytochrome C protein levels 
were observed. GAPDH was used as a loading control. Results were derived from three independent 
experiments. Data expressed as mean ± SEM. Blots were quantified by using Image J freeware. 
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4.18 - Discussion  
• Elimination of the C5b-9 complex by endocytosis 
  
Work  in  this  chapter  shows  that  when  C5b-9  was  allowed  to  form  on  the  basal 
surface of pRPE cells it did so rapidly, being evident at 1 h, and almost absent again 
by 24 h (Figure 27, 28, respectively). These studies formed the starting point for a 
detailed examination of the formation and elimination of C5b-9 on the basal surface 
of pRPE cells. Administration of dynasore led to retention of the C5b-9 complex on 
the basal surface of pRPE cells at 24 h (Figure 31), showing that C5b-9 complex 
elimination from the basal surface can be largely attributed to endocytosis.  
 
Endocytosis is one of several mechanisms that cells use to remove C5b-9. Previous 
research has demonstrated that some cell types survive C5b-9 attack by membrane 
vesiculation, a process that could involve exo-, ecto- and/or endo-cytosis (Figure 52) 
(Pilzer  et  al.,  2005a,  Lakkaraju  et  al.,  2014).  Thus,  when  Pilzer  et  al.,  (2005a) 
incubated K562 cells, a human erythroleukemic cell line, with 50 % complement-
competent  NHS,  C5b-8  and  C5b-9  complexes  were  expelled  to  the  extracellular 
space via membrane vesiculation. Western blot and ELISA analysis demonstrated 
that even after 5 min exposure to complement-competent media, mortalin, known for 
its ability to bind C8 and C9 proteins, was released to cell media (Saar Ray et al., 
2014). Other pore-forming molecules, such as streptolysin O did not induce release 
of mortalin, indicating the specificity of this protein for C8 and C9. This mortalin-
dependent mechanism aids the clearance of the cell membranes from complement 
attack.  When  K562  cells  were  treated  with  anti-mortalin  antibodies,  prior  to  the 
addition of NHS, they lysed due to the insufficient clearance of C5b-9 complex.  	 ﾠ 133	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Figure 52. Schematic representation of the mechanism(s) of C5b-9 elimination. Some cell types, 
including RPE cells, use the process of membrane vesiculation to remove C5b-9 complex. Membrane 
vesiculation  includes  the  processes  of  ecto-,  exo-  and/or  endocytosis.  Ectocytosis  involves  the 
removal of the membrane-bound C5b-9 to the extracellular space, whereas endocytosed C5b-9 can 
either  return  to  the  cell  surface,  from  which  becomes  expelled  (exocytosis)  or  gets  degraded  in 
lysosomes following its fusion with multi-vesicular bodies (MVB), in the cytoplasm. Image adapted 
from Pilzer et al., (2005a). 
 
 
Live cell imaging and immunofluorescence analysis of C5b-9-treated cells shed more 
light on the membrane trafficking of the C5b-9 complex. Upon treatment of K562 
cells with C9-deficient human sera and fluorescently-tagged C9 protein the C5b-9 
complex  was  expelled  from  the  cell  surface  via  outward  vesiculation. 
Simultaneously,  C5b-9  complex  was  found  in  the  perinuclear  bodies  along  with 
fluorescently-tagged transferrin, as a result of inward vesiculation (Moskovich and 
Fishelson,  2007).  The  process  of  inward  vesiculation  was  further  examined  by 
Moskovich et al., (2012), who demonstrated that endocytosis of C5b-9 complex is a 
dynamin-2 and caveolin-1 dependent process. Incubation of K562 cells with 60 or 80 
µM  dynasore  for  30  min  at  37 
oC,  inhibited  the  endocytosis  of  C5b-9  complex 
(Moskovich et al., 2012).  
 
If  it  is  assumed  that  outward  vesiculation  would  be  unaffected  by  dynasore,  the 
results suggest that endocytosis is the major mechanism by which pRPE cells dispose 
of C5b-9. The quantitative immunofluorescence studies were further validated by 
immuno-gold  labeling  specific  to  C5b-9  (Figure  32).  At  4  h  most  gold  particles 	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specific to the α-C5b-9 antibody were enriched at the basal surface of pRPE cells 
(Figure  32).  By  24  h  these  gold  particles  were  almost  all  localised  within  the 
cytoplasm of pRPE cells, however their precise location, for instance lysosomes, 
could  not  be  identified.  Upon  dynasore  administration,  C5b-9  did  not  become 
endocytosed  but  accumulated  on  the  basal  surface  instead.  Perhaps  direct 
conjugation of gold particles to purified C9, instead of the α-C5b-9 antibody, could 
provide a better insight into the cellular trafficking of the C5b-9 complex. However, 
in the event of rapid lysosomal degradation of C5b-9 within pRPE cells, this method 
may  also  have  limited  sensitivity  in  identifying  the  fate  of  internalised  C5b-9 
complexes. 
 
Overall, the above K562-related studies are in accordance with these pRPE studies. 
C5b-9 may assemble rapidly on the cell surface and it appears to be eliminated, 
primarily by endocytosis. It is worth noting in our studies that only a relatively high 
concentration of dynasore (200 µM) was able to inhibit the elimination of C5b-9 
complex  from  the  basal  surface  of  cells  (Figure  31).  In  pRPE  cells  lower 
concentrations of dynasore (80 µM) that are typically used in other cell types, did not 
inhibit endocytosis of C5b-9.  
 
 
• The C5b-9 complex and trans-epithelial resistance 
One  striking  and  highly  reproducible  observation  was  that  the  C5b-9  complex 
increases TER in pRPE cells (Figure 33). Basal assembly of C5b-8 conferred the 
same effect on TER, however the magnitude of the increase was significantly lower 
than that observed with C5b-9. It was observed that apical C5b-9 complex formation 
also increased the TER (Figure 34) demonstrating that the effect of C5b-9 did not 
depend on its formation site. 
 
Despite  the  consistency  of  our  observations,  they  are  at  odds  with  what  has 
previously been shown. TER measurements derived from both hfRPE and ARPE-19 
cells  incubated  with  hydrogen  peroxide  and  complement-sufficient  sera  were 
reported to be significantly lower than TER measurements acquired from control 
cells (Bandyopadhyay and Rohrer, 2012, Thurman et al., 2009, Joseph et al., 2013). 
These studies led the authors to conclude that C5b-9 can disrupt monolayer integrity. 	 ﾠ 135	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However, this C5b-9-induced decline in TER only occurred when ARPE-19 cells 
were  first  sensitised  with  hydrogen  peroxide  and  then  treated  with  complement 
proteins. Other studies have shown that C5b-9 on its own does not compromise TER 
in RPE cells (Lueck et al., 2012). These authors reported that when ARPE-19 cells 
grown  on  trans-well  plates,  were  treated  either  with  2  %  or  4  %  complement-
competent human sera at the basolateral surface for 24 h, TER remained stable.  
 
One  reported  case  in  which  TER  was  increased,  was  when  ARPE-19  cells  were 
exposed  to  endoplasmic  reticulum  (ER)  stress,  using  either  tunicamycin  or 
thapsigargin (Yoshikawa et al., 2011). Although this study examined ER stress alone 
and did not consider complement or C5b-9, other studies in glomerular epithelial 
cells have shown that the C5b-9 complex has the capacity to induce ER stress. Here, 
C5b-9 increased the expression of two well-known ER-stress-related proteins: bip 
and grp94 (Cybulsky et al., 2002). The increase in TER observed in our studies in 
C5b-9-treated pRPE cells could therefore be a consequence of ER stress. However, 
to further support this notion, western blot and RT-PCR studies would need to be 
performed  in  order  to  examine  the  expression  of  ER-stress-related  proteins  and 
mRNA, respectively. 
 
The above TER studies were combined with permeability assays using fluorescent 
dextrans to further investigate the integrity of the C5b-9-treated pRPE monolayer. 
Although  using  low  and  high  molecular  weight  dextrans  to  detect  changes  in 
monolayer permeability is an established method (Balda et al., 1996, Phillips et al., 
2008), in these studies, the method seemed to be less sensitive and yielded variable 
results.  
 
To further examine the mechanism/s behind the C5b-9-induced TER increase, as 
observed  in  Figures  33  and  34,  the  expression  of  two  junctional  proteins  was 
examined: claudin-19 and ZO-1. Claudin-19 is the most abundant junctional protein 
of the claudin family in RPE cells, therefore its expression was examined via western 
blotting and immunofluorescence in C5b-9-treated pRPE cells (Peng et al., 2011, 
Peng  et  al.,  2012).  Despite  the  failure  of  western  blotting  to  demonstrate  any 
differences in claudin-19 expression, immunofluorescence analysis detected a much 
stronger staining for claudin-19 at the cell junctions in C5b-9-treated cells at 4 h 	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(Figure 39). While no differences in claudin-19-specific staining were observed at 1 
h, 8 h and 24 h, at 4 h claudin-19 staining appeared to be more specific in C5b-9-
treated cells compared to the controls. As the increase in TER in C5b-9-treated pRPE 
cells is sustained from 1 h until 24 h (Figure 33) it is unclear whether this increase 
can be exclusively attributed to claudin-19, as western blotting did not detect any 
significant up-regulation of this protein at any of the timepoints examined. However, 
the fact that stronger junctional staining for claudin-19 was a reproducible result is 
noteworthy and could be in line with the findings of Yoshikawa et al., (2011) who 
showed that increased TER, due to ER stress, in ARPE-19 cells can be accompanied 
with an increase in the expression of several junctional proteins including ZO-1, 
occludin  and  claudin-1.  Perhaps  claudin-19  expression  can  be  affected  as  well. 
Furthermore,  the  link  between  claudin-19  expression  and  a  stable  TER  was 
established  by  Peng  et  al.,  (2011)  who  demonstrated  that  when  claudin-19  was 
knocked down via small-interfering RNA (siRNA), in hfRPE cells, TER was greatly 
reduced. siRNAs for other claudins had only minor effects on the TER. 
 
In combination with the claudin-19 studies, expression of ZO-1 was examined by 
western blotting and immunofluorescence. ZO-1 is essential for the homeostasis of 
the  RPE  monolayer,  as  its  down-regulation  may  result  in  RPE  dysfunction  and 
monolayer  breaks  (Georgiadis  et  al.,  2010).  Therefore,  it  was  a  good  candidate 
protein  for  a  role  in  regulating  TER  in  pRPE  cells.  However,  western  blotting 
(Figure  38-B)  and  immunofluorescence  data  (Figure  40)  failed  to  identify  any 
changes in ZO-1 expression that could account for the increased TER in C5b-9-
treated pRPE cells.  
 
Immunofluorescence  analysis  of  samples  obtained  from  AMD  patients  has 
previously shown the co-existence of human RPE cells with C5b-9, as this complex 
accumulates in drusen deposits, which are located between the RPE monolayer and 
the underlying Bruch’s membrane (Anderson et al., 2002, Mullins et al., 2014). As 
not much is currently known about how RPE cells would respond to the sustained 
presence of C5b-9, the TER of pRPE cells was measured, whilst simultaneously 
blocking the endocytosis of C5b-9. The results in Figure 41 show that when dynasore 
is used to inhibit the internalisation of C5b-9 from the basal surface of pRPE cells, 
no  C5b-9-induced  TER  increase  was  observed.  These  results  show  that  it  is  the 	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endocytosis of C5b-9 that is linked to the change in TER rather than simply the 
assembly  of  C5b-9  on  the  basal  cell  surface.  This  is  consistent  with  our  further 
observation that C5b-9 assembly on the apical cell surface had the same effect on 
TER.  Additionally,  an  increase  in  TER  was  observed  during  the  formation  and 
endocytosis  of  C5b-8  (regardless  of  its  formation  site),  but  to  a  lesser  extent 
compared  to  C5b-9-treated  pRPE  cells,  in  both  Figures  33  and  34.  This  finding 
suggests that the accumulation and therefore endocytosis of C5b-8 could influence 
TER as well, but C9 is the key protein to increase TER even further. The etiology for 
this observation is currently unknown and needs to be further investigated.   
 
In  summary,  C5b-8  and  C5b-9  both  increased  the  TER  of  the  RPE  monolayer. 
However, whilst western blotting did not reveal any up-regulation of either ZO-1 
and/or claudin-19 in C5b-9-treated cells, claudin-19 immunostaining appeared more 
aligned  with  cell  junctions.  C5b-9  might  enhance  the  de novo  synthesis  of  other 
proteins, whose expression was not examined during this project, or as C5b-9 has 
previously been shown to up-regulate ER-stress proteins, these proteins could in turn 
regulate TER via modulation of other factors. 
 
• Expression of DAF and CD59 in C5b-9-treated pRPE cells 
CD59  and  DAF  are  widely  expressed  membrane-bound  glycoproteins,  that  have 
been shown in ARPE-19 cells to be located on the apical and basolateral surfaces, 
and have the ability to prevent C5b-9-induced cell damage (Ma et al., 2010, Davies 
et al., 1994, Thurman et al., 2009). CD59 is a 17-20 kDa glycoprotein that prevents 
the assembly of C5b-9 complexes by binding either to the alpha-subunit of C8 in the 
C5b-8 complex and/or to the beta-subunit of C9 in C5b-9 (Tomlinson, 2006, Davies 
et  al.,  1989,  Watson  et  al.,  2014).  It  can  be  found  either  as  a  membrane-bound 
protein in several cell types and/or as a soluble protein in body fluids (Qin et al., 
2005). CD59 expression needs to be regulated as its over-expression may lead to 
tumour development, while its absence can lead to severe anemias (Li et al., 2013, 
Motoyama  et  al.,  1992).  DAF  is  a  70  kDa  glycoprotein  responsible  for  the 
accelerated decay of the C5 and C3 convertases, C4b2a and C3bBb, by attaching 
either to the C4b or C3b units respectively (Nishikawa et al., 1998, Medof et al., 
1984). Its depletion can lead to intravascular haemolysis and platelet activation in 
humans (Martinez-Hervas et al., 2014). 	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We therefore hypothesised that the C5b-9 complex would up-regulate the expression 
of these complement negative regulators in pRPE cells, possibly as part of a defense 
mechanism  against  a  potentially  harmful  insult.  However,  our  studies  failed  to 
identify any significant change in expression of CD59 or DAF in response to C5b-9, 
and although the expression of these proteins on RPE cells is well-documented, there 
is limited information about how these negative regulators are affected by C5b-9. It 
has previously been shown that when endothelial cells (ECs) were treated with 2.5 % 
NHS, DAF was significantly up-regulated (Mason et al., 1999). Sensitisation of ECs 
with a cytokine cocktail prior to the addition of the NHS, increased protein levels of 
DAF even further. However, it is unknown whether the complement system has a 
direct effect on the expression of DAF and/or CD59 in the RPE. Pro-inflammatory 
cytokines are able to up-regulate CD59, DAF and CD46 in human and mouse RPE 
cells and human hepatoma cells (Yang et al., 2009, Spiller et al., 2000). On the other 
hand, Lueck et al., (2011) showed that incubation of ARPE-19 cells with 5 % NHS 
for 1 h triggered the production and release of several pro-inflammatory cytokines 
(IL-6 and IL-8), VEGF and MCP-1. Therefore there could be a regulatory loop in 
which C5b-9 increases the production and release of pro-inflammatory cytokines and 
growth factors, which in turn up-regulate the complement negative regulators.  
 
•  C5b-9-induced mitochondrial stress  
Modifications in mitochondrial number, size, cristae architecture, matrix density and 
mitochondrial membrane integrity have been observed, via electron microscopy, in 
the  RPE  derived  from  AMD  patients  (Feher  et  al.,  2006).  These  findings  are 
supported by studies in aging RPE cells (RPE cells from 62-year-old individuals), in 
which mitochondrial dysfunction was associated with impaired ATP production and 
the  down-regulation  of  mitochondrial  proteins  (He  and  Tombran-Tink,  2010). 
Further  evidence  supporting  the  link  between  mitochondrial  damage  and  AMD 
emerged from analysis of aging retinas from AMD patients that revealed high levels 
of large mtDNA deletions and rearrangements in the AMD-affected RPE (Barreau et 
al., 1996, Udar et al., 2009, Kenney et al., 2010). In fact, it was reported that AMD 
patients not only have mtDNA damage to a much larger extent than age-matched 
controls  but  they  also  have  changes  in  proteins  associated  with  mitochondrial 	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translation, nuclear transport and adenosine triphosphate synthase activity, in their 
RPE (Karunadharma et al., 2010). 
 
Although AMD pathogenesis is linked with mitochondrial alterations in the aged 
RPE,  it  is  currently  unknown  whether  C5b-9  (a  constituent  of  drusen)  has  an 
immediate effect on mitochondrial integrity and/or mitochondrial numbers. A single 
previous study reported that in C5b-9-treated Ehrlich ascites tumor cells, the inner 
mitochondrial  membrane  potential  (ΔΨm)  was  compromised  soon  after  C5b-9 
complex assembly (Papadimitriou et al., 1994). However, the direct effect of C5b-9 
complex on mitochondria in RPE cells remains to be elucidated. 
 
In the initial experiments, Mitotracker
® CMX Red was used to stain the mitochondria 
of RPE cells while endocytosis of C5b-9 was arrested with dynasore  (Figure 46). 
While the C5b-9 complex did not seem to have a direct effect on mitochondria, 
under control conditions its prolonged presence greatly reduced the Mitotracker
®-
specific  fluorescence  staining  suggesting  that  maintenance  of  C5b-9  at  the  cell 
surface might have an effect on mitochondrial number and/or integrity.  
 
Mitotracker
® is a mitochondrial-specific fluorescent dye, commonly used in confocal 
microscopy. It has been used in the past to demonstrate mitochondrial fragmentation 
after the treatment of human RPE cells (derived from 62-76-year-old donors) with 
hydrogen  peroxide  (He  et  al.,  2010).  It  has  the  capacity  to  covalently  bind  to 
mitochondrial proteins once it accumulates in the mitochondrial matrix (Presley et 
al., 2003). This covalent bond occurs via any free thiol groups of cysteine residues 
within  mitochondrial  proteins.  Therefore,  proteins  that  do  not  possess  free  thiol 
groups  will  not  react  with  Mitotracker
®,  potentially  causing  a  reduction  of 
fluorescence.  
 
To address this possible concern the experiment was repeated but this time staining 
mitochondria with a Tim23 antibody (Figure 47). As previously discussed (Section 
4.15),  Tim23  is  an  essential  member  of  a  large  channel-forming  complex, 
responsible for protein transportation inside mitochondria (Pareek et al., 2013). It 
spans  the  outer  and  inner  mitochondrial  membranes  and  therefore  its  stability  in 
mitochondria  established  this  protein  as  a  good  target  to  examine  mitochondrial 	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integrity (Donzeau et al., 2000). Tim23 staining demonstrated similar results to those 
obtained with Mitotracker
®, as it was markedly reduced when endocytosis of C5b-9 
was blocked. 
 
Proteomic analysis of the human RPE, isolated from AMD patients, revealed that 
aged RPE cells, compared to control samples, were characterised by alterations in 
their  protein  content  (Nordgaard  et  al.,  2008).  More  specifically,  several  key 
mitochondrial proteins, essential for mitochondrial translation (Factor Tu), import of 
nuclear-encoded proteins (Hsp70) and ATP synthesis (α-, β- and δ-subunits of ATP 
synthase)  were  down-regulated.  With  regards  to  Tim23,  it  has  previously  been 
shown that in HeLa cells, when Tim23 was depleted with siRNA, cell proliferation 
and  long-term  cell  survival  were  inhibited  (Goemans  et  al.,  2008).  Depletion  of 
Tim23 led to mitochondrial self-destruction and therefore it was hypothesised that 
this protein is necessary for mitochondrial biogenesis and therefore cell viability. 
Although C5b-9 did not cause cell death in pRPE cells (as discussed in chapter 3), 
down-regulating Tim23 expression in mitochondria, might be a sign of cell stress 
due to the constant presence of complement.  
 
As the data in Figures 46 and 47 did not provide any information about mitochondria 
numbers between control and C5b-9-treated cells, electron microscopy (EM) studies 
were performed. Data from Figures 48, 49 and 50 show that C5b-9-treated pRPE 
cells (either treated with dynasore or not) appear to have fewer mitochondria. Also, 
the  cell  morphology  of  C5b-9  +  dynasore-treated  cells  exhibited  a  number  of 
abnormal ultra-structural features that were not observed in dynasore-treated cells, 
confirming  that  the  prolonged  presence  of  C5b-9  may  stress  pRPE  cells. 
Unfortunately,  EM  studies  did  not  permit  the  clear  examination  of  intra-
mitochondrial structures (integrity of mitochondrial membranes, matrix and cristae), 
however  the  observed  reduction  in  mitochondrial  numbers  is  in  accordance  with 
findings from Feher at el., (2006) who demonstrated that RPE cells derived from 
AMD patients had reduced numbers of mitochondria. 
 
To extend these studies, the expression levels of Tim23 and cytochrome C in C5b-9-
treated pRPE cells (Figure 51) were investigated by western blotting. Cytochrome C 
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and  inner  mitochondrial  membranes  (Goodsell,  2004).  No  differences  in  the 
expression levels either of Tim23 or cytochrome C were detected between control 
and C5b-9-treated pRPE cells. The lack of correlation between the Tim23 western 
blot data (Figure 51) and the Tim23 immunofluorescence data (Figure 47) might 
indicate that Tim23 is released from or not targeted to mitochondria, yet remains in 
the cell cytosol. Any differences in exposure of the antigen binding sites on Tim23 
between the two different methods may also contribute to different results.  
 
With  regards  to  cytochrome  C,  immunofluorescence  analysis  and  confocal 
microscopy may have been a more efficient method of detecting any expression and 
localisation  changes  in  pRPE  cells.  It  has  previously  been  demonstrated  that 
induction  of  cell  apoptosis  in  RPE  cells  (ARPE-19s  and  human  RPE  cells),  via 
chemical reagents, resulted in the release of cytochrome C in the cytoplasm (Zhang 
et al., 2003, Jin et al., 2005). In the event of cytochrome C release in C5b-9-treated 
pRPE cells, perhaps immunofluorescence would have been able to demonstrate the 
re-location of cytochrome C within pRPE cells. A possible re-location of cytochrome 
C  due  to  the  presence  of  complement,  (as  a  sign  of  cell  apoptosis)  would  not 
necessarily be expected to be accompanied by changes in protein expression levels. 
Staining of cytochrome C, via immunofluorescence, was performed in this study 
however, the available antibodies that were tested at the time did not yield specific 
staining.   
 
 
 
 
 
 
 
 
 
 
 
 
 	 ﾠ 142	 ﾠ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Chapter 5 	 ﾠ 143	 ﾠ
5. C5b-9 and retinal phagocytosis 
 
5.1 Preliminary phagocytosis studies in C5b-9-treated pRPE cells 
 
One of the specialised functions of RPE cells is the maintenance of the visual cycle, 
during  which,  all-trans-retinal  is  converted  back  to  11-cis  retinal  (McBee  et  al., 
2001).  This  biochemical  process  ensures  that  photoreceptors  preserve  their 
excitability and this can only be accomplished via phagocytosis of the POS from the 
underlying RPE monolayer (Lamb and Pugh, 2004). Once the re-isomerisation of 
retinal occurs, 11-cis retinal returns back to the photoreceptors (Baehr et al., 2003). 
 
It has previously been shown, in C5b-9-treated glomerular epithelial cells (GECs), 
that the C5b-9 complex has the capacity to regulate the actin cytoskeleton by up-
regulating RhoA, a small GTPase, necessary for actin organisation (Zhang et al., 
2007, Sit and Manser, 2011). Knowing that the binding and internalisation of POS 
from the RPE requires actin remodelling we asked here whether C5b-9 can affect the 
process of POS phagocytosis (Hayes et al., 2009, Law et al., 2009, Anderson et al., 
2002). 
 
To  investigate  this,  C5b-9-treated  pRPE  cells  were  incubated  with  fluorescently-
tagged POS. One advantage of the experimental model developed in chapters 3 and 4 
is that it allows assembly of C5b-9 on the basal RPE cell surface, with simultaneous 
delivery of POS to the apical surface, thus replicating the compartmentalisation of 
activities encountered by RPE cells in vivo. In more detail, in confluent pRPE cells, 
C5b-9  was  allowed  to  form  in vitro as  described  earlier  in  method  DT (section 
2.5.4.1) 1 h prior to the addition of POS. In the meantime, fluorescently-tagged POS 
were  prepared  and  used  as  described  in  section  2.7,  however  at  this  stage  the 
sonication and the washing steps were eliminated. Therefore POS were conjugated to 
the fluorophore and added to the apical surface of pRPE cells for 24 h without being 
fragmented into smaller sizes, and without removing any unbound POS after 1 h. 
 
Immunofluorescence  analysis  demonstrated  that  non-sonicated  POS  were  poorly 
phagocytosed by pRPE cells (Figure 53). Untreated- (Figure 53-Ai), C5b-8- (Figure 
53-Aii) and C5b-9-treated cells (Figure 53-Aiii) retained the majority of POS (red 
staining) on their apical surface (green staining), an observation that may have two 	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explanations: the large size of the POS used and the fact that POS were incubated 
with the cells for 24 h (without removing any unbound POS after 1 h). This 24 h 
incubation period could have induced saturation of the system, as RPE cells may 
have a threshold level above which are not able to phagocytose POS continuously. 
Whatever the explanation, we did not observe any C5b-9-induced changes (if any) in 
the binding, internalisation and/or degradation of POS in vitro (Figure 53-Aiii, -Biii 
and –Ciii). 
 
Therefore, improvement of the in vitro conditions was essential in order to further 
investigate the interplay between outer segment phagocytosis and assembly of the 
C5b-9 complex. These improvements included the sonication of the POS, to reduce 
their size, and additionally, incubation of pRPE cells with POS only for 1 h, not for 
24 h, with a wash to remove any unbound POS from the medium. Examination of the 
phagocytosis rate of these cultured pRPE cells was performed in the presence of 1 % 
FBS.  
 
Before  engaging  in  a  detailed  analysis  of  POS  phagocytosis  it  was  critical  to 
determine the timepoint at which POS became attached to the apical surface of pRPE 
cells and the timepoint by which they were completely phagocytosed. In turn, these 
timepoints could be used in subsequent immunofluorescence and western blot studies 
(Section 5.3 and 5.4, respectively). 	 ﾠ 145	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Figure 53. Phagocytosis of non-sonicated POS by pRPE cells. Two different controls were used: 
Untreated pRPE cells (Ai-iii – 1 % FBS DMEM, apically and DMEM basally) and C5b-8-treated cells 
(Bi-iii).  For  C5b-8  and  C5b-9  complex  formation  (Bi-iii  and  Ci-iii  respectively),  the  necessary 
complement proteins were added in DMEM at 37 
oC / 5 % CO2 for 1 h (method DT, section 2.5.4.1). 
After 1 h incubation with the complement proteins, POS (red) were added to the apical surface for 24 
h.  No  changes  were  observed  in  the  binding,  internalisation  and/or  degradation  of  POS  between 
untreated- (Ai-iii), C5b-8- (Bi-iii) and C5b-9-treated cells (Ci-iii). Green staining represents ezrin (an 
apical surface marker) and blue staining corresponds to DAPI. Scale bar represents approximately 
40µm. 
 
 
 
 
5.2 Phagocytosis of POS in cultured pRPE cells 
 
Having designed improvements to the in vitro phagocytosis conditions (as discussed 
in section 5.1), we examined the binding and internalisation of POS by pRPE cells. 	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These experiments were undertaken to optimise the key timepoints to be used later 
on, in studies aimed at investigating whether C5b-9 affects POS phagocytosis. 
 
To perform this study, confluent pRPE cells were allowed to phagocytose POS for 1 
h, 5 h, and 24 h (section 2.7). At the end of each time point cells were fixed with 
pure ice-cold methanol and stained as described in section 2.9. 
 
Figure 54 demonstrates that POS bound to the apical surface of pRPE cells within 1 
h (Figure 54-A). No internalised POS were visible at this stage, as can be seen in the 
z-sections (Figure 54-Ac). On the other hand, by 5 h most of the POS had been 
internalised, as the apical surface (green staining) had much less bound POS (Figure 
54-B), and internalised POS were clearly observable in the z-section (Figure 54-Bc). 
At 24 h (Figure 54-C) there were no POS visible on the apical cell surface and only a 
few were detectable within the cells (Figure 54-Cc).  
 
Figure  54.  Binding  and  internalisation  of  POS  by  pRPE  cells.  Confluent  pRPE  cells  were 
incubated with 10
7 POS / ml in DMEM containing 1 % FBS for 1 h. After 1 h, cells were washed with 
sterile  PBS,  which  was  then  replaced  with  DMEM  containing  1  %  FBS,  after  which  cells  were 
allowed to phagocytose bound POS for 1 h, 5 h and 24 h. At 1 h the binding of POS (red staining) is 
evident on the apical cell surface (green staining) (A). No internalisation of POS was observed at that 
stage (Ac). At 5 h there was a mixture of bound and internalised POS, with the majority of POS 
internalised (B, Bc). At 24 h all POS were internalised (C, Cc). Blue staining corresponds to DAPI. 
Scale bar represents approximately 20µm. 
 
 
Overall, this study provides insight into the kinetics of POS phagocytosis, that were 
exploited  in  the  next  experiment.  Thus,  for  the  immunofluorescence  studies,  the 
effects of C5b-9 on the binding, internalisation and/or degradation of POS, were 
examined at 1 h and 24 h. On the other hand, the effects of C5b-9 on POS-driven 
intracellular signalling was tested at 30 min, 1 h and 5 h. Signalling cascades may be 	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activated / de-activated rapidly and therefore 30 min was chosen as the starting point 
of these studies and 5 h the end point, as it is known that mediators such as MerTK 
and FAK are activated rapidly upon POS binding (Finnemann, 2003, Finnemann and 
Nandrot, 2006). 
 
 
5.3 The effect of C5b-9 on POS binding to pRPE cells 
 
Phagocytosis  of  POS  involves  the  sequential  binding,  internalisation  and 
degradation, with each step driven by a different molecular machinery (Nandrot et 
al., 2004). To examine whether C5b-9 interferes with the above processes or not, 
C5b-9-treated pRPE cells were fed with POS and examined by confocal microscopy. 
 
Briefly, in confluent pRPE cells, C5b-9 was allowed to form on the basal surface, (as 
described  in  method  DT (section  2.5.4.1),  1  h  prior  to  the  addition  of  POS  (see 
relevant  section  2.7).  Two  different  controls  were  used:  untreated  pRPE  cells 
(growing  in  1  %  FBS  DMEM  in  the  upper  chamber,  and  DMEM  in  the  lower 
chamber)  and  C5b-8-treated  cells.  C5b-8  complex  formation  was  accomplished 
according to method DT (section 2.5.4.1). Cells were allowed to phagocytose POS 
for 1 h and 24 h (POS incubation according to section 2.7) and at the end of each 
time point cells were fixed with pure ice-cold methanol and stained as described in 
section 2.9.  
 
Optical slicing on the confocal microscope enabled us to capture images of the apical 
surfaces of untreated-, C5b-8- and C5b-9-treated cells, viewed from both the extra-
cellular and intra-cellular aspect. The images reveal that both C5b-8- and C5b-9-
treated cells appeared to have reduced binding of POS at 1 h, when compared to the 
apical surface of untreated cells (Figure 55-Bi-ii, -Ci-ii and -Ai-ii, respectively). These 
observations are supported by quantitative analysis of surface bound fluorescence in 
the  different  samples  (Figure  55-D).  Each  bar  on  the  histogram  represents  the 
fluorescence  volume  specific  to  the  POS  (red
  staining)  from  three  independent 
experiments (three different Z-sections per sample per experiment). However, by 24 
h the amount of surface-bound POS was equivalent under all three conditions.  	 ﾠ 148	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Figure 55. C5b-8 and C5b-9 reduce POS binding to pRPE cells. Two different controls were used: 
untreated pRPE cells (Ai-iv) and C5b-8-treated cells (Bi-iv). For C5b-8 and C5b-9 complex formation 
(Bi-iv and Ci-iv respectively), all necessary complement proteins were added in DMEM, on the basal 
chamber of the trans-well, for 1 h (method DT, section 2.5.4.1). On the apical chamber of all samples 
only 1 % FBS DMEM was added. After 1 h of incubation with the complement proteins, POS (red 
staining) were added on the apical surface for 1 h after which, any non-bound POS were removed and 
replaced by fresh 1 % FBS DMEM. Cells were allowed to phagocytose for 1 h and 24 h. Optical 
slicing showed that both C5b-8- and C5b-9-treated cells appeared to have reduced binding of POS at 1 
h, however by 24 h the amount of surface-bound POS was equivalent under all three conditions. Each 
bar on the histogram (D) represents the fluorescence volume specific to the POS (red
 staining) from 
three independent experiments (three different Z-sections per sample per experiment). Green staining 
represents  ezrin  (an  apical  surface  marker)  and  blue  staining  corresponds  to  DAPI.  Scale  bar 
represents approximately 20µm. Data expressed as mean ± SEM, **P<0.05. 	 ﾠ 149	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Figure 56. C5b-9 and the internalisation of POS by pRPE cells. The control (Ai-ii) and test samples 
(Bi-ii and Ci-ii) were exactly as described in the legend of Figure 54.  Optical slices were obtained by 
confocal microscopy at approximately the mid point between the apical and basal cell membranes. 
POS are stained red, ezrin is green and nuclei are stained with DAPI (blue). The histogram shows 
quantification of internalised POS identified within the cytoplasm of untreated, C5b-8- and C5b-9-
treated pRPE cells at 1 h and at 24 h (D). Each bar on the histogram (D) represents the fluorescence 
volume specific to the POS (red
 staining) from three independent experiments (three different Z-
sections  per  sample  per  experiment).  Data  expressed  as  mean  ±  SEM.  Scale  bar  represents 
approximately 20µm. 
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To further investigate the internalisation of POS in pRPE cells exposed to C5b-9, we 
performed  a  similar  quantitative  analysis  of  images  representing  optical  sections 
taken through the middle of the nuclei, i.e approximately midway between the apical 
and basal membranes (Figure 56). At 1 h post-feeding of POS, internalised material 
was virtually undetectable in any of the samples, whereas at 24 h internalised POS 
were  present  throughout.  Note  that  although  the  differences  in  the  amount  of 
internalised POS were not statistically significant, the fact that there were equivalent 
levels of POS in cells treated with C5b-8 and C5b-9, compared to control, despite 
these cells having bound less POS at 1 h, suggests that exposure to these complement 
complexes may delay the degradation of POS once they are internalised. 
 
 5.4  Does  C5b-9  complex  affect  POS-dependent  signal  transduction  in  RPE 
cells? 
Phagocytosis of POS by RPE cells requires the concerted activities of a large number 
of specific proteins (Finnemann and Nandrot, 2006). While the initial step of POS 
binding on the apical surface of the RPE requires the expression of the ανβ5 integrin, 
the successful internalisation of POS is established by activation (phosphorylation) 
of  FAK  (Finnemann,  2003).  Tyrosine  phosphorylated-FAK  will  in  turn 
phosphorylate MerTK that is required for the engulfment of POS as well (Feng et al., 
2002). In the following studies phosphorylation of the Src tyrosine kinase was also 
examined, as FAK is a well-defined substrate for Src (Bellagamba et al., 1997). 
The aim of the experiments here was to investigate whether basal formation of C5b-9 
influences the activation of any of the afore-mentioned kinases. Confluent C5b-9-
treated pRPE cells, (C5b-9 complex formation is described in method DT (section 
2.5.4.1)), were allowed to phagocytose POS for 30 min, 1 h and 5 h (section 2.8.1). 
Two different controls were used: untreated pRPE cells and C5b-8-treated cells. At 
the end of each timepoint cells were prepared for western blotting as described in 
sections 2.8.2, 2.8.3 and 2.8.4.  
 
Western blot analysis did not reveal any significant changes in the phosphorylation 
of  MerTK  (Figure  57-A),  FAK  (Figure  57-B)  and  Src  kinases  (Figure  57-C)  in 
untreated,  C5b-8-  and  C5b-9-treated  pRPE  cells.  Each  bar  in  the  accompanying 
histograms  represents  the  average  value  of  three  wells  from  three  independent 
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Figure  57.  Phosphorylation  of 
MerTK, FAK and Src kinases in 
C5b-9-treated  pRPE  cells.  Two 
different  controls  were  used: 
untreated pRPE cells (1 % FBS in 
DMEM,  apically  and  DMEM 
basally)  and  C5b-8-treated  cells. 
For C5b-8 and C5b-9 formation, all 
relevant complement proteins were 
added  in  DMEM,  on  the  basal 
chamber of the trans-well for 1 h. 
(method DT, section 2.5.4.1). After 
1  h  of  incubation  with  the 
complement  proteins,  POS  were 
added to the apical surface for 1 h 
after  which  any  non-bound  POS 
were  washed  and  replaced  with 
fresh 1 % FBS in DMEM (section 
2.7).  Cells  were  allowed  to 
phagocytose for 30 min, 1 h and 5 
h.  Each  bar  in  the  histograms, 
represents  the  average  value  of 
three wells from three independent 
experiments.  Data  expressed  as 
mean  ±  SEM.  Cell  extracts  were 
resolved  by  SDS-PAGE,  and 
western  blotted  using  antibodies 
against  p-MerTK,  total  MerTK 
(A), p-FAK, total FAK (B), p-Src 
and total Src (C) and GAPDH, as a 
loading  control.  Blots  were 
quantified  by  densitometry  and 
bands  were  normalised  against 
GAPDH.  
	 ﾠ	 ﾠ 152	 ﾠ
5.5 Discussion   
 
•  Phagocytic activity of C5b-9-treated pRPE cells 
 
The renewal of retinal photoreceptors (PR) (rods and cones), in order to maintain 
nocturnal and diurnal vision respectively, is dependent on the phagocytosis of OS 
from  the  underlying  RPE  monolayer  (Rodieck  and  Rushton,  1976,  Hestrin  and 
Korenbrot, 1990). Renewal of these photoreceptors requires the efficient binding, 
internalisation, degradation and recycling of POS from the RPE in a synchronised 
fashion  (circadian  regulation)  (Young  and  Droz,  1968,  LaVail,  1976,  Qin  and 
Rodrigues, 2012). Circadian control ensures that every morning light can stimulate 
the  phagocytic  activity  of  RPE  cells  for  approximately  1-2  h.  In  addition,  this 
circadian rhythm has been found to be capable of regulating other cellular functions 
as well, including melatonin synthesis, ion channel sensitivity and pigment synthesis 
(Young and Droz, 1968, Ko et al., 2001, Goldman et al., 1980). 
 
Since RPE cell lines (such as ARPE-19 cells) and primary pRPE cells share much of 
the same phagocytic machinery, we investigated not only how efficiently but also 
how rapidly pRPE cells would perform synchronised phagocytosis of POS in vitro 
(Mao and Finnemann, 2013). It should be noted here that the isolated POS and the 
RPE cells used in this thesis were both of porcine origin. Although it is known that 
RPE cells from different species such as human, porcine, bovine and rat maintain 
their phagocytic activity when feeding them with POS from different species, by 
using POS and RPE cells from the same species (pig), we aimed to maximise the 
phagocytosis  rate  (Finnemann  et  al.,  1997,  Turowski  et  al.,  2004,  Mao  and 
Finnemann, 2013). 
 
The results in Figure 54 show that POS bind to pRPE cells in our experimental 
model and that by 5 h the majority of POS were internalised (Figure 54-B, -Bc). At 
24 h no POS were identified on the apical cell surface of pRPE cells (Figure 54-C, -
Cc). These findings are in agreement with previous in vitro phagocytosis experiments 
based on various types of RPE cells. When human embryonic stem cell-derived RPE 
cells (HESC-RPE) were fed with FITC-conjugated POS for 0.5 h, 1 h, 4 h and 20 h, 
confocal microscopy revealed that by 4 h there were already significant levels of 
internalised POS, but not at 1 h. At 20 h levels of phagocytosed POS were even 	 ﾠ 153	 ﾠ
higher (Carr et al., 2009). Further studies in which pRPE cells were fed with FITC-
labelled latex beads (opsonised with POS fragments) for various timepoints (0.5 h, 2 
h, 4 h, 6 h and 8 h), revealed that only between 6 h to 8 h there was maximum POS 
internalisation (Klettner et al., 2011). In support of the above studies, Westenskow et 
al., (2012), recently demonstrated that POS binding and internalisation levels in both 
hfRPE cells and in induced pluripotent stem cell-derived RPE cells (iPS-RPE) are 
slightly lower than in ARPE-19 cells. Thus, in hfRPE cells maximum binding levels 
were observed at 3 h while internalisation was reported at 5 h. Maximum levels of 
POS binding using iPSC-derived RPE cells were recorded at 4 h and internalisation 
at 5 h (Westenskow et al., 2012).  
 
Overall, these studies suggest that RPE cell lines might have a greater capacity for 
POS phagocytosis than primary and iPS-derived RPE cells, however the timeframe 
for  POS  binding  and  internalisation  remained  approximately  the  same  between 
HESC-RPE, pRPE, iPS-RPE and ARPE-19 cells. In the studies here we found that 1 
h  and  24  h  were  suitable  timepoints  at  which  to  measure  POS  binding  and 
internalisation respectively, and are broadly in line with the studies mentioned above. 
 
It is currently unknown whether the C5b-9 complex has the capacity to impair POS 
phagocytosis  or  not.  Only  until  recently  the  interplay  of  complement  with  POS 
phagocytosis was examined in ARPE-19 cells (Lueck et al., 2012). These authors 
demonstrated that when ARPE-19 cells were fed apically with POS and basally with 
4 % competent-human sera for 24 h, levels of IL-6, IL-8, MCP-1 and VEGF were 
significantly  up-regulated  when  compared  to  cells  only  treated  with  POS.  These 
results  suggested  that  C5b-9  complex  might  have  the  ability  to  cause  an 
inflammatory response in RPE cells that are undergoing phagocytosis. However, it 
still is uncertain to what extent the C5b-9 complex might affect this process in vitro.  
 
Recent  studies  demonstrated  that  C5b-9  also  has  the  capacity  to  trigger 
inflammasome  activation  (the  set  of  cytosolic  multi-molecular  protein  complexes 
responsible for regulating pro-apoptotic and pro-inflammatory events), and in turn 
that the activated inflammasome may impair POS phagocytosis (Triantafilou et al., 
2013,  Kaarniranta  et  al.,  2013).  In  more  detail,  Triantafilou  et  al.,  (2013) 
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leads to Ca
2+ influx and increased cytosolic Ca
2+ activation. Release of Ca
2+ in turn 
triggered  the  activation  of  several  proteins  including  IL-1β,  caspase-1  and  more 
importantly  NLRP3  (NLR  family,  pyrin  domain  containing  protein  3),  the  main 
indicator of inflammasome activation. On the other hand, Kaarniranta et al., (2012) 
showed  that  incubation  of  ARPE-19  cells  with  the  peroxidation  end  product  4-
hydroxynonenal  (HNE)  can  induce  oxidative  stress,  which  further  provokes 
inflammasome activation which has the capacity to impair both autophagy (removal 
of  damaged  organelles  and  proteins)  and  POS  phagocytosis  in  RPE  cells 
(Kaarniranta et al., 2013, Kauppinen et al., 2012). Therefore, there could be a link 
between  C5b-9  and  impaired  POS  phagocytosis  through  Ca
2+-dependent 
inflammasome activation. 
 
It has previously been reported that phagocytosis requires the co-operation of the 
cytoskeleton, as actin needs to be re-organised (May and Machesky, 2001). Once 
POS recognise and bind to the apically-expressed ανβ5 receptor of RPE cells, actin 
has to be remodelled in order for the nascent phagocytic cups to close (Hayes et al., 
2009, Finnemann and Rodriguez-Boulan, 1999). The C5b-9 complex might either 
have an effect on actin remodelling and/or might affect the expression levels of ανβ5 
receptor.  
 
C5b-9  complex  formation  was  previously  shown  to  be  capable  of  increasing  the 
number of stress fibers on pRPE cells grown either on glass coverslips and/or on 
trans-wells.  This  enhanced  appearance  of  stress  fibers  might  indicate  that  C5b-9 
inteferes with actin re-organisation. Perhaps when  pRPE cells (Figures 55 and 56) 
were treated simultaneously with POS (apical surface) and C5b-9, (basal surface) a 
conflict  between  the  phagocytic  and  endocytic  pathways  was  induced.  Both 
pathways have been shown to depend on  actin remodelling. As C5b-9 endocytosis is 
a caveolin-1 dependent process and POS phagocytosis requires actin to close the 
phagocytic cups on the apical cell surface, it could be possible that cells favour C5b-
9  endocytosis  and  delay  POS  phagocytosis  in  order  to  deal  with  both  processes 
(Moskovich  et  al.,  2012).  One  possible  explanation  as  to  why  pRPE  cells  could 
prioritise  C5b-9  endocytosis,  is  the  size  of  the  assembled  C5b-9  complexes. 
Caveolin-1 endocytosis only requires particules to have an approximate size of 50 
nm (Parton and Simons, 2007). C5b-9 complex is approximately 11 nm, significanlty 	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smaller than outer segments which reside on the apical cell surface (Finnemann and 
Rodriguez-Boulan, 1999, Ramm et al., 1985). In fact, as discussed in chapter 3, C5b-
9 has previously been associated with actin remodelling as it can regulate the actin 
cytoskeleton  via  RhoA  activation  (Zhang  et  al.,  2007).  This  mediator  of  actin 
remodelling becomes up-regulated upon activation of Erk1/2, in C5b-9-treated GECs 
(Etienne-Manneville  and  Hall,  2002,  Mouawad  et  al.,  2014).  Should  both 
phagocytosis and C5b-9 formation force actin to re-organise, then perhaps the actin 
cytoskeleton would be compromised in its ability to respond to these two distinct 
stimuli. At 24 h (Figure 55) no difference in the amount of bound POS was detected 
between untreated, C5b-8- and C5b-9-treated cells. It has been shown that the C5b-9 
complex by 24 h is mostly endocytosed and/or expelled from pRPE cells. Therefore, 
after 1 h pRPE cells can perform phagocytosis with no further delays, once they start 
to degrade (degradation pathway) or expell C5b-9 to the extra-cellular space (ecto-
/exo-cytosis). 
 
It is also possible that C5b-9 has the ability to regulate surface organisation of the 
ανβ5 receptor by inducing a Ca
2+ influx in pRPE cells. In support of this theory, it was 
previously shown that in human MG-63 osteosarcoma cells that the extracellular 
presence  of Ca
2+ led to the localisation of ανβ5 in focal contacts (Stuiver et al., 
1996). As there are numerous studies that have demonstrated the ability of C5b-9 to 
change Ca
2+ levels, therefore it could be suggested that C5b-9 assembly on the basal 
cell surface of pRPE cells might induce re-distribution of the ανβ5 receptor (Cybulsky 
et al., 1989, Papadimitriou et al., 1994, Wiedmer and Sims, 1991, Triantafilou et al., 
2013). This event in turn could, for a certain amount of time, impair the binding of 
POS  to  the  apical  cell  surface.  Therefore,  immunofluorescence  studies  using  an 
antibody against ανβ5 could reveal whether  ανβ5 becomes re-distributed on the apical 
cell surface due to the presence of C5b-9 in pRPE cells. 
 
Although the ανβ5 receptor is essential for POS binding to the apical cell surface of 
RPE cells, it does not bind substrate directly (Hanayama et al., 2002). Instead, the 
ανβ5 receptor needs to be ligated with milk fat globule-EGF-factor 8 (MFG-E8) in 
order  to  increase  POS  binding  (Hanayama  et  al.,  2002).  MFG-E8  is  a  heavily 
glycosylated protein whose diurnal expression has been found to peak soon after 
light  onset  in  mouse  RPE  cells  in vitro  (Nandrot  et  al.,  2007).  MFG-E8
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develop a similar phenotype to β5
-/- mice, which suffer from loss of synchronised 
daily  phagocytosis  due  to  failure  to  activate  MerTK  kinase,  essential  for  the 
engulfment of POS (Nandrot et al., 2006, Nandrot et al., 2004, Nandrot et al., 2007). 
Despite  this  loss,  MFG-E8  deficient  mice  still  maintain  a  low  level  of  ongoing 
phagocytosis,  indicating  that  MFG-E8  under  normal  conditions  promotes 
phagocytosis. It has previously been reported that MFG-E8 integrin becomes up-
regulated in mice gut epithelial cells (Chogle et al., 2011). Treatment of MFG-E8
-/- 
C57BL/6  mice  with  dextran  sulfate  sodium  (DSS)-induced  colitis  led  to  the  up-
regulation  of  this  integrin,  indicating  its  protective  role  in  inflammatory  bowel 
disease (Chogle et al., 2011). From these observations it might be inferred that upon 
inflammasome activation, due to cytosolic Ca
2+ increase, C5b-9 might lead to the up-
regulation of MFG-E8 in pRPE cells. If this is the case then we can speculate that the 
C5b-9-induced up-regulation of MFG-E8 enhances POS binding on the apical cell 
surface of pRPE cells and therefore compensates for the delayed POS binding, which 
is only observed at 1 h in C5b-9-treated pRPE cells (Figure 54). 
 
Another  candidate  protein  that  could  act  against  a  C5b-9-induced  delay  in  POS 
binding is CD36. CD36 is a class B scavenger receptor, expressed in several cell 
types including RPE cells (Ryeom et al., 1996). It is involved in various biological 
processes such as angiogenesis, atherosclerosis, inflammation, lipid metabolism and 
phagocytosis of photoreceptor outer segments (Febbraio et al., 2001). CD36 has been 
shown to aid the binding and internalisation of POS since blockage of this receptor in 
RPE-J cells with CD36-specific antibodies, decreased the process of  phagocytosis 
(Finnemann and Silverstein, 2001). Furthermore, CD36 has previously been shown 
to  prevent  the  accumulation  of  age-dependent  retinal  laminar  deposits  such  as 
oxidised low-density lipoproteins (oxLDL) (Picard et al., 2010). Laminal and drusen 
deposits  are  common  features  of  AMD.  CD36  is  responsible  for  the  uptake  of 
oxLDL in RPE both in vitro and in vivo and its protective role in AMD can be 
inferred from the observation that CD36
-/- mice accumulate oxLDL and develop sub-
retinal thickening (Picard et al., 2010). Should the elimination of C5b-9 from the 
basal cell surface of pRPE cells be partly dependent on CD36, then this could be 
another candidate protein that not only shields POS phagocytosis from the presence 
of C5b-9 but at the same time helps RPE cells to deal with C5b-9. 
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Figure 56 demonstrates that although the differences in the amount of internalised 
POS were not statistically significant, the fact that there were equivalent levels of 
POS in cells treated with C5b-8 and C5b-9, compared to control, despite these cells 
having  bound  less  POS  at  1  h,  suggests  that  exposure  to  C5b-9  may  delay  the 
degradation of POS once they are internalised. In order for RPE cells to successfully 
digest any bound POS, they have developed a maturation process which includes 
several fusion steps (Herman and Steinberg, 1982b). Internalised POS become fused 
with early endosomes, then with late endosomes which finally become fused with 
lysosomes where POS are degraded (Herman and Steinberg, 1982a). Each step is 
accompanied by the production and release of reactive oxygen species (ROS). POS 
phagocytosis  is  a  polarised  process,  during  which  apically-bound  POS  become 
internalised and organised in phagosomes (fusion with endosomes) which in turn 
transit towards the basal membrane of RPE cells, where they become degraded in 
lysosomes (Herman and Steinberg, 1982b, Gibbs et al., 2003). Mutations in the gene 
encoding  the  motor  protein  myosin  VIIa,  essential  for  the  transportation  of 
phagosomes,  lead  to  Usher  Syndrome  1B  in  humans,  during  which  POS 
phagocytosis  in  the  RPE  is  arrested  and  therefore  the  underlying  photoreceptors 
degenerate (Gibbs et al., 2003). One of the best-studied lysosomal enzymes, found in 
many  cell  types  including  the  RPE,  is  cathepsin  D,  which  is  essential  for  the 
lysosomal degradation of outer segments (Benes et al., 2008, Deguchi et al., 1994). 
Cathepsin D is an intra-cellular aspartic protease of the pepsin superfamily involved 
in several biological processes such as protein degradation, autophagy and apoptosis 
(Benes et al., 2008). It has also been associated in the past with several pathological 
conditions such as cancer and Altzheimer’s disease (Vetvicka et al., 1994, Zhou et 
al., 2006). Intracellular trafficking of cathepsin D to lysosomes is essential for its 
normal  proteolytic  function  (Benes  et  al.,  2008).  Translocation  and  increased 
secretion  of  this  enzyme  to  the  extracellular  space  by  cancer  cells  enhances  the 
invasive and metastatic ability of these cells, as cathepsin D will act in an autocrine 
and/or paracrine manner (Koblinski et al., 2000). 
 
Recent  studies  demonstrated  that  mtDNA  damage  and  therefore  mitochondrial 
instability has the potential to decrease the expression of cathepsin D in the RPE in 
vitro (Wang et al., 2009). Thus, when ARPE-19 cells were incubated with rotenone, 
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mtDNA  damage  (Wang  et  al.,  2009).  Rotenone  increases  mitochondrial  ROS 
production, by inhibiting mitochondrial complex I, and therefore induces mtDNA 
damage (Indo et al., 2007, Li et al., 2003). Decreased protein levels of cathepsin D 
were consistent with a decrease in this enzyme’s activity. However, the mechanism 
by  which  mtDNA  damage  leads  to  decreased  cathepsin  D  levels  needs  to  be 
addressed.   
 
Since we previously demonstrated that C5b-9 (either with the presence of dynasore 
or not) has the ability to decrease mitochondrial numbers, and perhaps to a certain 
extent  induce  mitochondrial  instability,  it  is  possible  that  the  basal  deposition  of 
C5b-9  in  pRPE  cells  can  lead  to  insufficient  POS  degradation  due  to  reduced 
cathepsin  D  levels  or  availability  of  ATP.  Additionally,  in  the  event  of  C5b-9-
induced cytoplasmic Ca
2+ release in the pRPE cells, C5b-9 might at 1 h slow down 
the ingestion of POS due to failure to properly activate protein kinase C (PKC). PKC 
activation has previously been demonstrated to be Ca
2+ dependent and it terminates 
POS phagocytosis in RPE-J cells (Heth and Marescalchi, 1994, Hall et al., 1991). 
Overall,  additional  experiments  such  as  Ca
2+  imaging,  western  blotting  using 
antibodies  against  PKC  and  cathepsin  D  should  provide  more  information  as  to 
whether the complement system has the ability to interfere with POS phagocytosis in 
the RPE. 
 
•  C5b-9 does not activate MerTK, FAK and Src kinases 
The process of POS internalisation requires the activation of a signalling cascade in 
order for RPE cells to re-organise their actin cytoskeleton which in turn will allow 
the internalisation and therefore the processing of outer segments (Finnemann et al., 
1997). Thus, once αvβ5 integrin binds to POS on the apical cell surface, it triggers 
the re-location of FAK, which is a non-receptor tyrosine kinase, to the apical cell 
surface where it becomes activated, via auto-phosphorylation (Finnemann, 2003). 
FAK  is  localised  at  areas  of  integrin  clustering,  termed  focal  adhesions,  and  is 
essential  for  the  engulfment  of  POS.  Phosphorylated  FAK  (p-FAK)  will  in  turn 
phosphorylate the tyrosine kinase MerTK (Finnemann, 2003). Activation of MerTK 
is a crucial part of POS engulfment since RCS rats lacking MerTK developed severe 
impairment  of  POS  internalisation,  an  event  that  leads  to  an  early  onset 
photoreceptor degeneration in vivo (D'Cruz et al., 2000, Gal et al., 2000). Ectopic 	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expression of MerTK in RCS RPE cells by a recombinant adenovirus, can rescue the 
RCS  phenotype  (Feng  et  al.,  2002,  Hall  et  al.,  2005).  MerTK  is  believed  to 
accomplish  its  role  with  the  help  of  ligands  such  as  Gas6  and  Protein  S,  both 
members of a family of K
+-dependent proteins known for their post-translational γ-
carboxylation of their glutamic acid residues (Hall et al., 2005, Hall et al., 2001). 
These residues aid the binding of POS. However, it is still under investigation how 
Gas6 and Protein S function precisely. For instance, it is currently uncertain to what 
extent Gas6 is needed for the MerTK-dependent internalisation of POS in the RPE, 
as in gas6 deficient mice RPE cells did not show any signs of POS phagocytosis 
disruption  (Hall  et  al.,  2005).  Activation  of  MerTK  leads  to  increased  levels  of 
inositol  tris-phosphate  (InsP3)  and  activates  the  tyrosine  kinase  Src  (Heth  and 
Marescalchi, 1994). InsP3 stimulates the release of Ca
2+ from intracellular stores, 
which in turn will activate PKC (Heth and Marescalchi, 1994). PKC has the capacity 
to terminate POS phagocytosis as was demonstrated in rat RPE cells in vitro (Hall et 
al., 1991). Thus, when these cells were incubated with phorbol myristate acetate 
(PMA)  PKC  activity  was  increased  and  the  phagocytosis  of  outer  segments  was 
rapidly  brought  into  a  halt.  Although  the  ingestion  of  the  outer  segments  was 
stopped, PKC activation did not inhibit the binding of outer segments to the apical 
cell surface of RPE cells (Hall et al., 1991). 
 
Figure 57 shows that C5b-9 complex did not alter the phosphorylation levels of any 
of  the  three  phagocytosis-related  kinases:  MerTK,  FAK  and  Src,  respectively. 
However, it should be noted that in the pRPE cells at 0 h, p-MerTK, p-FAK and p-
Src were all detectable. Therefore it might be concluded either that pRPE cells have 
an endogenous level of constitutively activated MerTK, FAK and Src, or that a more 
rigorous  serum  starvation  protocol  should  be  applied  in  order  to  fully  deactivate 
these kinases.  
 
It was expected that any differences observed (between untreated, C5b-8- and C5b-9-
treated pRPE cells) in POS uptake would be reflected by differences in the activation 
levels of MerTK, FAK and/or Src. Since we did not observe any differences in the 
phosphorylation of the above kinases, in future studies it might be worth performing 
this experiment using antibodies that recognise different phosphorylation sites on p-
FAK,  p-MerTK  and  p-Src.  For  instance  in  Figure  57  we  only  used  an  antibody 	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against  Tyr397-p-FAK.  In  contrast,  Finnemann  et  al.  (2003)  used  two  additional 
antibodies in order to detect activated FAK during POS phagocytosis in RPE-J cells: 
Tyr576-p-FAK  and  Tyr861-p-FAK.  Using  alternative  antibodies  not  only  could 
reveal a possible response of the phagocytosis-related signalling cascade but it could 
also provide an insight as to whether complement interferes with the activation of 
any of the above kinases. 
 
While  currently  no  direct  association  has  been  reported  between  C5b-9  complex 
formation and MerTK and/or FAK kinases in the RPE, it has recently been proposed 
that complement enhances the activation of Src (phospho-Src) (Kunchithapautham et 
al., 2012, Rohrer et al., 2014). These authors showed that when ARPE-19 cells were 
incubated with 0.5 mM H2O2 and 25 % NHS for 5 min, 10 min, 20 min, 30 min and 
60 min p-Src levels were significantly increased from 5 min until 60 min. ARPE-19 
cells treated only with 0.5 mM H2O2 for the same timepoints as above, did not active 
Src kinase. Kunchithapautham et al., (2012) suggested that C5b-9 formation on RPE 
cells increases the influx of Ca
2+ and Na
+ ions, which in turn depolarise the cell 
membrane.  This  membrane  depolarisation  activates  voltage-dependent  calcium 
channels (VDCC) that further increase the influx of Ca
2+ ions. This enhanced Ca
2+ 
influx is proposed to trigger the activation of Src. The Src pathway can also crosstalk 
with the Ras/Erk pathway, which is essential for VEGF secretion. Therefore one can 
envisage a model in which C5b-9, by increasing the influx of Ca
2+ ions, can activate 
Src kinase, which in turn indirectly drives the release of VEGF. A similar association 
between  complement-induced  Ca
2+  influx,  inflammation  and  therefore  kinase 
phosphorylation could exist for FAK and MerTK. 
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6.1 Summary and conclusions 
The aim of this thesis was to investigate the in vitro interaction of the retinal pigment 
epithelium with the terminal product of the complement system: the C5b-9 complex. 
To achieve this, initially the in vitro conditions of C5b-9 complex assembly had to be 
optimised. A range of C5b-9 complex assembly conditions were tested in ARPE-19 
cells and once the C5b-9 complex formation protocol was established, ARPE-19 
cells were replaced with primary porcine RPE cells.  
 
The initial studies demonstrated the necessity of using cells with authentic RPE-like 
phenotypic  characteristics,  in  order  to  investigate  the  effects  of  C5b-9  complex 
deposition on the RPE monolayer. Usage of ARPE-19 cells that were only cultured 
in vitro  for  10  days  did  not  permit  thorough  examination  of  the  precise  cellular 
localisation of the assembled C5b-9 complex. As the ARPE-19-derived monolayer of 
cells was relatively immature it was not possible to distinguish whether the C5b-9 
complex was on the apical surface and/or inside the cytoplasm of cells. This problem 
was overcome when ARPE-19 cells were incubated for 15 weeks before being used. 
These highly differentiated cells developed a well-organised monolayer, where it 
was  easy  to  identify  the  apical  deposition  of  C5b-9  complex  via 
immunofluorescence.  However,  this  was  an  impractical  solution  for  a  long-term 
study, and it could not be relied on as there were instances where monolayers would 
inexplicably  detach  from  the  substratum,  so  an  alternative  model  system  was 
required. 
 
Four different protocols were tested with the aim of efficiently forming significant 
levels of C5b-9 complex. Previous publications showed that C5b-9 complex could be 
induced by incubating cells either with various amounts of complement-competent 
human sera and/or with C5 + C5-depleted human sera (Johnson et al., 2011, Lueck et 
al.,  2011).  The  final  protocol  which  we  used  to  induce  uniform  levels  of  C5b-9 
complex on the apical surface of pRPE cells was C5b,6 complex + C7 + C8 + C9 
purified complement proteins in DMEM. This reductionist approach increased the 
simplicity of the in vitro system, as it eliminated the presence of various proteins and 
growth factors that are normally present in human serum. Also, the switch to pRPE 
cells, known for their ability to retain their phenotype in vitro, along with cultivation 
of these cells on trans-well plates, permitted formation of C5b-9 complex on the 	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basal surface of cells. We reasoned that basal complement deposition would mimic 
the in vivo deposition of C5b-9 complex (component of drusen deposits) on the RPE 
monolayer of AMD patients (Anderson et al., 2002). 
 
C5b-9  complex  assembly  in  both  ARPE-19  and  pRPE  cells  did  not  affect  cell 
survival, according to the MTT assays, consistent with propidium iodide studies in 
ARPE-19 cells demonstrating that, with only rare exceptions, C5b-9 did not make 
cell membranes permeable. Although C5b-9-treated pRPE cells remained viable, it 
was observed that by 24 h these cells developed abundant stress fibres indicating that 
C5b-9 can interfere with actin dynamics and induce actin remodelling. 
 
Having  establishment  of  an  in  vitro  model  using  pRPE  cells  we  examined  the 
kinetics of C5b-9 complex formation. Our studies demonstrated that C5b-9 forms 
rapidly  on  the  basal  surface  of  pRPE  cells,  remaining  stable  for  several  hours, 
followed by gradual elimination until after 24 h the complex is no longer detectable. 
While it has previously been reported that C5b-9 can be eliminated from cells via 
membrane vesiculation, Moskovich and Fishelson (2007) demonstrated in K562 cells 
that C5b-9 complex could be removed either via exocytosis and/or be sequestered in 
perinuclear bodies via endocytosis as well. Here we showed that incubation of C5b-
9-treated pRPE cells with dynasore led to the sustained presence of the complex on 
pRPE cells, demonstrating the endocytosis is a major route for C5b-9 elimination in 
these cells. Immuno-electron microscopy studies supported this conclusion. 
 
Interestingly, the C5b-9 and C5b-8 complexes both increased TER, however higher 
values were obtained from C5b-9-treated cells. In contrast, the prolonged presence of 
C5b-9  (dynasore  studies)  on  the  basal  surface  of  pRPE  cells  did  not  lead  to  an 
increase in TER and the mechanism for this observation is unknown. Only a few 
previous studies examined the effects of C5b-9 on TER. One report, using a different 
experimental approach in RPE cells showed that TER values were unaffected (Lueck 
et al., 2012), whereas TERs were reported to decrease when cells were treated first 
with  hydrogen  peroxide  and  then  with  complement-competent  human  sera 
(Bandyopadhyay and Rohrer, 2012, Thurman et al., 2009, Joseph et al., 2013).  
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Western  blotting  and  immunofluorescence  analysis  of  two  highly  expressed 
junctional proteins (ZO-1 and claudin-19) failed to demonstrate any signs of up-
regulation at the protein level. However, confocal microscopy revealed that staining 
for claudin-19 was more tightly aligned with cell junctions in C5b-9-treated pRPE 
cells than in serum-free- and C5b-8-treated cells. This observation provides evidence 
that the C5b-9 complex has an effect on claudin-19 (the predominant junction protein 
in pRPE cells) that may at least partly explain the C5b-9-induced TER increase. One 
previous report showed that TER increased in ARPE-19 cells in response to ER 
stress (Yoshikawa et al., 2011). This may be relevant since the C5b-9 complex has 
previously been shown to be capable of inducing ER stress in glomerular epithelial 
cells  (GECs)  (Cybulsky  et  al.,  2002).  In  future  work  it  would  be  interesting  to 
perform western blotting and RT-PCR in C5b-9-treated pRPE cells for ER-stress-
related proteins and mRNA respectively.  
 
Previous  studies  have  shown  that  AMD  is  associated  with  modifications  in 
mitochondrial architecture and/or mitochondria numbers. As it is currently unknown 
whether C5b-9 has the potential to affect mitochondrial integrity and/or mitochondria 
numbers in RPE cells, immunofluorescence and electron microscopy were performed 
in  C5b-9-treated  pRPE  cells.  Both  immunofluorescence  for  Tim23  (essential  for 
protein transportation in mitochondria) and Mitotracker
® (a mitochondrial-specific 
fluorescent dye) revealed that the prolonged presence of C5b-9 complex on the basal 
surface  of  pRPE  cells  (dynasore  studies)  reduces  mitochondria  numbers  and/or 
changes the component of mitochondrial proteins in pRPE cells. Tim23 staining was 
greatly reduced in pRPE cells in which C5b-9 endocytosis was arrested via dynasore 
but no changes in the Tim23 and the Mitotracker
®-specific staining were observed in 
cells  where  C5b-9  was  endocytosed.  These  observations  are  consistent  with 
persistent exposure to C5b-9 leading to deleterious effects on mitochondria in pRPE 
cells. Significantly, dynasore alone did not induce these changes in mitochondria. 
We also showed using electron microscopy that both C5b-9-treated and C5b-9 + 
dynasore-treated pRPE cells, exhibited reduced numbers of mitochondria. Western 
blotting for Tim23 and cytochrome C (essential for the electron transport between 
the two mitochondrial membranes) did not reveal any alterations in expression of 
either protein in C5b-9-treated pRPE cells. 
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Incubation of pRPE cells with fluorescently-tagged POS allowed us to investigate 
whether  the  C5b-9  complex  interferes  with  phagocytosis.  In  performing  these 
experiments we were able to verify that pRPE cells retained their phagocytic activity 
several days after their extraction from porcine eyes. Interestingly, basal deposition 
of C5b-9 seemed to have an effect on the binding of POS on the apical surface of 
pRPE cells. Thus, the C5b-9 complex (and C5b-8 complex to a lesser extent) delayed 
the binding of POS, when compared to pRPE cells in serum-free medium. There are 
numerous  potential  explanations  for  this  observation,  for  example  it  could  be 
attributed to changes in the expression levels of ανβ5 receptor and/or to the high 
demand  for  actin  remodelling.  Phagocytosis  of  POS  requires  extensive  actin  re-
organisation on the apical surface, and C5b-9 has been demonstrated in chapter 2 to 
alter the actin cytoskeleton by increasing the presence of stress fibers. The effects of 
the C5b-9 complex appeared to be specific to binding, as there was no impact on the 
internalisation of POS in pRPE cells. 
 
6.2 Future perspectives 
To obtain greater insight into the interplay between the complement system and the 
RPE, it would be of interest to examine C5b-9 complex formation on hfRPE and/or 
iPS-derived RPE cells. Although pRPE cells provide authentic polarised monolayers 
to  investigate  the  effects  of  C5b-9,  they  have  limitations.  It  is  possible  that  the 
current  in  vitro  conditions  of  C5b-9  complex  formation  might  be  more  or  less 
efficient in RPE cells of human origin, and the effects of C5b-9 may vary according 
to the AMD haplotype of the target cells. The immuno-gold labelling studies could 
be extended to learn more about the cellular localisation of C5b-9 complex once it 
becomes endocytosed. Using fluorescently-tagged C9 may also provide a strategy for 
following the assembly and internalisation of C5b-9 in live cell imaging. 
 
Although the propidium iodide experiments did not provide any indication of pore 
formation by C5b-9, Ca
2+ influx experiments might be a more physiological way of 
demonstrating  the  ability  of  the  C5b-9  complex  to  increase  the  cytoplasmic 
concentration  of  Ca
2+ ions.  It  should  be  kept  in  mind  that  C5b-9  complexes  of 
different sizes (C5b-9(1-12)) can be formed and therefore the ability to increase cell 
permeability  can  be  variable.  Additionally,  microarray  analysis,  RT-PCR  and 
western blotting could all be used to investigate whether C5b-9 alters the global 	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transcriptome of RPE cells, or more specifically, the expression levels of two of the 
most common ER stress related proteins: bip and grp94, as was reported in GEC 
cells (Cybulsky et al., 2002). 
 
Performing  RT-PCR  analysis  of  a  wider  range  of  complement  regulators  could 
reveal specific responses to C5b-9 beyond just CD59 and DAF negative regulators 
and  perhaps  sensitising  RPE  cells,  either  with  a  mixture  of  pro-inflammatory 
cytokines  and/or  hydrogen  peroxide  could  make  cells  more  susceptible  to  the 
presence of C5b-9. 
 
Finally,  to  further  examine  the  effects  of  alternative  pathway  activation  on 
mitochondria,  immunofluorescence  and  western  blotting  of  various  mitochondrial 
proteins  could  be  performed  in  conjunction  with  live  cell  measurements  of 
mitochondrial function. Also, repetition of the electron microscopy analysis would 
be essential to further validate the finding that C5b-9 reduces mitochondrial numbers 
in pRPE cells. 
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